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Abstract 
This thesis describes a number of studies which explore the hypothesis that 
endoneurial hypoxia is a major component of the pathogenetic mechanisms of diabetic 
peripheral neuropathy, and that peripheral neuropathy leads to structural changes in 
the diabetic foot. 
Microvascular blood flow and rheology were studied in three age and sex 
matched groups; diabetic patients with and without neuropathy, and non-diabetic 
control subjects. Peroneal nerve motor conduction velocity was significantly 
associated with transcutaneous oxygen tension, r=0.6. p<0.001. No significant 
differences in rheological parameters were found between non-neuropathic diabetic 
patients and controls, but significant adverse changes were found in rheological 
parameters, prostacyclin levels and fibrinolysis, in diabetic patients with neuropathy, in 
the absence of other complications. 
Peroneal nerve motor conduction velocity was measured in 10 non-diabetic 
and 6 diabetic patients before and after unilateral femoro-popliteal bypass surgery to 
assess the effect of improving tissue blood flow on nerve function. The contralateral 
leg served as a control. Restoring tissue oxygenation was associated with significant 
improvements in peroneal conduction velocity in both non-diabetic and diabetic 
patients, which may suggest new therapeutic strategies for peripheral neuropathy in 
man. 
The effects of diabetic neuropathy on the foot were examined by a 
radiographic survey of the prevalence of bone and soft tissue changes in the feet of 
diabetic patients and normal controls. This demonstrated that medial arterial 
calcification is significantly associated with peripheral neuropathy, making the use of 
ankle pressure indices unreliable in neuropathic patients. It also found an higher than 
previously recognised prevalence of traumatic and Charcot fractures amongst 
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neuropathic diabetic patients. Further work demonstrated that Charcot patients have a 
global neurological impairment when compared to matched neuropathic patients 
without Charcot changes, and significantly reduced bone mineralisation, a possible 
predisposing factor for the fractures which often initiate the destructive phase of a 
Charcot joint. 
Finally, a new treatment for acute Charcot neuroarthropathy, intravenous 
Pamidronate, was evaluated, and proved effective in reducing the increased bone 
turnover, swelling and discomfort associated with the Charcot process. 
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Introduction 
Peripheral sensorimotor neuropathy is one of the commonest of the long term diabetic 
complications, reported to affect 28.5% of 6487 patients in a survey of the United 
Kingdom hospital diabetes clinic population (Young M et al. 1993a). Despite the fact 
that foot problems have been recognised for over a hundred years (Pryce 1887), the 
considerable morbidity due to neuropathic foot problems in diabetic patients persists 
(Boulton 1990a), the aetiology of neuropathy remains unclear and no reliable 
treatment has yet been devised. 
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Measuring neuropathy 
The wide variation in the reported prevalence of peripheral neuropathy, from 0- 93%, 
is probably due to the relatively small size of most studies, to differences in the 
diagnostic criteria employed and to the different methods of patient selection. 
Epidemiological studies have either examined all patients irrespective of type 
(Goodman et al. 1953, Pirart 1979, Knuiman et al. 1986, Maser et al. 1989), or 
concentrate on a specific patient group; Type I patients (DCCT 1988); Type 2 
patients (Lehtinen et al. 1989, Franklin et al. 1990); insulin treated patients (Boulton et 
al. 1985); patients attending hospital clinics (Young M et al. 1993a). Individual 
studies have employed different criteria in the definition of neuropathy and whilst some 
authors have considered painful symptoms alone to be diagnostic (Goodman et al. 
1953), others have required signs of nerve dysfunction (Pirart 1979). 
The diagnosis of peripheral sensorimotor neuropathy has been made on the 
basis of symptoms (Franklin et al. 1990), signs (DCCT 1988, Dyck et al. 1991), 
quantitative sensory tests (Steiness 1957, Bertlesmann et al. 1985) or electrodiagnostic 
studies (Gregerson 1967). The consensus statement of the San Antonio conference on 
peripheral neuropathy (1988) recommended that an abnormality of one measure in 
each of these categories should be present before the diagnosis can be assured. Dyck 
et al. (1985) proposed that abnormalities in two of three criteria were sufficient to 
diagnose peripheral sensorimotor neuropathy. The suggested categories were signs, 
quantitative sensory testing and neurophysiological tests. Neuropathic symptoms are 
generally held to be too variable to be used reliably (Attali et al. 1990). 
The definitive test of neuropathy is still sural nerve biopsy (Veves et al. 1992a). 
However, as this is an invasive test, it is restricted to specialised research uses, 
particularly therapeutic trials of potential treatments for diabetic periph eral 
neuropathy, or where the diagnosis is unclear (Veves et al. 1992a) and other measures 
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of peripheral nerve function are usually used to diagnose and assess diabetic 
neuropathy in routine clinical and most research studies. 
Peripheral neuropathy can be painfW or painless and is recognised clinically by 
reduced sensation and / or absent or reduced ankle and knee reflexes, which may be 
accompanied by dysaesthesia or paraesthesia. Clinical scoring systems using these 
criteria have been employed in the diagnosis of clinical neuropathy for epidemiological 
surveys, and appear to correlate with quantitative sensory tests (Knuiman et al. 1986, 
DCCT 1988, Franklin et al. 1990, Young M et al. 1993a). Dyck et al. (1985) reported 
that clinical scoring systems can correlate with the results of histopathological 
examination of nerve biopsies from neuropathic diabetic patients but this is not a 
universal finding (Veves et al. 1991 a). Quantitative sensory testing can be used in 
addition to clinical scoring systems to provide numerical data for trial or clinical 
records. 
Vibration perception thresholds were found to be raised in diabetic patients by 
Steiness(1957). Subsequent studies have shown an age-related increase in vibration 
perception threshold in healthy subjects (Bloom et al. 1984, Wiles et al. 1991) in 
keeping with the decrease in peripheral sensation and loss of ankle reflexes in the 
elderly (Mayne 1965). A rise in vibration perception threshold has been described 
with increasing duration of diabetes (Young M et al. 1993a, 1993b) in keeping with 
the higher prevalence of peripheral neuropathy in patients with a long duration of 
diabetes (Pirart 1979, Knuiman et al. 1986, Franklin et al. 1990). A vibration 
perception threshold of greater than 25V has been shown cross-sectionally (Boulton et 
al. 1986), and more recently prospectively, to be associated with foot ulceration in 
diabetic patients, carrying a seven-fold increase in risk of ulceration over four years 
(Young M et al. 1992a). 
Thermal perception thresholds (Bertlesmann et al. 1985) are used to test small 
unmyelinated fibre function in peripheral nerves. However, even using a forced choice 
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protocol, they have a wide coefficient of variation (Attali et al. 1990) and therefore are 
generally used to complement other tests of nerve function. 
Current perception thresholds (Masson et al. 1989a) and pressure perception 
threshold (Kumar et al. 199 1) have also been used to quantify peripheral neuropathy. 
Pressure perception has bcen used extensively in the screening for neuropathy due to 
leprosy (Birke and Sims 1986) and may be ideally suited to rapid screening for diabetic 
patients at risk of foot ulceration (Kumar et al. 1991), but neither it nor current 
perception threshold are widely used in the diagnosis of diabetic neuropathy. 
Nerve conduction velocities are the most reliable measure of nerve function 
(Dyck et al. 1985, Attali et al. 1990). Nerve conduction velocities measure the 
conduction speed of the largest and fastest fibres within a nerve (Behse et al. 1977) 
and do not rely on the co-operation of the patient, a significant advantage over 
quantitative sensory tests, which improves their intra-subject co-efficient of variation 
(Attali et al. 1990). They have been shown to correlate with the mean fibre denifty in 
sural nerve biopsies from diabetic patients with mild peripheral neuropathy (Behse et 
al. 1977, Sima et al. 1992, Veves et al. 199 1 a). A low peroneal conduction velocity is 
associated with the risk of foot ulceration (Young R et al. 1986). Peroneal nerve 
motor conduction velocity has been shown to decline with age and duration of 
diabetes (Gregerson 1967) in keeping with other tests of neuropathy, and, as the sural 
sensory nerve action potential is frequently absent in diabetic neuropathy (Young R et 
al. 1986), is probably the 'gold standard' of non-invasive tests for quantifying 
peripheral neuropathy. 
16 
The pathogenesis of diabetic peripheral neuropathy 
If diabetic neuropathy affected all patients with diabetes then hyperglycaernia alone 
might be a satisfactory explanation for its development. -However, using careful 
clinical critcria, the prevalence of diabetic peripheral neuropathy is usually less than 
one third of all patients (Young M et al 1993 a) and therefore other factors must play a 
role. The pathogenesis of diabetic peripheral neuropathy is however, the subject of 
considerable debate, and whilst other pathogenetic mechanisms, including 
immunological mechanisms (Rabinowe et al. 1989), and those relating to the presence 
or absence of nerve growth factors (Levi-Montalcini 1987), have been proposed in the 
pathogenesis of diabetic peripheral neuropathy, the two main candidates are metabolic 
and vascular mechanisms. In general, opinion is divided between those who believe 
that metabolic abnormalities (Clements and Bell et al. 1982, Bays and Pfeifer et al. 
1988), including those of the polyol pathway (Greene et al. 1988), are the principal 
cause of diabetic peripheral neuropathy, and those who favour microvascular disease 
as its cause (Low 1987, Dyck 1989). - Within an individual however, both mechanisms 
are likely to be at work, and indeed, the two may be related (Low 1987, Bays and 
Pfeifer et al. 1988). Osmotic changes due to sorbitol accumulation have been 
demonstrated to cause nerve swelling, which may increase the inter-capillary distance, 
resulting in endoneurial hypoxia (Griffey et al, 1988), and increases in erythrocyte 
sorbitol are reported to result in stiff red blood cells (Robey et al. 1987), reducing 
capillary perfusion. 
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Metabolic theories of neuropathy 
In experimental diabetes, streptozotocin rats develop reduced nerve conduction 
velocities after four weeks of hyperglycaernia (Cameron et al. 1989,1991,1992ab, c, 
Eliason 1964, Greene et al. 1975). Nerve swelling and increased hydration have also 
been noted on pathological examination of peripheral nerve. Histochemical analysis of 
nerve biopsy specimens from experimental diabetic rats revealed sorbitol accumulation 
and reduced levels of myo-inositol (Stewart et al. 1967, Gabbay 1975, Greene et al. 
1975,1984,1988). This led to the main metabolic theory of diabetic neuropathy in 
which hyperglycaemia leads to excess glucose in the nerve axon, which is then 
converted to sorbitol via the pentose shunt. For a number of years this accumulation 
of sorbitol was believed to be accompanied by a reduction in the availability of myo- 
inositol phosphate which is required for cell membrane repair and ATPase activity 
(Greene et al. 1984,1988), but this concept has recently been discounted by many 
workers in peripheral neuropathy, as, although there is evidence of some improvement 
in nerve conduction with myo-inositol supplementation in experimental animals 
(Greene et al. 1975), there appears to no benefit in man (Gregerson et al. 1983), and 
normal levels of myo-inositol have been found in biopsy specimens from diabetic 
patients with neuropathy (Dyck et al. 1980, Hale et al. 1987), despite elevated levels 
of polyol metabolites (Dyck et al. - 1988). The rate limiting enzyme of the polyol 
pathway is aldose reductase and a number of aldose reductase inhibitors have been 
developed (Masson and Boulton 1990a). Despite the initial success of these 
compounds in animals, they have proved to be of limited benefit in established 
neuropathy in man (Boulton et al. 1990b). This is probably due to the primary 
difference in the nature of experimental neuropathy and neuropathy in human diabetes. 
In experimental diabetes the animal usually has uncontrolled, or poorly controlled 
hyperglycaen-da over a relatively short time. Although nerve fibre loss does occur, 
particularly late on in the course of experimental neuropathy (Sima et al. 1988), 
metabolic/toxic effects play the major role in any abnormality in the first few weeks, 
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this is probably similar to the reversible nerve conduction slowing noted in newly 
diagnosed diabetic patients (Ward J et al. 1971). Even in experimental animals the 
aldose reductase inhibitors have proved relatively ineffective in reversing established 
nerve conduction slowing to normal, and are more effective in prevention studies. 
In established diabetic neuropathy in man there is usually marked loss of nerve 
fibres, particularly the myelinated fibres (Malik et al. 1989). Attempts to reverse this 
pathological defect pharmaceutically are unlikely to be successful (Fagius et al. 1985), 
although the decline in conduction velocity with increasing duration of diabetes, and 
age, may be slowed (Boulton et al. 1986). A recent trial in early neuropathy has 
proved more promising with some improvement in nerve conduction velocities and 
symptoms (Giugliamo et al. 1993). 
Thus, other explanations for the development of diabetic peripheral neuropathy 
have been sought. In particular, there has been considerable research effort to 
demonstrate a microvascular component to peripheral neuropathy. Such a component 
would be in keeping with the microvascular hypotheses for retinopathy (Patel et al. 
1992) and nephropathy (Parving et al. 1983), providing an unified theory of diabetic 
complications. This hypothesis has been given recent support by the finding of 
increased capillary leakage of albumin, one of the hallmarks of early retinopathy or 
nephropathy, in patients with peripheral neuropathy alone-(Valensi 1991). 
19 
The microvascular theory of neuropathy 
Fagerberg (1959) described endoneurial abnormalities on histological examination of 
sural nerves. The changes in capillaries, including endoneurial basement membrane 
thickening paralleled the clinical severity of diabetic peripheral neuropathy. More 
recent studies including those of Malik et al. (1989) and Veves et al. (199 1 a) have also 
found correlations with microangiopathic changes and nerve dysfunction. 
The loss of nerve function following interruption of the blood supply is termed 
ischaemic conduction failure (Low et al. 1987). This is usually tested in man by 
applying a sphygmomanometer cuff around the limb to be tested and inflating above 
systolic blood pressure and measuring nerve function at timed intervals. Measuring 
the reduction in vibration perception using this technique, Steiness (1959) reported 
that diabetic patients with peripheral neuropathy demonstrated resistance to ischaemic 
conduction failure and suggested that endoneurial hypoxia might be responsible for 
this phenomenon. This 'resistance to ischaemic conduction failure' has been described 
as one of the hallmarks of diabetic neuropathy and a significant pointer to a role for 
endoneurial hypoxia in the pathogenesis of diabetic neuropathy (Low et al. 1987). 
Since then, the evidence that microvascular flow and endoneurial hypoxia are 
implicated in the development of-peripheral neuropathy is increasing in both animal 
and human studies. 
Direct measurement of endoneurial oxygen tension has demonstrated that this 
is reduced in chronically hyperglycaemic rats, and oxygen supplementation in 
hyperbaric chambers can ameliorate the fall in nerve conduction velocities that usually 
occurs (Low et al. 1987). Non-diabetic rats kept in a low oxygen environment have 
also been shown to develop a peripheral neuropathy (Low et al. 1986). Experimental 
assessments of nerve blood flow have confirmed that this too is reduced in diabetic 
rats (Cameron et al. 1992a), and recent research has also demonstrated that a 
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surgically created proximal arteriovenous shunt can significantly reduce nerve function 
in the rat hind limb by reducing distal blood flow (Sladky et al. 1991). Studies by 
Cameron et al. and others have shown that experimental neuropathy can be prevented 
in streptozotocin rats by treatment with vasodilators from the induction of diabetes 
(Cameron et al. 1992b). Repeated muscle stimulation with electric shocks has been 
shown to improve angiogenesis and ameliorate the decline in nerve conduction seen in 
experimental animals (Cameron et al. 1989). Angiotensin converting enzyme 
inhibitors may also be able to prevent the development of conduction velocity slowing 
in experimental diabetes (Cameron et al. 1992b) 
In man, direct measurement of endoneurial oxygen tension has also shown that 
the diabetic sural nerve is hypoxic compared to non-diabetic controls and that the sural 
oxygen tension was lower than that of the overlying vein (Newrick et al. 1986). The 
histopathological features of biopsies of sural nerve taken from neuropathic diabetic 
patients are those suggestive of a microangiopathy (Malik et al. 1989). The main 
features are patchy fibre loss, which is predominantly myelinated; capillary closure; 
basement membrane thickening and large spaces between capillaries, which may be 
widened by endoneurial oedema, thus increasing the diffusion gradient for oxygen. 
The increased water content of nerves in diabetic patients that has been demonstrated 
on magnetic resonance imaging may indirectly lend support to this concept (Griffey et 
al. 1988). 
It could be reasoned that if diabetic peripheral neuropathy is due to reduced 
endoneurial blood flow or hypoxia then a direct reduction in blood flow or impaired 
tissue oxygenation in non-diabetic patients should result in peripheral nerve 
dysfunction and the same histological features as those found in diabetes. Malik et al. 
reported that microangiopathy and myelinated fibre loss can be also be found in 
biopsies from non-diabetic hypoxic chronic obstructive airways disease patients (Malik 
et al. 1990), up to twenty percent of whom may develop a peripheral neuropathy 
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(Nowak et al. 1990). These patients also show the same electrophysiological features 
as diabetic patients, including resistance to ischaemic conduction failure (Masson et al. 
1988). In addition, a reduction in motor conduction velocity (Hunter et al. 1988) and 
morphological abnormalities, including a reduction in myelinated fibre density have 
been reported in patients with peripheral vascular disease (Rodriguez-Sanchcz et al. 
1991). Epidemiologically, peripheral neuropathy has been found to be associated with 
peripheral vascular disease (Maser et al. 1989) and clinical assessments of peripheral 
vascular disease have been shown to correlate with peripheral nerve function (Ram et 
al. 1991). In addition, the creation of arteriovenous shunts for haemodialysis has been 
demonstrated to lead to a distal neuropathy in a number of case reports (Wilbourn et 
al. 1983, Knezevic and Mastalgia 1984, Riggs et al. 1989). 
Tesfaye et al. (1992a) demonstrated that nerve conduction velocity fails to 
increase in diabetic patients with neuropathy following exercise, suggesting that there 
is an impairment of neural blood flow. In this study, diabetic patients with no evidence 
of neuropathy, diabetic patients with neuropathy and healthy controls performed 
exercise on a treadmill to their maximum capacity, Whilst the mean peroneal nerve 
motor conduction velocity of the non-neuropathic diabetic and non-diabetic subjects 
increased following exercise, and all three groups demonstrated an increase in skin 
temperature, suggesting an increase in limb blood flow, the neuropathic diabetic 
patients showed no increase in peroneal conduction velocity. This was thought to 
show that endoneurial blood flow-was impaired and is in keeping with the 
measurements of Newrick et al. (1986) and the experimental work described above. 
Tesfaye et al., by direct television microscopy of the epineurial vessels at open 
nerve biopsy have reported that the epineurial veins are larger in diabetic neuropathic 
patients when compared to controls (Tesfaye et al. 1990). When fluorescein is 
injected-into the epineurial arteries it appears in the epinqurial veins earlier in the 
diabetic neuropathic patients suggesting increased arterio-venous shunting in the 
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nerves of neuropathic patients. This work confirms, at the level of the nerve, earlier 
work by Boulton et al. (1982) which demonstrated that the oxygen tension in pedal 
veins was increased to levels above those found within the nerves, again suggesting 
arterio-venous shunting. In addition, the findings of Partsch (1978), that lower 
amounts of radioactive labelled albumin microspheres are trapped in the capillary beds 
of the foot, adds further support to the concept of direct arterio-venous channels in the 
microvasculature of neuropathic diabetic patients which bypass the nutritive supply. 
The reports of increased flow in the medium sized vessels of the foot are in 
keeping with the findings of Patel et al. (1992) in patients with diabetic retinopathy. 
Laser Doppler flowmetry of the branch arteries and veins of the fundus demonstrated 
an increase flow in diabetic patients with retinopathy. The increase in retinal blood 
flow was observed cross-sectionally in all grades of retinopathy, except when the eye 
had been treated by laser photocoagulation / ablation. Patel et al. hypothesised that 
the increased flow led to capillary damage and eventual capillary closure, which could 
result in microcirculatory ischaemia, in keeping with Tooke's theories of a 
haemodynamic component to diabetic microvascular complications (Tooke 1986). 
Thus, there is further evidence for a unifying microvascular hypothesis for long term 
diabetic complications. 
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Assessing the microvascular circulation 
From the studies outlined above, there is good evidence for arterio-venous 
shunting at the level of medium sized vessels. This shunting might be expected to lead 
to diversion of nutrient blood flow away from the capillary beds. However, a number 
of direct studies of the microvasculature have contradicted these findings. Tooke et al. 
have suggested that at rest there is no evidence of reduced nutritive flow with either 
laser Doppler flowmetry or direct capillary microscopy (Tooke 1986). However, 
some of the later work by this group has shown that although capillary pressure and 
flow are initially increased in diabetes there is a later defect in flow due to capillary 
sclerosis (Flynn and Tooke 1992). Work from this and other groups, has also shown 
that although the resting microvascular flow is similar in diabetic patients with and 
without complications, the hyperaemic response is markedly reduced, suggesting 
damage to the microcirculation (Rayman et al. 1986, Walmsley et al. 1989, Watkins 
1992). 
Transcutaneous oxygen measurements are widely used in the assessment of the 
microvascular and macrovascular blood supply to the foot (Hauser et al. 1984, 
Gaylarde et al. 1988, Pecoraro et al. 1991) and have been described as being more 
useful than laser Doppler in measuring tissue perfusion. Gaylarde et al. (1988) 
demonstrated that at 44 *C, transcutaneous oxygen levels were reduced in diabetic 
patients with peripheral neuropathy when compared with non-neuropathic diabetic 
patients, who had lower oxygen tensions than non-diabetic controls. The electrode 
temperature of 44 *C was preferred because this gave a better correlation with arterial 
oxygen levels due to arterialisation of capillary blood. At 37 *C the transcutaneous 
oxygen tension was higher in neuropathic patients than non-neuropathic diabetic 
patients or controls, but at 17 mmHg, the mean oxygen tension was lower than the 
described limit of tissue viability in patients with foot ulceration (Pecoraro et al. 1991), 
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and therefore should be interpreted with caution. A study by Stevens et al. (Stevens 
M et al. 1992a) in four non-diabetic patients with unilateral traumatic neuropathy of 
the lower limb showed a lower increase in transcutaneous oxygen levels following 
heating to 44 T in the affected limb than the contralateral limb. This study would 
suggest-that the lower oxygen tensions are a secondary phenomena due to the 
neuropathy, but this was only a small study and co-existent arterial damage may have 
been present in the patients who suffered injuries to the neurovascular bundle. A 
reduced hyperaernic response has also been noted in diabetic children before the onset 
of neuropathy (Shore et al. 1991), and on the abdomen of adults with diabetes 
(Rayman et al. 1986), suggesting that it is that the impaired hyperaemic response is 
likely to be a primary microvascular defect rather than a secondary neurogenic 
phenomenon. 
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Rheological changes in diabetes 
Rheology is the study of blood flow and its determinants. Blood flow is inversely 
proportional to viscosity in the capillary beds of the microvasculature, and therefore 
the direct measurement of viscosity and its determinants should indicate the likelihood 
of flow abnormalities. The principal components of whole blood viscosity are the 
plasma viscosity, haematocrit, red cell deformability, red cell aggregation and the 
levels of macroprotein molecules, particularly fibrinogen, which, at low shear rates 
increase red cell aggregation by forming cross links between red blood cells (MacRury 
and Lowe 1990). 
The role of rheological changes in the development of diabetic complications is 
still unclear. One study has demonstrated there was no difference in measures of 
rheology in diabetic and non-diabetic patients with renal fOure (Gordge 1990), 
although both had adverse rheological parameters when compared to healthy non- 
diabetic controls. A study by the Glasgow group (Lowe et al. 1980a) found no 
difference in whole blood viscosity between male diabetic patients with proliferative 
retinopathy versus those with minimal or no retinopathy. 
The spectrum of debate about the role of rheological factors in neuropathy 
ranges from the review of Simpson (1988), which concluded that rheological factors 
were paramount in the pathogenesis of many forms of peripheral neuropathy, to the 
work of MacRury et al. which, whilst recognising the potential role for rheological 
changes in the pathogenesis of peripheral neuropathy, has-not found significant - 
differences in any of the rheological parameters measured in neuropathic compared to 
non-neuropathic diabetic patients (MacRury et al. 199 1, MacRury et al. 1993 a). 
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Whole blood viscosity 
The evidence for increased whole blood viscosity in diabetes is generally accepted 
(MacRury and Lowe 1990). However most studies have examined whole blood 
viscosity in patients with established nephropathy (Gordge et al. 1990) (although the 
changes were similar in diabetic and non-diabetic patients), retinopathy (Lowe et al. 
1980a), or in abnormal metabolic states, including diabetic ketoacidosis (Reubi 1953). 
In contrast with these findings, there are studies to show that whole blood viscosity 
improves with good diabetic control (Paisey et al. 1980, Leiper et al. 1984). In 
addition, no increase in whole blood viscosity has been found in patients with 
background retinopathy when compared to diabetic patients with no evidence of 
retinopathy (Lowe et al. 1980a) or in diabetic patients with vs. those without 
microalbuminuria (Jay et al. 1991). Similarly, MacRury et al. (1991) found no 
difference in whole blood viscosity at high or low shear rates in diabetic patients with 
and without neuropathy either at native haematocrit or at a standardised haematocrit, 
although this study also included patients with other microvascular complications in 
the neuropathy and control groups. In this study neuropathy was diagnosed on a 
variety of clinical grounds, with conduction velocities only measured in IS of the total 
of 29 neuropathic patients and none of the 'non-neuropathic' and non-diabetic controls. 
The mean peroneal conduction velocity of the neuropathic patients in the study of 
MacRury et al. was 40.7 ± 4.3 ms-1, which is only mildly impaired, and above the 
threshold for many neuropathy intervention studies (Gregerson 1967, Young R et al. 
1986). In another study, which examined whole blood viscosity and other rheological 
parameters in diabetic patients with-and without neuropathy, no non-diabetic controls 
were studied (Ford et al. 1992). In this study the main determinant of neuropathic 
status was a peroneal motor conduction velocity of <40 ms-1. No significant 
differences were found in whole blood viscosity at high shear rates (23 0 s- I and 23 s- 
1) between a group of 'uncomplicated' diabetic patients, although microalbuminuria 
was not excluded, and neuropathic patients, 11115 of whom also had other 
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microvascular complications. In addition, there is no mention of the smoking status of 
the patients included in either of these studies, and the numbers of type I and type 2 
patients differ in each group, both of which are believed to influence a number of 
rheological parameters (Lowe et al. 1980b, MacRury and Lowe 1990). 
Haematocrit 
Changes in haematocrit have been shown to influence cerebral blood flow in diabetes 
(Thomas et al. 1977), but not capillary flow in non-diabetic patients with 
polycythaernia (Tooke and NElligan 1987). An increase in haematocrit increases the 
amount of red cell aggregation in a cell suspension, particularly at low shear rates 
(MacRury and Lowe 1990). For this reason, it is usual to correct whole blood 
viscosity to a standardised haematocrit (Matrai et al. 1987), to reduce the effect that 
differences in haematocrit between study groups would otherwise have on the 
measured value of whole blood viscosity. 
Red Cell Aggregation 
Red cell aggregation is related to haematocrit, fibrinogen concentration and shear rate. 
It is a major component of whole blood viscosity at low shear rates (MacRury and 
Lowe 1990). Recently, it has been reported to be increased in diabetic patients with 
cardiovascular disease (MacRury et al. 1993b), and was also increased in the diabetic 
subjects in the studies of rheology and peripheral neuropathy (MacRury et al. 1991, 
1993a), but again was not significantly different between neuropathic and non- 
neuropathic diabetic patients. 
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Plasma viscosity and Fibrinogen 
Most recent, widely published studies, confirm that plasma viscosity is increased in 
diabetic patients, a finding that was first reported by Cogan et al. in 1961. This is 
generally in association with increased fibrinogen levels in diabetic patients (Auwerx et 
al. 1988, Ganda 1992, MacRury et al. 1993b). However, other recent studies by 
MacRury et al. (1991 and 1993 a) have contradicted this. One (MacRury et al. 1991) 
reported an increase in plasma viscosity without an increase in fibrinogen, and the 
other, no difference in plasma viscosity between diabetic patients and non-diabetic 
control subjects, although in this study the control group had a very high plasma 
viscosity (MacRury et al. 1993a). 
The relationship between plasma viscosity and increased fibrinogen levels and 
complications is unclear. Diminno (1986) reported that fibrinogen binding was 
increased in both diabetic patients with and without retinopathy, but that the increase 
was only reversed by aspirin in diabetic patients without retinopathy, suggesting that 
fibrinogen may have a role in retinopathy. The studies of MacRury et al. (1991 and 
1993 a) and Ford et al. (1992) above reported no differences in either plasma viscosity 
or fibrinogen levels between diabetic patients with and without neuropathy, although 
in the study of Ford et al., fibrinogen concentration was strongly associated with 
increased nerve capillary basement membrane thickness, one of the hallmarks of 
microangiopathy (Williamson 1977). Therefore, the role of fibrinogen in 
microvascular complications remains to be clarified. 
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Red cell defonnability 
The small nutritive capillaries are-on average 3-5 pm in diameter, which compare-s with 
a mean red blood cell resting diameter of 8 [Lm. Therefore, in order to deliver oxygen 
within capillary beds the red cells have to deform and elongate. Most methods to 
determine red cell deformability depend on the filtration of red blood cells through a 
micropore membrane (Dormandy et al. 1985). Again, decreased red blood cell 
deformability has been reported between groups of diabetic patients and non-diabetic 
controls in the majority of studies (Kamada and OtsuJi 1983, MacRury et al. 1991) 
although this is not universal (Williamson et al. 1985). 
The defect in red cell membrane fluidity has also been reported in experimental 
diabetes in rats and has been shown to be partly reversible by aldose reductase 
inhibition. Fractionation of red cells into young and old populations has shown that 
the decrease in red cell deformability occurs soon after production (Kamada 1992). 
Glycation of the red blood cell membrane, without a significant change in 
deformability, has also been reported (Williamson et al. 1985). 
The relationsl-iip of red cell deformability with diabetic microvascular 
complications is also unclear. 
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The functional relevance of rheological changes 
The microcirculatory consequences of the changes in rheological parameters 
that occur in diabetes have not yet been fully established. Such changes may 
contribute to the lower 'maximal' microvascular blood flow, as measured by 
transcutaneous oxygen (Gaylarde et al. 1988) or laser Doppler (Rayman et al. 1986, 
Walmsley et al. 1989, Watkins 1992) reported in patients with diabetic neuropathy. In 
one of the few studies to examine tissue oxygenation and rheological parameters in 
diabetic patients, MacRury et al. (1993b) demonstrated that transcutaneous oxygen 
and whole blood viscosity were negatively correlated. Whole blood viscosity is 
believed to be increased in diabetic patients (MacRury and Lowe 1990), and therefore 
this may lead to a reduction in tissue oxygenation in diabetic patients. In a small study 
of non-diabetic patients with very high whole blood and plasma viscosities due to 
polycythaemia or Waldenstrom's macroglobulinaemia, capillary blood flow was 
reduced, but not significantly, when measured directly with television microscopy 
(Tooke and Nfilligan 1987). However, the authors suggest that the capillary 
circulation is able to auto-regulate to accommodate for these changes. Whilst this is 
true in non-diabetic patients, work from Tooke's unit suggests that auto-regulation in 
the nail-fold capillaries is lost in diabetic patients soon after diagnosis (Sandeman et al. 
1992). Therefore, if changes in viscosity and deformability do occur in diabetes, and 
are more marked in association with microvascular complications, they may contribute 
to the increased capillary pressure measured in diabetic patients. This in turn may lead 
to the endothelial damage, basement membrane changes and increased capillary 
transudation of albumin that are thcý hamarks of diabetic microangiopathy 
(Williamson et al. 1977). Indirect evidence for this may also be found in the study of 
Ford et al. (1992), although only three of the 10 Patient non-neuropathic group, 
compared to all of the fifteen neuropathic patients, had histopathological examination 
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of sural nerve biopsy specimens, significant correlations were found between basement 
membrane thickening and a number of determinants of microvascular flow. 
32 
Platelets, prostacyclin and thromboxane 
The balance of platelet aggregation -and the patency of the microcirculation -are -- 
believed to be regulated by the balance of thromboxane (TXB2) and the prostanoids, 
PGEI and prostacyclin (Moncada and Vane 1979). There is evidence in experimental 
diabetes that the balance of thromboxane and prostacyclins is disturbed, with an excess 
of thromboxane synthesis (Gerrard et al. 1980, Karpen et al. 1982) and this has also 
been reported in man (Halushka et al. 198 1). When this reported increase in 
thromboxane synthesis is taken together with evidence of increased thromboxane 
receptors on platelets in patients with type I diabetes (Modesti et al 1991) this may 
partially explain the abnormal platelet function in diabetes (Colwell et al. 1978), and 
the significantly increased platelet aggregation reported in association with 
microvascular complications (O'Malley et al. 1975, Dallinger et al 1987, O'Donnell et 
al. 199 1). 
Prostacyclin synthesis has also been reported to be reduced in animals with 
experimental diabetes (Ward K et al. 1989) and diabetic patients (Johnson et al. 1979, 
Silberkane et al. 1979, Ylikorkala et al. 198 1). Treatment with prostaglandin EI and 
its analogues, which have a similar antiplatelet aggregation and vasodilatory function 
to prostacyclin, has been shown to improve conduction velocity in experimental 
diabetes (Ohno et al. 1992). 
The balance of prostaglandin and thromboxane synthesis may be influenced by 
the balance of dihomo-gamma-linolenic acid and arachidonic acid (Jamal 1990). The 
block in the synthesis of gamma-linolenic acid described in diabetes has been reported 
to be greater in patients with microvascular complications (Jones et al. 1983). 
Supplementing the diet with dihomo-gamma-linolenic acid has been shown-to reduce 
platelet aggregation (Kernoff et al. 1977), but the levels of prostanoids were not 
measured in this study. 
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In experimental diabetic neuropathy, dietary supplementation with gamma- 
finolenic acid can prevent the decline in conduction velocity that develops in 
streptozotocin rats (Cameron et al. 1991, Stevens E et al. 1993). The study of 
Stevens et al. also demonstrated that endoneurial laser Doppler flux was reduced in 
untreated animals, but that this was maintained in rats given dietary supplementation 
with evening primrose oil. Their data also suggested that evening primrose oil 
reversed resistance to ischaemic conduction block (Stevens E et al. 1993). Two 
placebo controlled trials of gamma-linolenic acid in the treatment of diabetic peripheral 
neuropathy in man have now shown small but definite improvements in symptoms, 
signs and neurophysiological tests (Jamal and Carmichael 1990, Keen et al. 1993). 
These studies lend further weight to the hypothesis that microvascular and rheological 
abnormalities may be involved in the pathogenesis of peripheral neuropathy in 
diabetes. 
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Fibrinolytic parameters in diabetes 
In vivo, the balance between coagulation and fibrinolysis is carefully maintained. 
Although the majority of studies suggest that there is an hypercoagulable state and a 
defect in fibrinolysis in diabetes, the small size of some studies (Wieczorek et al. 
1993), the failure to define adequately the patient groups, with a mix of different 
complications and levels of complications, and the failure to control for smoking habit 
have further confused this question. 
The increased levels of von Willebrand factor (Doman et al. 1983), and 
fibrinogen (Auwerx et al. 1988, Ganda and Arkin 1992, MacRury et al. 1993a) 
reported in diabetes are thought to increase the risk of macrovascular disease, 
particular seen in patients with type 2 diabetes (Morrish et al. 1991). However, 
hypercoagulability and decreased fibrinolysis might also influence microvascular flow, 
and in particular might explain the closed capillaries seen in sural nerve biopsies from 
patients with diabetic peripheral neuropathy (Simpson 1988). Supportive evidence for 
Simpsotfs suggestion may be found in the study of Ford et al. (1992), in which 
capillary lumen size correlated with fibrinolytic activity. 
The main activators of the fibrinolytic system are tissue plasminogen activator 
(t-PA) and urokinase-like plasminogen activator (u-PA). Circulating t-PA is produced 
by the vascular endothelium; u-PA is produced by the liver and a number of other cell 
lines. There are two plasminogen activator inhibitors, PAI- I and PAI-2. PAI- I is 
found in plasma, hepatocytes, endothelial cells and platelets. PAI-2 is produced in the 
trophoblastic epithelium of the placenta and is the main form of plasminogen activator 
inhibition in pregnancy. Previous studies that have examined levels of t-PA and PAM 
antigen may not have provided a full picture of the balance of fibrinolysis as the 
majority of t-PA and its target plasminogen are bound to plasmin when a clot forms, 
and are then protected from inhibition by circulating PAI- I (Grant 199 1). 
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Overall, the fibrinolytic system is believed to be impaired in patients with 
diabetes (Small et al. 1987). It has been suggested that high insulin levels, either due 
to resistance or pharmacological treatment, are associated with increased_PAI-I levels 
(Juhan-Vaque 1989,1991). However, a number of euglycaemic clamp and related 
studies of non-insulin resistant patients have failed to show such a relationship and 
obesity and hypertension may be the main correlates of PAI-1 activity (Auwerx 1988, 
Grant and Metcalf 1990, Potter van Loon 1990, Landin 1991). The in vitro culture of 
hepatocytes in high concentrations of insulin has however been shown to induce PAI- I 
synthesis. Poor diabetes control has also been shown to reduce fibrinolytic activity 
(Small et al. 1987). 
In type I diabetes there are reports of increased, unchanged and decreased 
basal fibrinolytic activity based on studies of the euglobulin clot lysis time, a global 
parameter of fibrinolysis and levels of t-PA and PAI- 1 antigen (Fisher et al. 199 1). 
Studies measuring the activity of each of these parameters have shown lower t-PA or 
t-PA / PAI- I activity ratios in type I diabetes compared to controls (Auwerx et al. 
1988, Fisher et al. 1991, Wieczorek et al. 1993). Wieczorek et al. also demonstrated 
that there was an attenuated fibrinolytic response following either venous occlusion or 
insulin induced hypoglycaemia in type I diabetes. They suggested that this 
abnormality in fibrinolysis might be due to an underlying endothelial defect. A reduced 
response to venous occlusion in type I diabetes has also been noted in patients with 
neuropathy and retinopathy (Walmsley et al. 1991) and retinopathy alone (McLaren et 
al. 1990, Walmsley et al. 1991). Thus, despite the debate about the basal level of 
fibrinolysis in patients with type I diabetes, there is general agreement that the 
fibrinolytic response to stimulation is attenuated, and that this deficit may be 
exaggerated in type I patients with complications. 
In type 2 diabetes there is a consensus that fibrinolytic activity is reduced, 
whether clinically without complications (Fuller et al. 1970, Schneider et al. 1988, 
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Grant 1991, Walmsley et al 1991), or in association with retinopathy (Garcia Frade et 
al. 1990). 
Overall in diabetes fibrinolysis appears to be reduced basally and markedly 
impaired following stimulation, such as venous occlusion. This pattern has largely 
been associated with macrovascular disease (Hamsten et al. 1985, Meade et al. 1980), 
but, as outlined above, has also been found in association with microvascular 
complications. As yet no study has looked at the fibrinolytic system in diabetic 
patients with neuropathy in the absence of other complications. The study of Ford et 
al. (1992) used fibronectin release as its measure of fibrinolysis. This study showed 
that in mixed groups of type I and type 2 patients, fibronectin release, and by 
association fibrinolysis, was reduced after venous occlusion in patients with peripheral 
neuropathy. 
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Summary 
In summary, there appears to be a consensus that microvascular flow is abnormal in 
diabetic peripheral neuropathy. The histological features found on sural nerve biopsy, 
including capillary basement membrane thickening, are also found in skin biopsies and 
in the kidneys suggesting generalised microvascular disease. Rheological parameters 
and fibrinolysis are adversely affected by diabetes, and although these changes may be 
greater in diabetic patients with microvascular complications this has not been 
demonstrated in well controlled studies of patients with single complications, such as 
diabetic neuropathy alone. There is potential for possible interaction between 
abnormal capillary compliance and size, increased arterio-venous shunting, and the 
effects of individual adverse rheological parameters to reduce microvascular flow. 
Such an interaction might explain some of the functional changes in tissue oxygenation 
and laser Doppler flow described in diabetes. However, to date there is only patchy 
evidence to support this hypothesis. 
Supporting evidence for the role of microvascular abnormalities and 
endoneurial hypoxia in the pathogenesis of diabetic peripheral neuropathy includes 
extensive animal work, and evidence of similar histological and clinical findings in 
patients with respiratory and peripheral vascular diseases. However, although 
reported in rat , models of neuropathy, the reversal of conduction velocity abnormalities 
by improving tissue oxygenation has not been demonstrated in man. 
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The Effects of Peripheral Neuropathy 
on the Diabetic Foot 
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Introduction 
A greater understanding of the pathogenesis of diabetic peripheral neuropathy may 
help to develop treatments to reduce the high prevalence of this complication.. 
However, type 2 diabetic patients often have peripheral neuropathy at diagnosis when 
preventative strategies will be too late (Young M et al. 1993 a). Therefore, it is equally 
as important to understand the effects of peripheral neuropathy-upon the diabetic foot 
in order to reduce the current toll of foot ulceration and amputations in patients with 
established neuropathy. A 50% reduction in amputations in diabetic patients is one of 
the stated aims of the St. Vincent Declaration (WHO/IDF 1988), and this has been 
shown to be achievable in specialised foot clinics (Edmonds et al. 1986, Thomson et 
al. 1991). In order to continue this improvement in the outlook for the diabetic foot, 
the patterns of foot abnormalities caused by peripheral neuropathy require further 
study. 
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Foot ulceration 
Peripheral neuropathy is a major component of over 90% of diabetic foot ulceration 
(Edmonds et al. 1986, Thomson et al. 1991). The prevalence of foot ulceration and 
amputations in almost 6500 diabetic patients attending United Kingdom hospital 
diabetic clinics was reported to be 4.5% (Macleod et al. 199 1), around 13 % of the 
prevalence (28.7%) of peripheral neuropathy in the same sample (Young M et al. 
1993a). A community based survey of type 2 diabetic patients registered with general 
practices in three cities in the North of England reported similar rates of peripheral 
neuropathy and foot ulceration (Kumar et al. 1992). 
The principal mechanisms of foot ulceration in neuropathic patients are largely 
understood at the macroscopic level. Pressure, whether from walking or from 
inappropriate shoes, leads to autolysis of the skin and eventual breakdown if not 
removed (Koziak 1959, Brand 1983). The generation of higher plantar pressures 
during walking that has been reported in neuropathic patients (Veves et al. 1991b) is 
believed to be a function of the foot deformity, limited joint mobility and prominent 
metatarsal heads that are more common in these patients (Boulton et al. 1993). High 
dynamic plantar foot pressures, in patients with peripheral neuropathy (Masson et al. 
1989b), have been shown to be predictive of foot ulceration (Veves et al. 1992b). 
Neuropathic diabetic patients tolerate tight shoes. They also tolerate the initial 
inflammatory injury response to walking on high pressure areas (Brand 1983, 
MacFarlane et al. 1993). This is because neuropathic patients lack the normal 
protective sensation of pain which would lead to the removal of the shoes, or a change 
in gait to shift the abnormal loading. 
At the microscopic level, it is believed that pressure overcomes the nutritive 
flow of the skin and this leads to localised tissue necrosis and breakdown (Flynn and 
Tooke 1992). The demonstration of increased arterio-venous shunting (Partsch 1978, 
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Boulton et al. 1982, Edmonds et al. 1982) in the diabetic foot, and the impaired 
hyperaernic injury response (Rayman et al. 1986, Walmsley et al. 1989) in neuropathic 
patients may also contribute to the increased risk of ulceration. 
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Bone changes in the diabetic foot 
It has been reported that both type I and type 2 diabetic patients have a decreased 
bone mass when compared to age and sex matched control subjects (Selby 1988). 
Although renal failure secondary to diabetic nephropathy may contribute to this 
problem Coburn 1980), there are suggestions that bone mass is reduced in diabetic 
patients with normal renal function. Edmonds et al. (1985) have shown that 
radioisotope uptake is increased in the feet of neuropathic diabetic patients. They 
suggested that this implied increased bone blood flow, as a consequence of increased 
arterio-venous shunting within bone, and increased osteoclastic activity. This 
increased osteoclastic activity may be part of the explanation for the reduced bone 
mass, and also has implications for the pathogenesis of Charcot neuroarthropathy, as 
outlined below. 
Bone mass is measured by two methods; single photon absorptiometry (SPA) 
and dual energy X-ray absorptiometry (DEXA). Single photon absorptiometry was 
first described in 1963 (Cameron J et al. ). The technique involves the measurement of 
the absorption of photons passed through the forearm at the proximal and distal 
radius. The forearm is placed in a water bath to provide a constant thickness of 'soft 
tissue' density, and the absorption of photons is then compared to a sample of bone 
with known mineral content. Dual energy X-ray absorptiometry (Stein et al. 1988) 
scans the entire skeleton and associated soft tissue with an X-ray beam of around 2mm 
diameter, the differential absorption of two energy intensities being used to derive the 
mineral content in a given area of bone. Reference ranges exist for the bone mass in 
the radius (using SPA), lumbar vertebrae and neck of femur (using DEXA) because of 
the increased risk of osteoporotic fractures in these regions, but are not widely 
reported for the feet (Seeman and Martin 1989). 
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The reduced bone mass reported in the feet of neuropathic diabetic patients 
(Cundy et al. 1985) can be expected to lead to a direct reduction in bone strength, as 
over 90% of the variance in bone strength is due to differences in bone mass (Carter 
and Hayes 1977). Such a reduction in bone strength, together with the increased risks 
of tripping and falling (Cavanagh et al. 1992), and the increase in repetitive trauma 
from higher foot pressures in neuropathic diabetic patients (Veves et al. 1991b) might 
be expected to contribute to the increased risk of foot fractures in reported in diabetic 
patients (Paganini-IFEII et al. 198 1). Whilst the association between unperceived 
recurrent minor trauma and stress-fractures has been made (Baldwin and Black 1986), 
the report of fractures with no history of injury (Coventry and Rothacker 1979) is 
probably a reflection of the degree of insensitivity to pain that may be present in 
neuropathic patients. 
The risk of a fracture acting as an initiating event in Charcot neuroarthropathy 
has also been previously described (Johnson 1967, Connolly and Jacobsen 1985) and 
small periarticular fractures are a common early finding in patients with Charcot 
neuroarthropathy (McEnery et al. 1993). 
Periosteal. reaction along the metatarsal shafts is reported to be a common non- 
specific finding in radiographs of the diabetic foot (Williams et al. 1988), however 
another possible explanation for this finding is the elevated plantar pressure at the 
metatarsal heads in diabetic patients. In animal studies increased mechanical stress has 
been demonstrated to induce periosteal reactions (Uhthoff and Jaworski 1985) but this 
association has not been made in man. 
Other radiographic findings, including exostoses and pencilling of the 
metatarsal heads are reported as 'common' in diabetes (Geoffroy et al. 1979) but there 
are few studies with matched control groups to allow for valid comparisons of the true 
effects of diabetic neuropathy on the structure of the foot. 
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Medial arterial calcification 
Medial arterial calcification has been reported to be more ftequent in patients with 
diabetes than in healthy subjects (Morrison and Bogan 1929, Strandness et al. 1964, 
Ferrier 1964, Neubauer 1971), and is reported to be associated with diabetic 
peripheral somatosensory and autonomic neuropathy (Edmonds et al. 1982b, Goebel 
and Fuessi 1983, Everhart et al. 1988). Few previous studies have examined the 
distribution of medial arterial calcification quantitatively within the diabetic foot- 
Medial arterial calcification is significantly associated with an increased prevalence of 
cardiovascular mortality (Everhart et al. 1988, Lachman et al. 1977, Nillson et al. 
1967, Janka et al. 1980), although this may also be related to the increase in medial 
arterial calcification associated with diabetic nephropathy (Edmonds et al. 1982b, 
Goebel and Fuessi 1983), an independent marker of increased mortality in diabetes 
(Jensen et al. 1987). 
Peripheral vascular disease is more common in diabetic patients than healthy 
control subjects (Janka et al. 1980) but the relationship between medial arterial 
calcification and the development of clinically important peripheral vascular disease is 
disputed (Neubauer et al. 1971, Goebel and Fuessi 1983, Nillson et al. 1967, 
Chanteleau et al. 1990). However, screening for the presence of peripheral vascular 
disease in diabetic patients usually involves clinical examination of the foot pulses and 
a measurement of the ankle brachial pressure index (Carter S 1969, Yao et al. 1969, 
CutaJar et al. 1973). Medial arterial calcification, when present, is known to alter the 
pulse waveform and falsely elevate ankle pressures in diabetic patients (Reimann and 
Bollinger 1974, European Consensus 1989). For this reason it has been suggested that 
toe systolic pressure measurements might replace ankle-pressure measurements as an 
index of arterial inflow to the diabetic foot (European Consensus 1989). However, 
the accuracy of toe pressure measurements would only be superior if medial arterial 
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calcification in the diabetic foot was less prevalent in the distal foot than the hind foot 
or ankle region and this has not been described in the literature and therefore such a 
study is required. 
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Charcot neuroarthropathy 
The original text of Jean Marie Charcot's descriptions of a destructive arthropathy 
which starts 'rather suddenly, without precipitating cause' in neuropathic patients was 
recently translated into English and republished (Charcot 1992). The original French 
text was published in 1868 (Charcot 1868) and described Charcot's observations of 
patients with tabes dorsalis. However, it was not until 1936 that the first case report 
of neuroarthropathy in a diabetic-patient was described (Jordarf 1936). Since thit-time 
the devastating effects of Charcot neuroarthropathy in the diabetic foot have been 
acknowledged (Sinha et al. 1972, Cofield et al. 1983, Sammarco 1991), and diabetes is 
now the commonest cause of Charcot neuroarthropathy (Fryckberg 1987), but it is 
fim-Ay held by those who regularly treat patients with Charcot feet that such changes 
are 'frequently overlooked' (Sanders and Frykberg 1993). The prevalence of Charcot 
change amongst 68,000 diabetic patients attending the Joslin Clinic was estimated as 
0.15% (Sinha et al. 1972) but rates as high as 7% (of 242 patients) in other clinic 
populations (Pogonowska et al. 1967), and 2.9% in a selected group of 333 
neuropathic diabetic patients (Cofield et al. 1983) have also been reported. 
Eighty percent of the patients who develop Charcot neuroarthropathy have a 
known duration of diabetes of over 10 years (Sanders and Frykberg 1993). The 
duration of diabetes appears to be more important than age alone, as there is a report 
of a series of 18 type I diabetic patients with Charcot neuroarthropathy, in whom the 
average age was 33.5 years (range 25-52), but in whom the mean diabetes duration 
was 20 years (Clohisy and Thompson 1988). The long duration of diabetes prior to 
the initiation of the Charcot process reflects the degree of neuropathy that is usually 
present in these patients. Recently it has been suggested that a specific small fibre 
neuropathy of cool perception is present in diabetic patients with Charcot 
neuroarthropathy (Stevens M et al. 1992b) although this would seem unlikely given 
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the wide range of conditions, including leprosy and syphilis, in which Charcot 
neuroarthropathy occurs, and the density of neuropathy at the time of the initiating 
event. 
The initiating event of the Charcot process is often a seemingly trivial injury 
(Sanders and Frykberg 1993), which may result in a minor periarticular fracture 
(McEnery et al. 1993) or in a major fracture (Johnson 1967, Connolly and Jacobsen 
1985), despite the inability of the patient to recall the injury in many cases. Following 
this there is a rapid onset of swcHing, an increase in temperature in the foor and often 
an ache or discomfort. The blood supply to the Charcot foot is always good (Sinha et 
al. 1972), indeed there are case reports of the Charcot process starting in patients 
following arterial bypass surgery (Edelman et al. 1987). It is assumed that autonomic 
neuropathy plays a part in the increased vascularity of bone, possibly by increased 
arterio-venous shunting (Edmonds et al. 1985), and this increases osteoclastic activity, 
resulting in the destruction, fragmentation, and remodelling of bone. It is these 
processes which, if left untreated, lead to the characteristic patterns of deformity in the 
Charcot foot (Sanders and Frykberg 1993), including the collapse of the longitudinal 
and transverse arches leading to a rocker bottom foot. 
The natural history of Charcot neuroarthropathy passes from this acute phase 
of development through a stage of coalescence, in which the bone fragments are 
reabsorbed, the oedema lessens and the foot cools, into the stage of reconstruction, in 
which the final repair and regenerative modelling of bone takes place, to leave a stable, 
chronic Charcot foot (Eichenholtz 1966). The time course of these events is variable 
but intervention must be made in the earliest phase to prevent subsequent deformity. 
The first principles of management are rest and freedom from weight-bearing. 
In the United States of America in particular, the practice of prolonged, (one year or 
more), immobilisation in a plaster of paris cast is the usual treatment (Sanders and 
Frykberg 1993). Even with this protracted period of casting the process can restart 
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once the cast is removed. The vogue for surgical stabilisation in the acute phase has 
now largely been abandoned because it often accelerated the destruction. However 
surgery may still be used, for example to remove a plantar prominence once the 
process has finally settled. The progress of the Charcot process may be determined by 
following clinical signs, skin temperature and radiographic change until they settle 
(Sanders and Frykberg 1991). In the United Kingdom total contact casting (Coleman 
et al. 1986), or bed-rest, are still the mainstays of treatment, although the Scotch-Cast 
Boot (Burden et al. 1983) is also used to provide a safer system of pressure 
redistribution. However, as yet there is no definitive treatment -aimed at the -underlying 
over-activity of osteoclasts in the active phase of Charcot neuroarthropathy. 
Reflex sympathetic dystrophy (Sudeck's atrophy) is thought to be a similar 
process to Charcot neuroarthropathy, precipitated by an injury and associated with 
swelling, increased skin temperature, pain, and bone destruction (Duncan 1990). A 
clinical trial of the use of intravenous pamidronate (Aredia, Ciba-Geigy), in patients 
with reflex sympathetic dystrophy proved successful in reducing the amount of bone 
loss, the swelling and associated discomfort (Rehman et al. 1992), all of which are 
seen in acute Charcot neuroarthropathy. Pamidronate is a bisphosphonate, one of a 
relatively new class of therapeutic agents. Bisphosphonates are analogues of the 
naturally occurring compound pyrophosphate that become attached to the surface of 
hydroxyapatite crystals in the skeleton and are potent inhibitors of osteoclastic bone 
resorption. Because of this they have become widely used in the management of 
metabolic bone disease being particularly successful in the treatment of 
hypercalcaemia, osteoporosis and Paget's disease. The bisphosphonates are well 
tolerated and appear to have few long term side effects (Fleisch 199 1). The success of 
pamidronate in the treatment of reflex sympathetic dystrophy led to the suggestion that 
this drug might prove useful in acute Charcot neuroarthropathy and to the pilot study 
described in Chapter 8. 
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Summary 
Peripheral neuropathy is a factor in 90% of foot ulceration in diabetic patients and is 
believed to be associated with the presence of medial arterial calcification, which may 
be a marker of increased mortality in diabetic patients. If present to a significant 
degree in the ankle plexus of patients with diabetes then medial arterial calcification 
may interfere with ankle systolic pressure measurements. In addition, skeletal changes 
as a result of peripheral neuropathy, together with the increased risk of injury, might 
be expected to increase the risk of traumatic foot fractures in neuropathic patients. As 
traumatic fractures are believed to initiate Charcot neuroarthropathy, then this too may 
be more prevalent in neuropathic diabetic patients than previously assumed. However, 
controlled studies of radiographic changes in the feet of diabetic patients have not been 
reported to confirm these proposals. 
The proposal of a specific neuropathic deficit in diabetic patients with Charcot 
neuroarthropathy seems unlikely given the broad range of conditions in which Charcot 
joints develop. If a generalised deficit was the usual pattern of neuropathy in diabetic 
patients with Charcot neuroarthropathy then this too could partly account for the high 
prevalence of Charcot change reported in some studies. 
Even if Charcot neuroarthropathy is a rare complication of diabetic 
neuropathy, a definitive treatment is still required, and there is indirect evidence to 
suggest that intravenous pamidronate may prove successful in this condition. 
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Chapter Two 
General Methods 
General 
All the studies performed in this thesis were approved by the Central Manchester 
Hospitals NHS Trust Ethical Committee. The patients and control subjects gave 
informed consent prior to their participation. 
The microvascular and neurophysiological measurements described in this 
thesis were made with the subject resting semi-recumbent on a couch in a warm room, 
with the temperature maintained above 25 *C. 
All the studies of rheological, fibrinolytic and microvascular parameters in 
diabetes were performed in the morning between 0900 and 1100. Patients and 
controls were asked to refrain from drinking tea, coffee or caffeine containing soft 
drinks from the evening prior to testing. Subjects were asked to attend after a fight 
breakfast of orange juice and dry toast. Blood glucose was monitored during all the 
neurophysiological and haematological tests. No patient was hypoglycaemic during 
the tests. Hypoglycaemia, reported in the 24 hours prior to testing, led to a 
postponement of tests in two patients, who were tested later. 
In all the studies IbAlc and HbAl were measured in the routine biochemistry 
service of the Manchester Royal Infirmary. The assay method used, and result 
reported, by the laboratory was changed during the course of this thesis and therefore 
both IbAlc and EbAl are used in this thesis. Where reported, insulin assays were 
measured independently by Dr Chris Gordon using a radioimmuno-assay for total 
insulin concentration with a total coefficient of variation of less than 9%. 
52 
Neurological assessments 
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Peroneal nerve motor conduction velocity 
Peroneal nerve motor conduction velocity (MCV) was measured with standard surface 
electrodes. A Medelec (Medelec, Woking, UK) neurophysiology system was used for 
all recordings. 
Nerve stimulation was performed proximally at the head of the fibula and 
distally on the shin, 10- 15 cm above the ankle, with the recording electrode over 
extensor digitorum brevis on the lateral border of the foot. All stimulations were 
performed using a supramaximal stimulus. Averaging of 30 stimulations was used in 
severely neuropathic patients when the action potential was reduced. Tracings were 
taken of the motor action potentials and the latencies were measured by an 
independent observer without knowledge of the subject's identity or oxygen 
measurement. 
The mean conduction velocity of both lower limbs was used for between group 
comparisons and in all correlation analyses, except where stated. In the studies of 
rheology and fibrinolysis in diabetic patients, patients were designated as neuropathic if 
they had a mean peroneal nerve motor conduction velocity of <40 ms-1 (Gregerson 
1967, Young R et al. 1986, Ford et al. 1992). 
In all intra-individual comparisons, the value for each leg was used as 
appropriate, as for example in the studies of the effects of arterial bypass surgery on 
peripheral nerve function, or in the study of neurological changes in Charcot patients, 
where the leg was designated as bypass or control, or Charcot or non-Charcot 
respectively. 
54 
Quantitative Sensory Tests 
Vibration Perception Threshold 
Vibration perception threshold was assessed using a Biothesiometer (Biomedical, 
Newbury, Ohio). The biothesiometers used during the course of the studies performed 
in this thesis had been recently calibrated, and where possible the same biothesiometer 
was used (Masson and Boulton 1990b). 
In the studies of radiographic changes in diabetic patients (Section 2) the 
vibration perception threshold was expressed as the mean of five ascending thresholds 
from each foot with the probe balanced perpendicular under its own weight, measured 
at the hallux, first metatarsal head, fifth metatarsal head, heel and on the dorsum of the 
mid-foot. This method was chosen to give a wider spread of values around the 
biothesiometer measurement ceiling limit of 50 V, in order to reduce the number of 
subjects with unmeasureable vibration perception thresholds. A mean vibration 
perception threshold of 30 V was used as the dividing line between neuropathic and 
non-neuropathic groups because of the high median age of the subjects (Bloom et al. 
1984). 
In the study of the differences between Charcot and non-Charcot patients, 
vibration perception threshold was measured as the mean of three ascending thresholds 
measured with the probe balanced perpendicular, under its own weight, on the pulp of 
the great toe. 
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Thennal Perception Thresholds 
Thermal perception thresholds were measured using the Amsterdam 
Thermoaesthesiometer and a forced choice protocol (Bertlesmann et al. 1985). The 
temperature of the skin of the chosen test site on the dorsum of the foot was measured 
using the integral thermo-couple, this was the reference temperature. One of the two 
test plates was set at the reference temperature and the second plate at a chosen -- 
temperature difference above or below the reference temperature. Each plate was then 
applied in turn, at random, and the subject asked which plate was warmer, whilst 
measuring warm thermal perception threshold, or cooler whilst measuring cool thermal 
perception threshold. The temperature difference was reduced until the subject was 
unable to accurately detect the difference in temperature. Repeated assessments with 
small variations around the presumed threshold are then performed, as in the method 
of limits. This determines the thermal perception threshold for an individual patient. 
Neurological disability score 
The neurological disabilty score used in the studies of Charcot and non-Charcot 
patients was that devised for the epidemiological survey of neuropathy in the United 
Kingdom, as this scoring system was known to correlate with vibration perception 
threshold, r--0.8, p<0.001 (Young M et al. 1993a). The score was derived from 
examination of the ankle reflexes, and vibration, pin-prick and temperature (cold 
tuning fork) sensation at the great toe in both feet. Each of the sensory modalities 
were scored as either normal=O or abnormal= I and reflexes as nonnal=O, present with 
reinforcement= 1 or absent=2 for each side. Thus the maximum total deficit score was 
10. 
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Autonomic function tests 
Cardiovascular autonomic function tests were performed on patients in the study of 
differences between neuropathic patients with and without Charcot autonomic 
neuropathy. Three tests of heart rate variation were used to assess autonon-k 
function. (Young P, et al 1986). These were: 
1. R-R Inspiration : Expiration ratio during deep breathing 
Patients were asked to inhale and exhale deeply for five breaths and the mean 
variation in R-R between inspiration and expiration was derived. 
2. Valsalva manouevre 
Patients were asked to perform a maximum expiration against a closed glottis 
for 15 seconds. The 30: 15 ratio of R-R intervals before the manoeuvre and after 
release was then calculated. 
3. Postural change 
The lying: standing R-R interval ratio was also assessed. 
All heart rate changes were compared to age related normal values (O'Brien et al. 
1986), and were reported as abnormal if two of three were abnormal. 
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Vascular assessments 
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Transcutaneous oxygen measurements 
Transcutaneous oxygen was measured using a TINA TCM3 meter, (Radiometer, 
Copenhagen, Denmark), at 44 *C on the dorsum of the foot over the muscle extensor 
digitorurn brevis (EDB) in all studies. The electrode was calibrated with a standard 
oxygen / 20% carbon dioxide source and adjusted to atmospheric barometric pressure 
each time it was used. The electrode was attached to a self-adhesive fixation ring-with 
a glycerol surface wetting agent added and left in place for 20 tninutes A stable 
reading of more than one minute after this time was used for the analysis. 
The within subject coefficient of variation of the oxygen tension using this 
method was assessed by measuring one subject daily for ten days and was 2.4%. This 
is better than previously reported (Lukkari-Rautiarinen et al. 1989), and may reflect 
the later model monitor used in this study, the improved calibration system, the longer 
site time allowed before a reading was taken, and the higher mean p02 of the subject 
tested. 
Again, the mean transcutaneous oxygen of both feet was used in any 
correlation and regression models to limit the values to one per patient. 
Laser Doppler flowmetry 
Laser Doppler flowmetry was measured on the dorsum of the foot with a Periflux PF3 
laser Doppler perfusion monitor (Perimed, Stockholm, Sweden) at native skin 
temperature before, and at 44 'C immediately following measurement of TcP02 and at 
the same site. Measurements were taken using the standard perpendicular probe and 
holder, attached to the skin with the double sided adhesive rings supplied. All readings 
were taken at 12 kHz bandwidth. The within subject coefficient of variation was 
measured at 17% at 44 oC. Readings were taken for I minute per recording. 
Baseline value was set to zero. 
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Skin temperature 
Skin temperature was measured using a Nlikron Infra-Red thermometer (Mikron 
Instrument Company, Inc., New Jersey, USA). 
In the studies of of the relationships between tissue oxygenation, and 
reconstructive vascular surgery and neurological function (Chapter 4), the temperature 
of the foot was measured on the dorsum of each foot over the belly of EDB, after 30 
minutes equilibration with room temperature. A mean of three readings was-take-n- at 
each site. The within subject variation for this method was 3%. 
In the study of the use of pamidronate in the treatment of Charcot 
neuroarthropathy (Chapter 9), to allow for the changes in temperature which might 
result from differences in ambient temperature over such a prolonged period of study, 
the temperature of the affected foot was expressed as the difference between the 
maximum temperature recorded on the affected side and the mean of four readings 
(three dorsal and one plantar) from the non-affected foot. The intra-individual 
coefficient of variation using this method was assessed by repeated measurement of 
patients during the assessment period prior to pamidronate treatment and was <3%. 
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Ankle Systolic Pressure and Ankle / Brachial Pressure Indices 
Ankle systolic pressures were measured with a Doppler ultrasound stethoscope 
(Sonicaid, Oxford, UK). A standard blood pressure cuff was placed around the calf, 
above the ankle. The ultrasound probe was placed over the dorsalis pedis artery, or 
tibialis posterior if the dorsalis pedis was not detectable, and the cuff inflated until the 
flow was occluded. The ankle systolic pressure is taken as the pressure at which the 
pulse waveform returns. Incompressible arteries were given a pressure of 300mmHg. 
The ankle brachial pressure index is derived by dividing the ankle systolic 
pressure by the brachial systolic pressure. 
The mean ankle pressure and ankle brachial systolic ratios were used in all 
correlations to supply one value per patient in order to prevent the artificial elevation 
of the significance of the result which occurs when a given correlation has twice as 
many variables associated with it. 
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The Measurement of 
Rheological and Fibrinolytic Parameters 
62 
Rheological Parameters 
General 
All subjects had blood samples taken after resting semi-supme in a warm room, 
minimum temperature 24 T, for at least ten minutes. Blood samples were drawn 
without occlusion using a 19G butterfly cannula into multiple polypropylene syringes 
and anticoagulated with potassium EDTA. All the blood samples in this study were 
analysed blindly by Mrs S Liderth and Mrs J Bennett to avoid potential bias of the_ 
results. Rheology was performed on whole blood (except plasma viscosity). 
No measurement had a total coefficient of variation of greater than 10%. 
Individual parmneters 
The following rheological parameters were assessed using recognised techniques 
(MacRury et al. 1991,1993a, b). 
Red cell deformability was measured using a Carri-Med St. George filtrometer 
(Carri-Med, Dorking LJK) which measures the transit of red cells through a micropore 
filter (Dormandy et al. 1980). The results are expressed as red cell filtration index. 
Red cell aggregation was measured using a photometric method with a 
Myrenne cone-plate aggregometer (Myrenne GMBfL Roetgen, Germany). 
Plasma viscosity was measured at 37 "C using a Coulter-Harkness Viscometer 
(Coulter Electronics Ltd., Harpenden, Hertfordshire, UK). 
Fibrinogen was measured using the Claus method (Claus 1957) in an ACL 300 
Coagulation Laboratory analyser (Instrumentation Laboratory Ltd, Warrington UK. ) 
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Whole blood viscosity 
Whole blood viscosity was measured at 37 *C using a Contraves Low Shear 40 
viscometer (Contraves Industrial products, Ruislip, UK). This uses a rotational bob 
viscometer method (Isogai et al. 1984), and is able to measure whole blood viscosity 
over a range of shear rates. The shear rates chosen in this study were 100 s- I (I-1igh 
Shear), I s-1 (Low Shear) and 0.01 s-1 (Very Low Shear), (MacRury and Lowe 1990, 
MacRury et al. 1991). The sample was measured at native haematocrit (measured in a 
Hawkesley microcentrifuge, Gallenkamp, Glasgow, UK) and then the result was 
corrected to a standard haematocrit of 45% as previously described (Matrai et al. 
1987). 
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Measurement of Fibrinolytic Parameters 
General 
Blood samples were taken from the antecubital fossa with a 19G butterfly needle into 
multiple syringes. Samples were then mixed in a 0.9: 0.1 ml ratio with sodium citrate 
in tubes which were kept at 4 *C on ice. Nothing was added to the samples for PAI 
estimation, but an additional step was required for the samples to be used in the t-PA 
activity assay. The citrated blood samples, in Iml aliqouts, were immediately acidified 
in Iml acetate buffer solution. Both sets of samples were then centrifuged in a cooled 
centrifuge (temperature 4 'C) at 3000 rpm prior to being snap frozen in liquid nitrogen 
and stored at -70 *C until analysed simultaneously at the end of the study by Mrs S 
Liderth and Dr J Douglas, again without knowledge of an individual subject's study 
group. 
Samples were measured before, and at the end of fifteen minutes venous 
occlusion of the arm. Venous occlusion is known to stimulate fibrinolysis in normal 
subjects (Wieczorek et al. 1993). Venous occlusion was achieved by placing a 
sphygmomanometer cuff around the upper arm and inflating to half-way between 
systolic and diastolic blood pressures (Wieczorek et al. 1993). 
Activity assays were chosen because of the problems associated with binding 
of t-PA antigen during activated thrombosis leading to potentially inaccurate results 
(Grant 1991). 
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Individual parameters 
The following direct measures of fibrinolytic activity were used: 
Tissue Plasminogen Activator (t-PA) Activity 
t-PA activity was analysed using an ELISA technique and a standard commercial test 
kit, (COA-SET t-PA, Chromogenix AB, MoIndal, Sweden). 
Plasminogen Activator Inhibitor (PAI-1) Activity 
PAI- I activity was analysed using an ELISA technique and a standard commercial test 
kit, (COA-SET PAI, Chromogenix AB, MoIndal, Sweden). 
All analyses were perfomed using the recommended standard procedure as described 
in the product instructions. The plates of ELISA test cells were read automatically 
using a Dynatech MR7000 plate reader (Dynatech Laboratories, Billinghurst, Sussex). 
The inter-assay coefficients of variation were around 6% for both the t-PA and PAM 
assays,. 
Results were expressed as levels of Activity units ml-I and also as t-PA/PAI-I 
ratios to give a measure of the balance of fibrinolytic activity (Grant 199 1). 
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Measurement of Prostacyclin and Thromboxane 
The blood samples used for these assays were taken at the same time as the other 
samples, and without occlusion. The samples were placed into tubes containing 
EDTA and 0.05 n-d of 0.04M Indomethacin solution, to inhibit arachidonic acid 
metabolism. 
Prostacyclin 
Prostacyclin (PG12) is unstable in plasma, with a half life of around three minutes, and 
degrades via hydrolysis to 6-keto-prostaglandin F I. This can then be measured, and, 
as the reaction displays first order kinetics, is a direct measure of prostaglandin 
production (Cho and Allen 1978). 6-keto-prostaglandin FI was measured using a 
standard commercial ELISA kit, Biotrak 6-keto-prostaglandin FI 
enzymeimmunoassay (EIA) system (Amersharn International p1c, Amersham, UK). 
Thromboxane 
Thromboxane (TXB2) is the stable degradation product of Thromboxane A2 and was 
the compound measured in this study to reflect thromboxane synthesis in vivo. TXB2 
was measured with a standard commercial test kit, Biotrak Thromboxane B2 
enzymeimmunoassay (EIA) system (Amersham International p1c, Amersham, UK). 
The Thromboxane B2 was estimated using the standard liquid phase technique 
outlined in the assay instructions. 
Both assays were read using the Dynatech MR 7000 automated plate reader. The' 
concentrations of 6-keto-prostaglandin-F. 1 and TXB2 are expressed as ng m17 
Ile 6-keto-PGF1 and TXB2 assays were each-performed simultaneously using one kit 
only. Ile intra-assay coefficients of variation (using three assays of the internal 
standards) were 6.2% and 5.8% respectively, 
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Radiographic Techniques and Analysis 
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Technique for Weight Bearing Radiographs of the Feet 
Weight-bearing (standing) true antero-posterior (A-P) and lateral radiographs 
were taken of each foot using a standardised protocol and fine grain x-ray film and 
screen (Kodak Ektamat G 100 film and X-omatic cassette with X-omatic fine 
intensifying screens, Kodak p1c, Hemel Hempstead, UK). All the radiographs were 
taken by a single radiographer. True lateral radiographs were taken with a horizontal 
beam centred 2cm above the fifth metatarsal head, the x-ray focus-film distance (FFD) 
was I 00cm, exposure 63 kV and 25 mAs. A-P radiographs were taken with a 20* 
cranial tilt from the vertical at FFD 80cm, 63 kV and 20 mAs. Each foot was imaged 
separately with the beam centred on the second metatarsophalangeal. joint. A 
plasticine wedge filter was used for the dorsi-plantar view to create a uniform 
exposure over the toes. There is little radiosensitive tissue, and no bone marrowin 
the adult foot and the radiobiological equivalent dose from these radiographs was 
calculated at 1 00th that of a standard chest x-ray (Judith Adams, personal 
communication). 
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Interpretation of Radiographic Findings 
A scheme for interpretation of the radiographs was devised in which the 
abnormalities in the soft tissue, tendons, joints, and bones shown in Table 2.1 were 
assessed in different regions (Table 2.2) of each foot and ankle. Abnormalities, such 
as fractures (Figure 2.1) or evidence of infection, were assessed as either present or 
absent. Periosteal reaction (Figure 2.2), medial arterial calcification (Figure 2.3,2.4) 
and similar quantitative changes were graded as absent, moderate, or marked. All the 
radiographs were interpreted by the same consultant radiologist (DrJudith Adams) 
who was unaware as to whether the film was from patient or control. An abnormality 
was judged present in a given patient if observed in one or both feet. 
The designation of a Charcot process (Figure 2.5) required the simultaneous 
presence of bone and joint destruction and fragmentation, together with hypertrophic 
periosteal reaction (Cofield et al. -1983). Any missing bone, including individual 
phalanges, due to surgical intervention was deemed an amputation. Medial arterial 
calcification was defined as parallel tran-dine calcification and, if present, was graded as 
mild or severe according to previously published criteria (Morrison et al. 1929). 
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Table 2.1. Categories of abnormalities assessed for each component of the foot. 
Bones Joints Soft Tissues 
Destruction Dislocation Arterial calcification 
Fractures Exostoses 
Fragmentation Narrowing 
Infection Sclerosis 
Osteopaenia Subluxation 
Pencilling Widening 
Periosteal reaction 
Waisting 
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Table 2.2. Regions of the foot examined for each category of abnormality. 
Bones Joints Soft Tissue 
Phalanges Inter-phalangeal Toes 
Metatarsals Metatarsophalangeal Metatarsal 
Tarsus Lisfranc's Mid-foot 
Calcaneus Intertarsal I-Endfoot 
Talus Chopart's Ankle 
Tibia/Fibula Subtalar 
Talocrural 
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Figure 2.1. Fractures through the shaft of the fifth metatarsal and bases of the 2nd, 
3rd and 4th metatarsals. The patient gave no history of trauma that might have 
resulted in these fractures. 
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Figure 2.2. Moderate degree of periosteal reaction along the shafts of the 2nd and 3rd 
metatarsals. 
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Figure 2.3. Heavy medial arterial calcification between the I st and 2nd metatrsal 
shafts showing classical tramline appearance. Patient had peripheral neuropathy and a 
raised serum creatinine. 
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Figure 2.4. Heavy medial arterial calcification of the posterior tibial and plantar 
arteries. 
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Figure 2.5. Charcot neuroarthropathy. Destruction and fragmentation of the mldfoot 
with loss of bone architecture and dislocation, and subluxation of the midfoot joints. 
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Bone Mass Measurement 
Bone mass was measured at the proximal and distal radius using single photon 
absorptiometry (SPA) and in the lumbar spine and both femoral necks using dual 
energy absorptiometry (DEXA), as part of the routine clinical service of the University 
Department of Radiology. Results were compared to the age, sex and weight related 
normal ranges for this department. Results are expressed as Z scores of deviance from 
the normal bone mass (a score of 0). AZ score of -I or less is indicative of increased 
fracture risk and -2 or less reflects highly significantly reduced bone mineral content 
(Seeman and Martin 1989). 
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Protocol for treatment with Pamidronate 
Each subject received intravenous infusions of parnidronate according to an 
established protocol for the treatment of Paget's disease of bone (Anderson et al. 
1993). Treatment commenced with an infusion of 30mg pamidronate (Aredia, Ciba 
Laboratories, Horsham, W Sussex, UK) in 250ml 0.9% saline over two hours. This 
was followed at fortnightly intervals by five further infusions of 60mg pamidronate in 
500ml saline over four hours. 
If patients had complained of any mild febrile reaction following the previous 
dose, they were given paracetamol Ig prior to subsequent infusions and advised to 
take paracetamol at regular intervals for 24 hours. 
Prior to the commencement of each infusion, and two weeks after the final 
infusion, the skin temperature was measured in the Charcot and non-Charcot foot 
using the infra-red thermometer, (detailed on page 60), and blood was taken for serum 
creatinine, calcium, phosphate and alkaline phosphatase. 
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Statistical Methods 
All the descriptive and standard comparative statistics were analysed using Minitab 
Software (Minitab Inc., State College, Pa, USA). Paired results were analysed using 
Student's West or Wilcoxon rank sum tests. Multiple comparisons were made using 
analysis of variance or Kruskal Wallis tests with appropriate follow up tests to 
determine the site of apparent differences. Correlations were analysedwith Spearman 
Rank corelations and tests of association with Chi-squared tests. 
The complex statistical methods used to model the relationship of medial 
arterial calcification and neuropathy, and the analysis of the response to Pamidronate, 
are detailed in the appropriate sections of this thesis, in proximity to the results they 
describe, to aid cross reference. 
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Section Two 
Studies of the Microvascular Hypothesis of 
the Aetiology of Diabetic Neuropathy 
Chapter Three 
Rheology, Fibrinolysis and Microvascular Blood Flow 
in Diabetic Patients and Non-Diabetic Control Subjects 
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Patients and Control Subjects 
The diabetic patients were selected from the computer database of the Manchester 
Diabetes Centre. No diabetic patient had microalbuminuria, or retinopathy, as 
assessed by fundoscopy through dilated pupils. Microalburninuria was assessed by 
timed overnight collection of urine, and no patient had an overnight albumin excretion 
rate of more than 20 pg min-1. Neuropathy was defined as a peroneal conduction 
velocity of less than 40 ms-1. Twelve neuropathic type I diabetic patients were age 
and sex matched to twelve non-neuropathic type I patients (Table 3.1). Twelve type 2 
neuropathic patients were similarly matched to twelve non-neuropathic patients (Table 
3.2). For the purposes of these studies the type I and type 2 diabetic patients were 
considered in combined groups of neuropathic and non-neuropathic patients (Table 
3.3). 
Twenty-four control subjects were age and sex matched to the diabetic subject 
groups. Control subjects were drawn from the staff of the Manchester Royal 
Infirmary and spouses of the diabetic subjects, and all were in good health at the time 
of study. Control subjects were asked about symptoms of diabetes, and as to whether 
they had a family history of diabetes; no positive responses were obtained. All had a 
random blood glucose measured during the study, and all were less than 7 mmol 1-1. 
No diabetic patient or control subject smoked, and none was taking aspirin, 
non-steroidal anti-inflammatory drugs or evening primrose oil at the time of study. 
Patients taking vasoactive medication, such as B-blockers, calcium antagonists 
and_ACE inhibitors were also excluded from the study. 
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Table 3.1. Physical characteristics of the type I patients in this study. 
Type 1 
Non Neuropathic 
Type 1 
Neuropathic 
Number 12 12 
Age (years) 43.4 (33.3-47.5) 38.6 (35.1-46.4) 
Duration of diabetes (years) 31.0 (15.0-33.0) 22.0 (11.2-27.7)_ 
Insulin (U n-d-I) 21.0 (14.0-28.0) 40.0 (5.0-110.0) 
Glucose (mmol 1-1) 7.4 (4.9-18.7) 16.4 (13.0-21.8) 
HbA I (1/o) 10.0 (7.8-11.8) 10.2 (8.9-11.3) 
Total Cholesterol (mmol 1-1) 5.20 (4.80-5.60) 5.8 (5.4-6.6) 
Creatinine (pmol 1-1) 81.0 (71.5-86.2) 79.0 (75.0-97.0) 
Weight (kg) 70.0 (62.8-83.8) 71.3 (60.0-88.0) 
Height (m) 1.73 (1.66-1.75) 1.72 (1.65-1.80) 
BMI (kg m-2) 23.4 (21.5-28.1) 22.9 (22.0-26.8) 
Systolic blood pressure (mmHg) 116 (110-139) 126 (116-145) 
Diastolic blood pressure (mmHg) 70(61-80) 70(63-80) 
Results are shown as median (interquartile range). 
There are no significant differences between any of the parameters. 
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Table 3.2. Physical characteristics of the type 2 patients in this study. 
Type 2 
Non-Neuropathic 
Type 2 
Neuropathic 
Number 12 12 
Age (years) 49.2 (44.5-53.5) 56.5 (49.9-60.6) 
Duration of diabetes (years) 5.0 (4.4-15.5) 4.0 (3.0-10.0) 
Insulin (U nil-1) 11.5 (5.5-18.5) 9.0 (6.2-17.7) 
Glucose (mmol 1-1) 11.0 (8.7-13.6) 9.8 (8.7-12.7) 
HbA I (1/o) 8.5 (8.0-9.7) 8.8 (7.7-10.6) 
Total Cholesterol (mmol 1-1) 6.6 (5.3-6.9) 5.3 (4.8-7.5) 
Creatinine (gmol 1-1) 76.0 (64.2-81.2) 87.0 (67.0-92.0) 
Weight ft) 77.7 (69.6-86.7) 80.2 (70.0-87.9) 
Height (m) 1.66 (1.62-1.72) 1.72 (1.67-1.76) 
BMI (kg M-2) 28.9 (69.6-86.7) 26.5 (23.9-31.6) 
Systolic blood pressure (mmHg) 139 (116-159) 164 (143-173) 
Diastolic blood pressure (mmHg) 82(75-90) 84(76-92) 
Results are shown as median (interquartile range). 
There are no significant differences between any of the parameters. 
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Table 3.3. Physical characteristics of the study groups 
Non-diabetic 
control subjects 
P 
Non-neuropathic 
diabetic patients 
(D) 
Neuropathic 
diabetic 
patients (N) 
Number 24 24 24 
Male: Female 11: 13 13: 11 11: 13 
Age (range' ) (years) 42.5 (25-68) 44.1 (29-60) 48.1 (26-67) 
Type of diabetes IJI 12: 12 12: 12 
Duration of diabetes - 17.4 ± 11.6 15.6 ± 12.3 
(years) 
Creatinine (gmol 1-1) 63.0 ± 11.0 77.1 ± 10.8 85.1 ± 11.9* 
Cholesterol (mmol 1-1) 4.6 0.7 5.5 ± 1.1 6.0 ± 0.9* 
HbAl (%) - 9.3 ± 2.0 9.9 ± 1.8 
Insulin (U rrA- 1) 9.6 6.6 15.8+8.8 18.5 ± 28.2 
Glucose (mmol 1-1) 5.0 0.7 11.9 6.9 14.9 ± 6.3 
Systolic BP (mmHg) 120 20 125 23 145 ± 22* 
Diastolic BP (mmHg) 74 ± 12 73 ± 11 78 ± 11 
BMI (kg M-2) 25 ±3 22 ±5 26± 5 
All results (except age) are shown as mean ± SD. Age is shown as mean (range). 
There were no significant differences between any of the parameters except creatinine 
(p<0.05 N vs. Q, cholesterol (p<0.01 N vs Q, and systolic blood pressure (p<0.05 N 
vs. 
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Methods 
All diabetic patients and control subjects were seen after a light fat free breakfast. No 
diabetic subject was hypoglycaemic at the time of study, or had symptomatic or 
biochemical hypoglycaemia for 24 hours preceding the study. After resting semi- 
recumbent in a warm room for at least ten minutes, blood samples were drawn without 
occlusion for rheological and fibrinolytic parameters. Venous occlusion was then 
performed using a sphygmomanometer cuff inflated to half way between systolic and 
diastolic blood pressures for 15 minutes after which time blood was drawn for post 
venous occlusion assessments of fibrinolysis. The measurement of the rheological and 
fibrinolytic parameters is further described in the Methods (Chapter 2, pages 62-67). 
Transcutaneous oxygen tensions and laser Doppler flux were then measured on 
the dorsum of the foot over extensor digitorum brevis. Finally, measurements of the 
peroneal nerve motor conduction velocities in both legs were performed. The 
microvascular and neurophysiological assessment methods are detailed in Chapter 2, 
pages 53-60. 
Statistical Analyses 
Multiple group comparisons were initially performed by analysis of variance and 
Kruskal-Wallis, tests (Mnitab Software, Mnitab Inc., State College, Pa. ), with 
appropriate follow up tests. 
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Results 
Rheological Parameters 
Patients 
The type 2 diabetic patients were significantly older than the type I patients and had a 
shorter duration of diabetes (Tables 3.1,3.2). However, as only red cell filtration 
correlated weakly with duration of diabetes r= -0.35, p<0.05, and was not 
significantly different between the type I and type 2 diabetic patients, the two types of 
diabetes were combined to form one group of neuropathic patients and one group of 
non-neuropathic patients with equal numbers of type I and type 2 patients in each 
(Table 3.3). 
Individual parameters 
The results of the neurophysiological, circulatory and rheological parameters are 
shown in Table 3.4. 
Nerve conduction was reduced in the 'non-neuropathic' diabetic patients when 
compared to control subjects and by definition was lower in the neuropathic diabetic 
patients (p = 0.043 C vs D, p<0.0001 D vs N). Transcutaneous oxygen tension, 
measured at 44 *C, was significantly lower in the neuropathic diabetic patients when 
compared to non-diabetic control subjects and non-neuropathic diabetic patients 
(p=0.017NvsCandNvsD). There was no significant difference in the laser Doppler 
flux between the non-neuropathic diabetic patients and the non-diabetic control 
subjects, but the neuropathic diabetic patients had a lower laser Doppler flux when 
compared to controls (C 72 ± 40 vs D 64 ± 41 vs N 50 ± 26 flow units, p= NS C vs 
D, p=0.04 N vs Q. 
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No significant change in any of the rheological parameters measured was found 
between diabetic patients without neuropathy and the non-diabetic control subjects. 
Red cell deformability was sinfilar in all groups (Table 3.4). 
The neuropathic diabetic patients had a significantly higher red cell 
aggregation, plasma viscosity, and fibrinogen concentration than non-diabetic control 
subjects (Table 3.4). Red cell aggregation and fibrinogen concentrations were higher 
in the neuropathic diabetic patients than in the non-neuropathic diabetic patients (Table 
3.4). 
Whole blood viscosity at 100 s- I and I s- I was significantly higher in the 
neuropathic diabetic patients compared to the non-diabetic control subjects. There 
were no significant differences in whole blood viscosity at these shear rates between 
neuropathic and non-neuropathic diabetic patients, and no significant differences 
between all groups measured at 0.01 s- I (Table 3.4). 
In the diabetic patients as a whole, fibrinogen concentrations correlated 
negatively with transcutaneous oxygen measurements r= -0.49, p<0.001 and peroneal. 
nerve conduction velocity r= -0.40, p<0.01. Red cell aggregation was significantly 
negatively correlated with transcutaneous oxygen concentration r= -0.36, p=0.02, but 
not with peroneal conduction velocity, r= -0.27 (p=O. 1). 
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Table 3.4. Results of microvascular and rheological tests in each of the three groups 
of subjects. 
Non-diabetic Non- Neuropathic p value 
control neuropathic diabetic 
subjects diabetic patients 
patients 
Peroneal. 
conduction 51.7: L 6.0 45.1 ± 5.2 34.5 ± 5.8 p<0.05 C vs D 
velocity (ms-1) - p<0.0 fN vs C 
Transcutaneous 
oxygen (mniHg) 76.0: L 16.3 71.1 ± 10.3 62.9 ± 8.7 p<0.05 N vs C 
Laser Doppler 
flux (flow units) 72 ± 40 64 ± 41 50 ± 26 p<0.05 N vs C 
Red cell 
filtration (U) 0.54± 0.03 0.52 ± 0.05 0.52 ± 0.04 p=NS - 
Red cell 
aggregation (U) 6.5 ± 1.8 6.7+1.6 8.8+2.0 p<0.05 N vs C 
Plasma viscosity 
(mPas-1) 1.21 ± 0.04 1.24 =L 0.10 1.27 ± 0.06 p<0.05 N vs C 
Fibrinogen (g 1-1) 2.9 ± 0.6 
I 
3.0 ± 0.8 3.6 ± 0.8 p<0.05 N vs C 
Whole blood viscosity (Corrected to 45% haematocrit) (mPas-1) 
loos-I 
I S-1 
5.2 ± 0.4 
17.5 ± 2.9 
5.4 ± 0.8 5.7 ± 0.6 
19.6 ± 3.5 
61.5 ± 18.4 
p<0.05 N vs C 
O. Ols-I 
17.9 :h3.7 
67.4 ± 17.7 60.4 ± 12.2 
All results are shown as mean ± SD. 
p<0.05 N vs C 
p=NS 
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Thromboxane and Prostacyclin 
Thromboxane (TXB2) 
There was no significant difference in plasma TXB2 concentrations between the 
diabetic groups and the non-diabetic control subjects. (Table 3.5). 
Prostacyclin 
Peripheral venous prostacyclin was reduced in neuropathic diabetic patients compared 
to non-diabetic control subjects, mean 0.11 ± 0.07 ng ml-I vs 0.18: L 0.05 ng ml-1, 
p=0.03, with non-neuropathic diabetic paitents having an intermediate level of 
prostacyclin (0.18 -+ 0.13 ng rnl- 
1), (Table 3.5). 
Prostacyclm / Thromboxane ratio 
The balance of Pi6stacýclin'/ Thromboxane concentrations was also reduced in 
neuropathic diabetic patients (0.65 ± 0.30 ng ml-1) when compared to non-diabetic 
control subjects (0.91 ± 0.21 ng ml-1), p=0.01, but just failed to reach standard 
significance versus non-neuropathic diabetic patients (0.84 ± 0.26 ng ml-1), p=0.07. 
Table 3.5. Thromboxane B2 and 6-keto prostaglandin FI concentrations in peripheral 
venous blood in neuropatl& (N) and non-neuropatMc (NN) diabetic patients and non- 
diabetic controls (C). 
6-keto PGFI (ng ml-1) 
TXB2 (ng ný- 1) 
PC / TXB2 ratio 
N NN 
0.11 ± 0.07 0.18 ± 0.13 0.18 ± 0.06 
0.17 ± 0.08 0.18 ± 0.14 0.19 ± 0.05 
0.65 ± 0.30 0.84 ± 0.26 0.91 ± 0.21 
Results are expressed as mean ± SD. 
91 
p value 
=0.03 N vs C 
NS 
=0.01 N vs C 
Fibrinolytic parameters. 
Results 
There was no difference in basal or stimulated fibrinolysis between type I and type 2 
patients (Table 3.6). Therefore, as with rheological variables, the two types of 
diabetes are considered together as two groups, non-neuropathic and neuropathic 
patients, for comparison with non-diabetic controls. The results are detailed in table 
3.7. 
In summary, when comparing the non-neuropathic and neuropathic diabetic 
patients with non-diabetic controls, basal levels of t-PA activity were similar in all 
groups. In the diabetic groups however the activity of PAM, the principal inhibitor of 
t-PA, was markedly increased. This resulted in significantly lower t-PA/PAI- I ratios 
in the diabetic groups. There was no significant difference between the neuropathic 
and non-neuropathic patients in basal levels of t-PA, PAI- I or in the t-PA/PAI- I ratio. 
Following 15 mins venous occlusion, the stimulated fibrinolytic response was 
significant greater in control subjects than non-neuropathic diabetic patients (t- 
PA/PAI-I ratio C 3.96 vs D 0.44, p<0.001), rising 21 times baseline. 
The final t-PA/PAI-I ratios (t-PA/PAI-I D 0.44 vs N 0.41, p=0.38), and 
fibrinolytic response to venous occlusion were similar in neuropatl& and non- 
neuropathic diabetic patients (D 8.5 vs N 5.0, p=0.67). 
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Table 3.6. Results of basal and stimulated fibrinolytic parameters in type I and type 2 
diabetic patients with no evidence of complications. 
Type I Diabetic Type 2 Diabetic 
Patients Patients 
Basal 
t-PA (Au ml-1) 1.0 (0.1-1. ) 0.5 (0.1-1.4) 
PAM (Au ml-1) 12.5 (2.5-15.0) 11.5 (7.7-20.4) 
t-PA/PAI-I ratio 0.09 (0.02-0.17) 0.05 (0.01-0.13) 
Post Venous Occlusion 
t-PA (Au H- 1) 3.5 (0.7-6.2) 5.2 (1.9-8.0) 
PAM (Au ml-1) 3.5 (0.1-16.7) 7.0 (0.8-20.2) 
t-PA/PAI-I ratio 1.42 (0.09-4.10) 0.46 (0.06-2.10) 
Results are shown as median and interquartile range. 
All comparisons p=NS. 
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Table 3.7. Results of basal and stimulated fibrinolytic parameters in control subjects, 
and non-neuropathic and neuropathic diabetic patients. 
Control subjects Non-Neuropathic Neuropathic p 
(C) (D) (N) 
Basal 
t-PA (Au ml-1) 0.9 (0.4-1.2) 0.9 (0.1-1.7) 0.4 (0.1-1.2) 
PAI- I (Au ml-1) 5.0 (3.4-8.3) 13.0 (5.5-15.5) 12.0 (2.0-19.5) 
t-PA/PAI-I 0.16 (0.06-0,39) 0.06 (0.01-0.14) 0.08 (0.01-0.12) 
Post Venous 
Occlusion 
t-PA (Au ml-1) 4. ý'(3.6-6.8) 6.5 (2.2-7.4) 4.9(l. 7-7.6) 
PAI- I (Au ml-1) 1.0 (0.5-7.0) 4.5 (0.1-15.0) 7.0 (0.4-20.4) 
t-PA/PAI-1 3.96 (0.50-8.89) 0.44 (0.01-1.44) 0.41 (0.11-3.23) *** 
Results are shown as median and interquartile range. 
* p=NS C vs D vs N. 
** p<0.05 C vs D or N 
*** p<0.05 C vs. N 
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Correlations 
Fibrinolytic activity was weakly inversely correlated with body mass index in both 
diabetic patients and control subjects, and diastolic blood pressure in controls. PAI- I 
levels increasing and t-PA levels generally decreasing with increasing BMI or blood 
pressure. Insulin and blood glucose concentration were not significantly correlated 
with fibrinolytic activity in diabetic patients or controls, nor was MAI in the diabetic 
groups. 
Table 3.8. Spearman rank correlation coefficients for t-PA and PAI- I with various 
indicators of 'insulin resistance' and diabetes control. 
Diabetic patients Control subjects 
PAM t-PA PAM t-PA 
BMI 0.36* -0.21 0.26 -0.45* 
Diastolic 0.12 -0.13 0.39* -0.43* 
Insulin -0.18 -0.08 -0.14 -0.14 
Glucose 0.08 -0.18 -0.26 0.05 
HbAl -0.17 0.08 
* P<0.05 
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Tissue oxygenation and nerve function 
Results 
Diabetic Patients 
In the diabetic patients Peroneal Nerve MCV correlated with TcP02, r--0.59 p<0.001, 
(Figure 3.1), but not with skin temperature, r--O. 16 p=NS. 
Comparing the leg with the higher TcP02 (mean 70.2 ± 9.3 (SD) mmHg) with 
that with the lower TcP02 (61.7 ± 2.1 mmHg) in each patient, peroneal nerve MCV 
was significantly higher, 45.3 ± 7.1 vs 41.5 ± 6.3 ms-1, p<0.001, though no significant 
difference in skin temperature was observed, 31.4 ± 0.4 vs 31.1 ± 0.5 T. 
Non-Diabetic Control Subjects 
In the non-diabetic controls subjects a similar correlation was found between tissue 
oxygenation and nerve conduction, r=0.7, p<0.01, Figure 3.2. 
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Figure 3.1. Relationship between mean 
transcutaneous oxygen and mean peroneal 
conduction velocity in diabetic patients. 
r=0.59, P<0.001 
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Figure 3.2. Relationship between transcutaneous 
oxygen and peroneal conduction velocity in 
non-diabetic controls. r= 0.7, P<0.01 
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Laser Doppler Flowmetry and Microvascular Reactivity 
Results 
The results are detailed in Table 3.9 and Figures 3.3-3.5. 
At native skin temperature (N 30.6 ± 2.0 OC, D 30.4 ± 1.4 OC, C 29.3 ± 2.1 OC), there 
were no significant differences in laser Doppler flux between the three groups of 
subjects (Table 3.9). There were also no significant differences in skin temperature 
between the three groups. 
Heating the skin to 44 OC caused a significant rise in laser Doppler flux in all 
three groups of patients (Figures 3.3-3.5). There was no significant difference in the 
maximal laser Doppler flux between neuropathic and non-neuropathic diabetic 
subjects. The mean maximal Laser doppler flux was 57.0 -+ 38.4 perfusion units in the 
diabetic patients and Laser doppler flux correlated with TcP02, r=0.36, p<0.01 
(Figure 3.6). 
The laser Doppler flux at 44 'C was significantly lower in the neuropathic 
diabetic patients when compared to control subjects (median (range) 49.0 (33.5-60.5) 
vs 76.5 (47.5-84.7), p=0.029). 
These results were also reflected in the proportional increase in laser Doppler 
flux in response to heating the skin to 44 *C. The increase in laser Doppler flux in 
non-diabetic subjects was 75.0 (56.0-88.2) times baseline, compared to 25.0 (11.9- 
70.0) in non-neuropathic diabetic patients (p = 0.03 vs Controls) and 29.2 (5.6-51.4) 
times baseline in neuropathic subjects (p = 0.005 vs Controls). 
There was no significant difference in the proportional increase in laser 
Doppler flux in neuropathic compared to non-neuropathic patients (p=0.63). 
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Table 3.9. Results of laser Doppler flux (LDF) measurements in the non-diabetic 
control subjects and the neuropathic and non-neuropathic diabetic patients. 
Non-diabetic 
control subjects 
Non-neuropathic 
diabetic patients 
Neuropathic 
diabetic patients 
Basal 
Mean LDF 1.2 ± 0.4 4.8 ± 4.7 2.8 ± 3.1 
Median LDF 1.0 (0.8-1.6) 3.5 (0.7-7.2) 1.4 (0.7-3.5) 
44 T 
Mean LDF 72.1 ± 38.7 64.2+41.2 50.0 ± 22.3 
Median LDF 76.5 (47.7-84.7) 42.0 (38.0-90.0) 49.0 (33.5-60.5) 
Proportional 
Increase in LDF 
Mean 69.4+23.9 49.1+61.6 31.2 ± 24.7 
Median 75.0 (56.0-88.2) 25.0 (11.9-70.0) 29.2 (5.6-51.4) 
Results are shown as mean ± SD and median (interquartile range). 
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Figure 3.3. 
temperature 
patients. 
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Figure 3.4. Laser Doppler f lux at native skin 
temperature and at 44 C in non-neuropathic 
diabetic patients. -- 
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Figure 3.6. Laser Doppler f lux at native skin 
temperature and at 44 C in non-diabetic controls. 
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Figure 3.6. Graph 
, 
of the relationship between 
laser Doppler flux at 44 C and transcutaneous 
oxygen tension in the diabetic patients. 
Spearman rank correlation r= 0.36, p<0.010 
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Chapter Four 
The Effects of Revascularisation on Peripheral Nerve Function 
105 
Patients and Methods 
Non-Diabetic Patients 
The non-diabetic patients selected for the study comprised ten consecutive patients 
with no past history of diabetes, mean age 59 (range 52-77) years, with 
angiographically proven superficial femoral artery thromboses suitable for unilateral 
femoro-popliteal bypass. 
All non-diabetic patients had fasting plasma glucose measurements on the day 
of operation and all were less than 6 mmol/l. 
Diabetic Patients 
The diabetic patient group comprised six consecutive type 2 diabetic patients with 
superficial femoral thromboses, median age (interquartile range) 64 (58-72) years, 
duration of diabetes 7 (3-14) years. 
All the patients were under the care of Mr. MG Walker, Consultant Vascular Surgeon 
at the Manchester Royal Infirmary, but were otherwise unselected. 
Methods 
All subjects had transcutaneous oxygen, peroneal nerve MCV and skin temperature 
measured in both legs, using the techniques described on pages 54,59, and 60. The 
measurements were made the day before and six to eight weeks following surgery. 
The contralateral leg, which did not undergo surgery, was used as the control 
in aH cases. 
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Results 
Non-Diabetic Patients 
In the bypass leg TcP02 increased from 59.3 ± 10.7 mmHg preoperatively to 70.7 
7.2 mmHg postoperatively (p<0.01) (Figure 4.1). Peroneal nerve MCV increased 
ftom 42.6 ± 6.1 to 46.7 ± 3.2 ms-1 (p<0.01) (Figure 4.2), but skin temperature was 
unchanged 30.3 ± 0.4 vs 30.4 ± 1.3 C (p=NS). 
There was no significant difference in TcP02 63.2 ± 8.8 vs 63.0 ± 4.6 mmHg, 
peroneal nerve MCV 45.1 ± 7.8 vs 43.4 ± 7.2 ms-I or skin temperature 30.8 4- 1.3 vs 
30.2 ± 1.2 C (all p=NS) in the unoperated leg. 
Diabetic Patients 
In the revascularised legs, transcutaneous oxygen increased from a median 37.5 (28.5- 
45.7 interquartile range) mmHg to 55.5 (53.5-62.5), p=0.036, mean increase 20.2 
(14.8-25.6 95% confidence intervals) (Figure 4.3). This was accompanied by a 
significant improvement in peroneal nerve MCV from a median 31.7 (26.5-3_6.3) ms: -1 
to 33.5 (32.9-39.4) ms-1, p=0.04. The mean increase in peroneal nerve MCV was 
4.7 (1.7-7.7 95% C1) ms-1 (Figure 4.4). 
There was no significant change in transcutaneous oxygen or peroneal nerve 
MCV in the contralateral limb. The median transcutaneous oxygen tension was 58.0 
(49.2-66.0) mmHg pre operation and 53.0 (45.0-65.5) mmHg post, and peroneal 
nerve MCV, pre 35.5 (25.5-39.5) ms-1, post 34.2 (26.7-40.3) ms-1, p=0.83 and 
p=l. o respectively. 
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Figure 4.1. Graph showing improvement in 
transcutaneous oxygen in non-diabetic patients 
following revascularisation. 
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Fi ure 4.2. Change in peroneal conduction 
veto-city following revascularisation in non-diabetic 
I 
patients. 
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Figure 4.3. Graph showing improvement in tissue 
oxygenation of the foot in the diabetic patients 
following revasculariation. 
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Chapter Five 
Discussion of Results in Section One 
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Discussion 
The evidence that microvascular flow and endoneurial hypoxia are implicated in the 
development of peripheral neuropathy is increasing in both animal and human studies 
(Introduction, pages 17-23). The clear relationship between tissue oxygenation and 
nerve function observed in this study supports the view that hypoxia is implicated in 
the aetiopathogenesis of peripheral neuropathy and extends the findings of Ram et al. 
(1991). In their study, clinical correlates of peripheral vascular disease were found to 
correlate with peroneal conduction velocity, and again differences were found between 
each leg. These findings are, however, apparently in contrast with other studies which 
have shown that blood flow in the neuropathic diabetic foot is actually increased 
(Edmonds et al. 1982). One possible explanantion for this is the considerable evidence 
of arterio-venous shunting (Ward et al. 1983), including a high oxygen concentration 
in dorsal foot veins (Boulton et al. 1982) in the diabetic foot. Arterio-venous shunting 
has also been demonstrated in the blood supply of the sural nerve of diabetic patients 
with neuropathy (Tesfaye et al. 1990) and it is likely that the lower skin oxygen 
tensions measured in this study reflect shunts away from nutritive flow (Boulton et al. 
1982, Edmonds et al. 1982, Ward et al. 1983, Rayman et al. 1986, Tesfaye et al. 
19go). other explanations for a lower transcutaneous oxygen tension in neuropathic 
patients might include basement membrane thickening, which has been reported in the 
skin of neuropathic patients as part of a wider microvasculopathy, and would act as a 
barrier to diffusion. The role of adverse rheological changes in reducing 
transcutaneous oxygen measurements in diabetic patients is discussed below. 
The absence of a direct correlation between changes in temperature and nerve 
function has been demonstrated previously in diabetic patients using subcutaneous 
thermometers and was thought to reflect the failure of endoneurial blood flow to 
improve in diabetic sural nerve (Tesfaye et al. 1992). It is also possible that the auto- 
sympathectomy described in these patients (Watkins and Edmonds 1983) removes the 
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association between temperature-and blood flow in diabetic patients. The high basal 
temperature values in each group of subjects also suggests that the warm room in 
which the studies were performed reduced any differences in temperature between the 
neuropathic and non-neuropathic subjects, thus removing any possible correlation that 
might have existed in a cooler room. 
This study reports abnormalities in a number of rheological and 
microcirculatory parameters in diabetic patients with peripheral neuropathy when 
compared to matched non-diabetic control subjects. The lack of a statistically 
significant difference in all but red cell aggregation and fibrinogen concentration, 
between diabetic patients with and without peripheral neuropathy, is in keeping with 
the other comparable studies which have ýxamined rheological parameters in diabetic 
peripheral neuropathy (MacRury et al. 199 1, MacRury et al. 1993 a). However, in 
these studies too, the neuropathic diabetic patients contributed the major component 
of the differences reported between'all diabetic patients', which comprised the 
neuropathic and non-neuropathic patients grouped as a whole, and the non-diabetic 
control subjects. In addition, in these studies the control groups were also younger 
than the diabetic groups. The degree of neuropathy in the diabetic patients in the 
studies of MacRury et al. was also milder, with a mean peroneal conduction velocity 
of 40.7 ms- I- (MacRury et al. 199 1). In the study of Ford et al. (1992) the diabetic 
patients had the same degree of neuropathy as the patients in this study, but the 
methods used were not entirely comparable and no non-diabetic control group was 
included for comparison. 
Studies of haernorheology in patients with the microvascular complications of 
diabetes have generally reported mixed results (MacRury and Lowe 1990). The 
evidence for increased whole blood viscosity in diabetes is generally accepted, 
however most studies have examined whole blood viscosity in patients with 
established complications such as nephropathy (Gordge et al. 1990) (although the 
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changes were similar in diabetic and non-diabetic patients with renal failure) or 
retinopathy (Lowe et al. 1980a, 1986). In addition, no significant increase in whole 
blood viscosity has been found in patients with background retinopathy when 
compared to diabetic patients with no evidence of retinopathy (MacRury and Lowe 
1990) or in patients with and without microalburninuria (Jay et al. 199 1). Similarly, 
MacRury et 0. (MacRury et al. 199 1) reported that there was no significant difference 
in whole blood viscosity at high or low shear rates in diabetic patients with and 
without neuropathy, either at native haernatocrit or at a standardised haernatocrit, 
although non-statistically significant increases were reported at both the shear rates 
examined in this study (98 s-1,0.98 s-1). This study also included patients with other 
microvascular complications in the neuropathic and non-neuropathic control groups, 
and smokers in all groups, which might have influenced the findings. 
Most recent, widely published studies, confirm that plasma viscosity is 
increased in diabetic patients (MacRury and Lowe 1990), a finding which was first 
reported by Cogan et al. in patients with retinopathy (Cogan et al. 1961). This 
increase is generally in association with increased fibrinogen levels in diabetic patients 
(Ganda and Arkin 1992). However, other recent studies by MacRury et al., have 
shown an increase in plasma viscosity without an increase in fibrinogen (MacRury et 
al. 199 1) and no difference in plasma viscosity between diabetic patients and controls 
(MacRury et al. 1993 a). 
MacRury et al. (1993b) have also examined red cell aggregation in diabetic 
patients in relation to cardiovascular disease. In mixed groups of type I and type 2 
diabetic patients with and without microvascular complications red cell aggregation 
was increased compared to control subjects. There are however; few studies of red 
cell aggregation in the absence of microvascular disease or poor control (MacRury and 
Lowe 1990). The patients in this study had average diabetes control and were well 
matched to the non-diabetic control subjects. The absence of a significant difference in 
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rheological parameters between non-diabetic control subjects and uncomplicated 
diabetic patients may therefore be a new finding. 
The reduced transcutaneous oxygen tensions and laser Doppler flux in the 
neuropathic diabetic patients, measured at 44 *C is in keeping with previous studies 
(Eickhoff and Jacobsen 1980, Railton et al. 1983). In particular, this may reflect 
microvascular sclerosis with a resultant reduction in the maximal hyperaemic response 
to heating in neuropathic patients, and/or an increase in arterio-venous shunting (Flynn 
and Tooke 1992). A recent review of rheological changes in diabetes suggested that 
the increase in blood viscosity, particularly at lower shear rates, reported in diabetes 
might be reflected in reduced flow in the post-capillary venules (MacRury and Lowe 
1990). It was also suggested that this might in turn promote capillary stasis, leading to 
local hypoxaernia, and contribute to microvascular complications. This hypothesis is 
supported by the correlations between nerve conduction and tissue oxygenation and 
rheological parameters found in this study. When these correlations are taken together 
with the association between fibrinogen concentration and basement membrane 
thickening reported in the study of Ford et al. (1992), rheological mechanisms might 
also provide a further explanation for the reduced endoneurial and transcutaneous 
oxygen levels reported in patients with neuropathy (Railton et al. 1983). The finding 
of reduced prostacyclin and reduced prostacylin / thromboxane ratio in neuropathic 
diabetic patients is in keeping with previous reports (Moncada and Vane -1979) and 
might also contribute to the reduced capillary flow in neuropathic patients suggested 
by the results of this study. 
As well as adverse rheological changes, a reduced fibrinolytic response has 
been implicated in the increased prevalence of macrovascular disease in diabetic 
patients (Meade et al. 1980). The attenuated fibrinolytic response in diabetic patients 
has been related to hyperinsulinism (Juhan-Vague et al. 1989), and therefore may 
reflect insulin treatment in the type 1 patients and insulin resistance in the type 2 
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patients, although obesity and hypertension are believed to be the primary 
abnormalities leading to impaired fibrinolytic function (Juhan-Vague et al. 1987, 
Auwerx et al. 1988, Potter van Loon et al. 1990, Grant 1991, Landin et al. 1991). 
The current findings would support the hypothesis that basal fibrinolysis is reduced in 
diabetic patients (Small et al. 1987), and would agree with the assumption that this is 
due to increased body mass and higher blood pressure levels in diabetic patients. 
Stimulated fibrinolysis was also reduced in the diabetic patients compared to 
controls. There was a trend to a lower stimulated fibrinolytic response in non- 
neuropathic patients with a significantly impaired response in the neuropathic diabetic 
patients. This result implies that neuropathic patients may have a'reduced ability to 
clear microthrombi in the microcirculation. Such microthrombi would be more likely 
to form in neuropathic patients due to the greater level of adverse rheological changes 
and higher concentrations of fibrinogen. Impaired clearance of microthrombi has been 
suggested by the findings of thrombi within endoneurial capillaries, and the suggestion 
that they might then play a part in the microvascular abnormalities, including capillary 
closure, that have been reported in diabetic neuropathy (Simpson 1988). Indeed the 
study of Ford et al. (1992), which demonstrated that capillary luminal area was 
inversely proportional to fibrinolytic activity adds significant support to such a 
concept. 
Further evidence of microvascular abnormalities in diabetic patients has been 
supplied by studies of microvascular flow using laser Doppler techniques. Rayman et 
al. (1986) examined the response of skin to thermal and mechanical trauma and found 
that reactive hyperaemia was reduced in diabetic patients with microvascular 
complications in the foot and the abdominal wall, where neuropathy is unlikely to have 
directly influenced the response. Similar work from the Exeter group (Shore et al. 
1991, Flynn and Tooke 1992) and the King's group (Stevens M et al. 1992ab, 
Watkins 1992) has confirmed this finding, and work from Exeter has shown that this 
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reduced hyperaemic response can be found in children with diabetes prior to the 
development of complications (Shore et al. 1991). The finding of a reduced 
hyperaemic response in neuropathic patients in this thesis is therefore in keeping with 
previous reports. The mechanism behind this impaired response "kmight possibly be a 
function of abnormalities of local neurogenic responses (Stevens M et al. 1992a), as a 
result of the lower prostacyclin production in diabetic patients (Moncada and Vane 
1979), or, as is more likely in view of the early onset of such changes and presence of 
changes on the trunk, a result of microvascular sclerosis. Nficrovascular sclerosis may 
have a basis in the basement membrane thickening described in diabetes (Faris et al. 
1982), and therefore, indirectly, the finding of an impaired hyperaernic response also 
adds to the evidence of increased microvascular dysfunction in neuropathic diabetic 
patients. 
Revascularisation 
It could be reasoned that if diabetic peripheral neuropathy is due, at least in 
part, to impaired endoneurial blood flow, then a reduction in blood flow or tissue 
oxygenation alone should result in peripheral nerve dysfunction in non-diabetic 
subjects. This is supported by the reports of peripheral neuropathy in hypoxic chronic 
obstructive airways disease patients (Nowak et al. 1990), morphological changes in 
the sural nerve of patients with peripheral vascular disease (Rodriguez-Sanchez et al. 
1991) and the observations of the effects of proximal shunts described on nerve 
function (Sladky et al. 1991, Wilbourn et al. 1983, Knezevic and Mastalgia 1984. - 
Riggs et al. 1989). The studies which examined patients with unilateral femoral artery 
thromboses undergoing reconstructive surgery were used as a model of impaired 
endoneurial flow alone in the development of peripheral nerve dysfunction, and to 
study effects of its improvement. Unilateral surgery allowed the contralateral (control) 
leg to act as a control for other variables such as smoking, changes in diabetic control 
or drugs. The marked increase in tissue oxygenation following surgery was 
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accompanied by a significant rise-in-peroneal conduction velocity in both diabetic and 
non-diabetic patients. This is in contrast to a previously published study by Hunter et 
al. (1988). However in the previous study, there were mixed groups of diabetic and 
non-diabetic patients and the degree of vascular impairment was greater, with half of 
the femoro-popliteal reconstructions being performed for limb salvage, at which stage 
irreversible changes are likely to have occurred. Also this study looked at patients 
after a year, by which time restenosis may have occurred in a number of patients. 
The absence of a significant rise in skin temperature following reconstructive 
arterial surgery may reflect the half hour or more of equilibration in a warm room that 
was allowed before the measurements were taken. 
Although not significant in these relatively small numbers of patients, there was 
a fall in transcutaneous oxygen tension, peroneal nerve MCV and skin temperature in 
the control leg of the non-diabetic patients following surgery. This may reflect a form 
of steal phenomenon, as peripheral vascular disease is usually bilateral, although 
asymmetrical, and the side of the bypass operation is directed by clinical indications. 
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Conclusions 
In summary, well matched groups of otherwise uncomplicated, non-smoking, 
neuropathic diabetic patients have been demonstrated to have adverse changes in 
haemorheological, fibrinolytic, and microvascular parameters, which are significant 
when compared to non-diabetic control subjects. These changes add further evidence 
to support the role of the microvascular dysfunction in the pathogenesis of diabetic 
neuropathy, in keeping with the other principal long term complications of diabetes 
(Simpson 1988, Valensi et al. 1991), and suggest that rheological abnormalities are 
found in diabetic neuropathy in the absence of other complications. 
In addition, these studies demonstrate that there is a significant relationship 
between tissue oxygenation and peripheral nerve function in diabetic and non-diabetic 
patients, and that in both, improving tissue oxygenation is accompanied by a 
significant improvement in nerve function. These findings lend support to the 
hypothesis that endoneurial hypoxia is implicated in the aetiopathogenesis of diabetic 
peripheral neuropathy, and suggest that therapeutic strategies to improve blood flow, 
particularly in early neuropathy, should be considered in diabetic patients. 
120 
Section Three 
The Effects of Peripheral Neuropathy 
on the Diabetic Foot 
Chapter Six 
A Radiographic Survey of Abnormalities in the Feet of 
Neuropathic and Non-Neuropathic Diabetic Patients 
and Matched Non-Diabetic Controls 
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Patients and Methods 
A total of 137 diabetic patients and 50 age and sex matched healthy control 
subjects (C) were included in this study. Their characteristics are detailed in Table 
6.1. In summary, there were 54 diabetic patients with neuropathy and a history of 
foot ulceration (U), 40 with neuropathy without foot ulceration (N) and 43 with no 
clinical neuropathy (NN). No patient had a foot ulcer at the time of study. 
Diabetic subjects were chosen at random from the appropriate clinical 
groupings as identified on the computer database at the Manchester Diabetes Centre. 
In total, 179 patients were known to have had neuropathic ulceration. In 1988-1989, 
520 consecutive patients had their vibration perception measured, and of these, 177 
had a vibration perception threshold greater than 30V and no history of ulceration, 
and 260 had a vibration perception threshold of less than 25V. These patients 
formed the patient pool for recruitment. The diabetes centre is a hospital based 
diabetes clinic and, as with most studies of this type may not be representative of the 
distribution of diabetes within the general population. Therefore, this study examined 
comparisons between groups and relationships within them rather than stating 
absolute prevalence rates for abnormalities within the diabetic population as a whole. 
Normal non-diabetic control subjects were taken from the age-sex register of 
a general practice within the referral area of the diabetes centre. These patients had 
no history of renal failure, alcoholism or other cause of neuropathy and no symptoms 
of intermittent claudication. 
Vibration perception was measured using a Biothesiometer (Biomedical, 
Newbury, Ohio, USA) and was recorded as the mean value of five sites in each foot. 
Patients were designated as neuropathic if they had a mean vibration perception 
threshold of greater than 30V. A previous history of foot and leg ulcers and known 
fractures was sought by direct questioning. 
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HbAlc (laboratory normal <8%) and serum creatinine were determined on all 
diabetic patients. 
The physical characteristics of the patients and control subjects are shown in 
Table 6.1. After recruitment to the study the diabetic neuropathic patients with 
previous foot ulceration were found to have a longer duration of diabetes and an 
excess of type I (insulin-dependent) diabetic patients than the non-neuropathic 
diabetic patients (p<0.05). Type I diabetic patients had an overall significantly longer 
duration of diabetes than the type 2 diabetic patients, median 26 (20-35 interquartile 
range) years vs. 11 (8-19) years (p<0.01). The non-ulcer neuropathic diabetic 
patients were older than the other diabetic groups and the non-diabetic control 
subjects (p<0.05), (Table 6.1' K-The median VPT of the neuropathic patients with a 
history of foot ulceration was similar to that of the neuropathic non-ulcer patients, 
despite the latter patients being significantly older. 
The diabetic patients as a whole, and the non-neuropathic patients (NN) in 
particular, were well matched for age and gender ratio to the non-diabetic (C) 
controls, (Table 6.1). 
The brachial systolic blood pressure was measured in the right arm and the 
ankle systolic pressures were measured at the dorsalis pedis artery on each foot using 
an handheld Doppler ultrasound (Oxford Sonicaid Ltd., Oxford, UK). The mean 
ankle systolic and ankle-brachial pressure index was used in the analyses. Foot pulses 
were assessed by palpation: their absence was recorded if no pulses were palpable in 
either foot. 
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Radiographic technique and analysis 
Weight-bearing (standing) true dorsi-plantar and lateral radiographs were 
taken of each foot using the standardised protocol described in the methods, Chapter 
2, page 69. All the radiographs were read by a single radiologist (Dr Judith Adams) 
without knowledge of the subjects' clinical category. The presence and grade of bone 
and joint changes were assessed as detailed in the methods section, pages 70-77. 
Soft tissue calcification was classified as described below. 
Medial arterial calcification was defined as parallel tramline calcification and, 
if present, was graded as mild or severe according to previously published criteria 
(Morrison and Bogan 1929). Absent calcification was scored as 0, n-dld calcification 
as 1 and severe as 2. Medial arterial calcification was assessed in four soft tissue 
regions on dorsum. and plantar aspect of each lateral radiograph, these were the 
ankle, hind foot, mid-foot and metatarsals. As the interdigital and intermetatarsal 
arteries are not normally visible on lateral views, three regions on the A-P 
projections, the toes, metatarsals and mid-foot were also assessed. 
For the purposes of analysis the calcification data were analysed in two ways. 
The total amount of medial arterial calcification (total arterial calcification score) was 
assessed as the sum of the scores in each region, giving a total maximum score of 44 
if severe calcification was present in all eleven regions of each foot. Amputees were 
scored as twice the score of the remaining intact foot. For comparing the regions and 
modelling the prevalence of calcification, the presence or absence of calcification on 
any view in each region of either foot was used. 
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Statistical analysis 
General 
All the standard statistics, other than Fishees exact test, were performed using 
Minitab software (Minitab Inc, State College, Pa., USA). The majority of the data 
was not normally distributed and Mann-Whitney U tests have been used throughout 
for the standard comparisons between groups. Chi-squared tests have been used to 
assess the distribution of gender and diabetes type between groups and for tests of 
associations except when the number of occurrences of the abnormality was small 
(expected value < 5), when Fisher's Exact test using SAS software (SAS Institute 
Inc., Cary, N. C., USA) was used. Mantel-Haentzel risk ratios were also calculated 
where appropriate. Spearman Rank correlations were used to assess the inter- 
relationships between parameters. 
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Medial arterial calcification data 
The ceiling effect of a maximum VPT of 50 V and a skewed distribution of 
calcification would artificially inflate the correlations in the diabetic groups. All 
correlations therefore include only those subjects with a measurable VPT and/or a 
minimum calcification score of 1, this left 86/137 of the diabetic patients in 
correlation analyses. 
Within the control group the total calcification score, median 0.0 (range 0-10, 
inter quartile range 0.0-0.0) was markedly skewed to the left, with 40 of the 44 
subjects scoring 0. Therefore correlations of the total arterial calcification score and 
other parameters using this group were not performed. 
An ordered categorical model was fit to the data (Agresti 1990) in order to 
determine the existence and nature of any ordered progression in the prevalence of 
calcification along the axis of the foot (ankle to toe) and between groups of patients. 
The presence or absence of medial arterial calcification in a given region represented 
the dichotomous variable of interest. The ordered categorical data analysis was 
performed using'Proc Catmod'in SAS software (SAS Institute Inc., Cary, N. C., 
USA). The complete absence of calcification in the toe region of the non-diabetic 
control subjects resulted in a zero cell for that data point. As this caused a 
singularity, which would not allow the program to run, the value 0.0000 1 was placed 
in this cell. Running the model with values as high as 0.0 1 did not alter the result and 
therefore 0.00001 was felt to be as near zero as to be insignificant in its effects on the 
model. 
A statistical model was fit to this ordered data to reveal any trends which may 
have been suppressed by the underlying variability in the data. The log odds of the 
probability of calcification was modelled using nominal group effects (U, N, NN, Q 
128 
and ordinal region effects (heel, hind-foot, mid-foot, metatarsals, toes), with an 
indicator term for calcification in the toe region. 
Finally, to examine the multivariate predictors of mild and severe calcification 
in diabetic patients, two stepwise logistical regression models were used to predict 
the probability of calcification in any region of the foot. In the first model patients 
were allocated in two groups as those with any calcification versus those with no 
calcification. In the second model those with severe calcification in at least one 
region were contrasted with all the others. The potential predictor variables offered 
to the models were ankle systolic pressure, ankle pressure index, VPT, age, sex, 
duration and type of diabetes, MAI and serum creatinine. The analysis was 
performed using the SAS procedure ? roc logit. The p values for entry and exit of 
the model were set at 0.1. The procedure was run with and without patients with off 
scale VPT (>50 V) and the results were similar. The results shown below are those 
without these patients to remove the ceiling effect created by these patients. 
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Results 
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Bone abnormalities 
There were no significant differences in any of the bone changes recorded in non- 
neuropathic diabetic patients (NN) and the age and sex-matched non-diabetic (C) 
controls (Table 6.2). 
Traumatic fractures were found in 12 (22.2%) of the neuropathic patients 
with previous foot ulceration (U), however, 9 of the 12 patients could not recall any 
injury to the foot. In contrast, the three other diabetic patients, one in the non- 
neuropathic group and two (5%) in the neuropathic patients without foot ulceration 
(N) found to have traumatic fractures were all able to recall the traumatic event 
which caused the fracture, and seeking treatment for it. The total number of 
fractures in the neuropathic patients with a previous history of foot ulceration was 
significantly greater than in the neuropathic patients without previous foot ulceration, 
(p<0.04 U vs. N). 
The neuropathic patients without a history of foot ulceration (N) had a 
significantly higher prevalence of periosteal reaction then the non-neuropathic 
diabetic group (32.5% vs. 13.9%, p<0.04). In addition, in the neuropathic foot ulcer 
(U) patients, the presence of bone destruction (25.9% vs. 0%, p<0.001) was 
significantly greater than in the neuropathic diabetic patients without a history of foot 
ulceration. 
Juxta-articular exostoses were present in approximately three quarters of all 
individuals examined irrespective of group. Atrophic changes (such as 'pencilling' or 
Iwaisting') were not significantly different between all diabetic patients and controls, 
but pencilling was more common in the ulcer compared to non-ulcer neuropathic 
diabetic patients (p<0.03). 
Fourteen of the neuropathic diabetic patients with previous foot ulceration 
had an amputation of part (9 patients, I forefoot, 2 rays, I all toes, 2 hallux, 2 minor 
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toes, I metatarsal head resection) or all (5 patients, 4 below knee, I above) of one 
foot. There were no amputations in any of the other groups, (p<0.001). 
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Joint Abnormalities 
There were no significant differences in the frequency ofjoint abnormalities between 
the non-diabetic control subjects and non-neuropathic diabetic patients. 
Charcot changes were noted in 9 (16.7%) of the neuropathic ulceration group 
but in none of the other groups, (p=0.009). 
Joint fragmentation and dislocation were also significantly greater in the 
diabetic neuropathic ulcer group (p=0.009 and p=0.02 respectively). Although 
failing to reach statistical significance against the non-ulcer neuropathic group, joint 
destruction was twice as common in the ulcer patients and three times that of the 
non-neuropathic patients (p<0.05, risk ratio 4.67 (1.22-20.3 95% confidence limits)) 
Abnormal joint alignment, osteophyte formation, subchondral sclerosis, and 
narrowed joint spaces (principally at the distal interphalangeal joints) were present in 
at least three-quarters of all subjects. The high prevalences observed were not 
significantly different between groups. 
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Medial Arterial Calcification 
Overall prevalence of medial arterial calcification 
The prevalence of calcification in each region of the foot in each group of subjects is 
detailed in Table 6.4. There was a gradient in the distribution of medial arterial 
calcification with a greater prevalence at the ankle and hind foot than at the toes in all 
groups (Table 6.4). This is further explored in the statistical model below. 
The total calcification score in the neuropathic diabetic group with a history 
of foot ulceration was significantly higher than the neuropathic group without foot 
ulceration, (U vs. N p<0.01) (Table 6.5). The neuropathic diabetic patients without 
foot ulceration had significantly higher total calcification scores than the non- 
neuropathic diabetic control subjects, (N vs. NN p<0.01). There was no significant 
difference between the total calcification score in the non-neuropathic diabetic and 
non-diabetic groups, (p=0.25). 
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Table 6.4. Prevalence of medial arterial calcification in the foot by subject group and 
region (%) 
n Ankle Ifind 
Foot 
MidFoot Metatarsals Toes 
ulcer neuropathic (U) 54 1 78.8 75.0 69.2 69.2 40.4 
Neuropathic no ulcer (N) 40 61.9 47.6 50.0 40.5 23.8 
Non-neuropathic (NN 
_ 
43 25.0 29.5 16.0 22.7 6.8 
Non diabetic controls (C) 
150 122.5 16.0 110.0 16.0 10.0 
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Table 6.5. Total calcification score in each subject group 
Mean total 
calcification 
score 
Median total 
calcification 
score 
Inter 
quartile range 
Ulcer neuropathic (U) 18.4 18.0a 3.0-31.0 
Neuropathic no ulcer R 6.83 2.0b 0.0-13.0 
Non-neuropathic (NN) 4.3 O. Oc 0.0-3.0 
Non diabetic controls (C) 
10.7 1 0.0 1 0.0-0.0 
a p<o. ol U vs N. 
b p<0.01 N vs NN. 
C p=NS NN vs C. 
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Duration and type of diabetes. Sex and age 
The total calcification score correlated with the duration of diabetes, r=0.3 2 p<O. 0 1. 
No significant association was found between age and total arterial calcification 
score, either in the diabetic patients alone, r= -0.18 p=NS, or in the total group of all 
the diabetic patients and control subjects combined, r= -0.01 p=NS. 
In the diabetic patients total arterial calcification score was sioficantly higher 
in type I (insulin-dependent) diabetic patients than in type 2 (non-insulin-dependent) 
diabetic patients in all groups, overall median score 13.0 (1.5-28 inter quartile range) 
vs. 1.0 (0-14), p<0.01. The prevalence of medial arterial calcification was equal in 
type I (insulin-dependent) diabetic patients and type 2 (non-insulin-dependent) 
diabetic patients in each group. Type 1 (insulin-dependent) diabetic patients in each 
group had a longer known duration of diabetes than type 2 (non-insulin-dependent) 
diabetic patients, overall median duration 20 vs. 11.5 years (p<0.01). 
There was no significant difference in total calcification score between males 
and females in the diabetic patient groups, 4.0 (0-20.5) vs. 2.5 (0-18.8), p=NS. 
Vibration perception threshold 
There was no significant difference between the VPT of the ulcer and non-ulcer 
neuropathic diabetic patients, median 48.0 (40-51 inter quartile range) Volts vs. 45.8 
(3 6.7-5 1) Volts, p=NS and no difference between the non-neuropathic diabetic and 
non-diabetic groups, 17.6 (12.3-2 1.1) Volts vs. 15.2 (11.0-24.2) Volts, p=NS, nor 
there were more 'off-scale' VPT readings in the neuropathic with foot ulceration 
group (16 vs. 11, p=NS). By definition the neuropathic groups had significantly 
higher VPT than the non-neuropathic and control groups (Table 6.1). 
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In the diabetic patients VPT correlated with total calcification score, r=0.35 
p<0.01. An off scale VPT (51) was associated with a higher prevalence of arterial 
calcification than a measurable VPT (<50), (Chi squared test, p<0.01). It predicted 
the presence of calcification with a specificity 96%, sensitivity 29.1%, and positive 
predictive value (ppv) 92.6%. 
Serum creathiine and HbAl 
Total calcification score was significantly associated with serum creatinine in the 
diabetic patients, r=0.41 p<0.01. Serum creatinine was significantly higher in the 
ulcer neuropathic diabetic group than the other diabetic groups. The median 
creatinine in the non-ulcer neuropathic group was significantly higher than the non- 
neuropathic group (Table 6.1). A serum creatinine of greater than 130 Pmol 1-1 was 
not significantly associated with an excess of MAC (p=NS) but a creatinine of >I 50 
pmol 1-1 was, (p<0.01, sensitivity 23.5%, specificity 94%, ppv 87%). 
MAI did not correlate with total arterial calcification score, r=0.05 p=NS 
and was not significantly different between groups (Table 6.1). 
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Ankle and brachial systolic pressures 
The ankle and brachial pressures are detailed in Table 6.6. The brachial systolic 
blood pressure was significantly higher in the group of neuropathic diabetic patients 
with a history of foot ulceration than the non-neuropathic diabetic group and the non- 
diabetic group but not the diabetic patients without previous foot ulceration (p=NS U 
vs. N, p<0.01 U vs. NN or Q. The brachial systolic blood pressure did not correlate 
with calcification score in the diabetic patients, r=0.09 p=NS. 
The ankle systolic pressure was significantly higher, (p<O. 0 1), in the 
neuropathic diabetic patients with previous foot ulceration than in any of the other 
groups. None of the other groups differed significantly. The median ankle brachial 
pressure index did not differ significantly between the four groups. In the diabetic 
patients ankle systolic blood pressure correlated significantly with total arterial 
calcification score, r=0.40 p<0.01 as did the ankle brachial pressure index, r=0.35 
P<O. 0 1. 
The specificity and sensitivity of ankle systolic blood pressure to detect the 
presence of medial arterial calcification is shown in Figure 6.1. An ankle systolic 
pressure of 190 mmHg has a 90% specificity for the presence of MAC, but with the 
low sensitivity (43.2%), 56.8% of patients with MAC had ankle systolic pressures 
below this level. A third of all patients with MAC in this series had an ankle systolic 
pressure below 150 mmHg and an ankle pressure index <1.0. 
The diabetic patients with a history of foot ulceration had a higher prevalence 
of patients with both foot pulses absent than all other groups, but this did not reach 
statistical significance (Table 6.6). 
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Figure 6.1. Sensitivity / Sensitivity of a given level 
of ankle systolic pressure to infer the presence of 
medial arterial calcification. 
The graph demonstrates that arterial calcification is 
present in 100% of patients with ankle pressures 
>240 mmHg, but may also influence arterial pressures 
below 100 mmHg. 
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Model of the distribution of medial arterial calcification 
The statistical model was fit to the entire data set and retained the structure of the 
data whilst suppressing the underlying variability. The Goodness of Fit statistic 
p=0.273 demonstrated no significant difference between the model and the data, i. e. a 
good fit (usual criterion p>O. 10). The predicted probabilities of calcification for each 
region of the foot in each group are shown in Figure 6.2. 
A significant difference in odds of calcification was found between 
neuropathic diabetic patients with and without previous foot ulceration (p<0.01). 
There was no significant difference between the predicted probability of calcification 
in non-neuropathic patients than in non-diabetic control subjects (P=0.09). 
Neuropathic diabetic patients had a significantly higher probability of calcification 
than non-neuropathic (diabetic or control) patients (p<0.001). 
There was a significant association between odds of calcification and region 
of foot. (p<0.001). The odds of calcification was found to increase by a multiple of 
1.16 (1.07-1.26 95% confidence intervals) for each region nearer the ankle. In 
addition to this ordered effect of region, a significant toe effect was noted (p<0.0001) 
which decreased the odds of calcification by an additional factor of 0.42. Overall, the 
predicted odds of calcification in the ankle were 4.35 (2.94-6.43) times greater than 
in the toes (p<0.001). - 
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Multiple logistic regression 
The presence of any calcification, either rnild or severe, in a patient was predicted by 
two variables, VPT and duration of diabetes, where 
logodds (P(calcification)) = -2.943 + 0.069 * VPT + 0.060 * duration 
This indicated that a5 volt increase in vibration perception threshold increased the 
logodds of the presence of any calcification in the foot by a multiple of 1.42 
(calculated from exp(5 * 0.069) and a5 year increment in diabetes duration 
increased the logodds of calcification by a multiple of 1.34 (exp {5 * 0.060)). 
The presence of severe calcification in at least one region of the foot could be 
modelled using three variables, VPT, duration of diabetes and serum creatinine. 
logodds (P(calcification)) = -4.841 + 0.053 * VPT + 0.076 * duration + 0.012 * creatinine 
By a similar analysis of the individual coefficients as shown in the previous model, a5 
volt increase in vibration perception threshold increased the logodds of the presence 
of severe calcification in any region of the foot by a multiple of 1.3, a5 year 
increment in diabetes duration increased the logodds of calcification by a multiple of 
1.46 and a 30 pmol. 1-1 increase in serum creatinine increased the logodds of 
calcification by a multiple of 1.42. 
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Discussion 
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This study found higher rates of bone and joint abnormalities in diabetic patients with 
peripheral neuropathy than those previously reported, especially in patients with a 
history of foot ulceration. Non-neuropathic diabetic patients did not appear to have 
any excess of abnormalities when compared to non-diabetic control subjects. 
The frequency of traumatic fractures (12/54 patients - 22.2%) in the 
neuropathic ulcer diabetic patients was notable, particularly since 9 of these 12 
patients had no recollection of - and received no treatment for - fractures. This 
probably reflects the profound sensory loss that can occur in these patients. 
The 16% prevalence of hypertrophic Charcot changes in this otherwise 
unselected group of ncuropathic patients with foot ulcers contrasts strongly with the 
value of 0.15% reported by Sinha et al (1972) in a 21 year retrospective review of 
68,000 Joslin Clinic patients who were presumably of mixed neuropathic and non- 
ncuropathic status. Although the latter figure is still frequently quoted in the 
literature, there are rcports of higher prevalence in a variety of groups with different 
inclusion and exclusion criteria - including values of 7% (Pogonowska et al. 1967) 
and 37% (Tawn et al. 1988). These rcports, and our results, suggest that the index 
of suspicion for Charcot changcs must be high in the ncuropatWc diabetic patient, 
particularly those with a history of foot ulceration, and support the view that many 
such changes may have bccn overlooked or misinterpreted in the past (Sanders and 
Frykbcrg 1993). 
The increased frequency of pcriostcal reaction in ncuropathic patients 
confirms the findings of Williams et al. (1988). While pcriosteal reaction. is 
sometimes regarded as evidence of response to infection (Renton 1990) it was 
thought by Williams ct al (1988) to be a non-spccific finding in the foot of diabetic 
patients. An alternative explanation, in the absence of foot ulceration, may be 
elevated mechanical stress. Animal experiments have shown a clear association 
between increased bending stress in long boncs and pcriosteal reaction (Uhtoff and 
Jaworski 1985). Since it is now accepted that ncuropathic diabetic patients have 
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elevated loads under the metatarsal heads (Boulton et al. 1983, Veves et al. 199 1 b), 
this could explain the increased periosteal reaction in these patients. 
Although radiological evidence of bone infection was present in only one 
patient, 14 patients had an amputation of part or all of one foot, and since all of these 
had a history of plantar ulceration, infection may have been present in the majority of 
these cases. 
The small number of atrophic or osteopaenic changes found in the present 
study contrasts with the frequent anecdotal reports of such findings (Kerr et al. 
1991). The finding of no significant excess of abnormal joint alignment in any of the 
diabetic groups compared to controls is surprising. Only dislocation was significantly 
higher in the ncuropathic ulcer diabetic group, which also had a large proportion of 
patients with Charcot ncuroarthropathy, subluxations were approximately equal in all 
groups. However, clawing of the toes has been reported to be more prevalent in 
patients with diabetic ncuropathy (Renton 1990) and the results of this study are in 
contrast with these previous findings. The majority of abnormalities in the control 
group were at the intcrphalangeal joints, and it may be that the reduced toe use 
reported in diabetic patients (Boulton ct al. 1983) results in less deforn-&y than would 
otherwise occur. 
Other factors, in addition to ncuropathy, may have played a role in the large 
nuinbcr of bony abnormalities scen in the present sample. In particular, the high 
median value for serum creatinine in the patients who had experienced a plantar ulcer 
is a possible explanation for some of the findings of this survey, and it may be 
beneficial to stratify the subject groups based on renal function in future studies. 
The significantly greater number of bonc and joint abnormalities found in the 
ncuropathic group should increase the index of suspicion for such changes in 
ncuropathic diabetic patients %ith otherwise equivocal clinical findings. Although the 
increased prevalence of amputation might be expected in patients with a history of 
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foot ulceration, and the finding of greater degrees of periosteal reaction may have 
little direct clinical relevance, the prompt recognition of traumatic fractures has 
considerable clinical importance as it is widely believed that a traumatic fracture in a 
neuropathic patient can lead to Charcot neuroarthropathy. For example, in the series 
of 118 cases of Charcot ncuroarthropathy reported by Johnson (1967) traumatic 
fractures were the initiating factor in 'the majority of cases. In addition, whilst 
Charcot changes may only be clinically apparent unilaterally, they are bilateral on 
radiographs in at least 24% of cases (Sinha et al. 1972). Current clinical practice 
suggests that immobilisation of an early Charcot process may limit deformity 
(Sanders and Frykberg 1993), and in the future, the early use of intravenous 
Pamidronate may Im used to limit the destruction of neuroarthropathy (Chapter 8). 
Therefore, increased surveillance, particularly of patients with peripheral neuropathy 
and previous Charcot changes, might allow such treatments to be started earlier in 
the disease process, reducing the subsequent deformity and morbidity. 
This study also dcscribW a significant, association between diabetes, 
peripheral ncuropathy and the presence of medial arterial calcification. There is also 
a significant gradient in the prevalence of medial arterial calcification from the ankle 
to the toe. The association of medial arterial calcification with diabetes (Morrison 
and Bogan 1929, Ferrier 1964, Strandricss ct, al. 1964, Neubauer 1971) and 
ncuropathy (Edmonds et al. 1982, Goebel and Fucssi 1983, Everhart ct al. 1988) has 
been described previously but there have been no previous studies of groups with 
different levels of diabetic complications or %ith age and sex matched normal control 
subjects using a standardiscd radiographic technique for each patient to allow for 
accurate comparisons between regions and groups. 
The development of medial arterial calcification is believed to be due to 
autonomic dcnervation of the intima media of the small muscular arteries of the foot 
(Edmonds et al. 1982, Goebel and Fucssi 1983, Everhart et al. 1988), and increased 
medial arterial calcification has been reported following sympathectomy (Goebel and 
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Fuessi 1983). Edmonds et al. (1982) described increased vascular calcification in the 
knee, the hands and the feet in diabetic patients with autonomic and peripheral 
sensory neuropathy. In the present study the total amount of medial arterial 
calcification was significantly higher in the neuropathic diabetic groups than in the 
non-neuropathic diabetic group. The total arterial calcification score also correlated 
significantly with the vibration perception threshold and provides quantitative 
confirmation of this hypothesis. 
Uncomplicated diabetes, as represented in the non-neuropathic diabetic 
group, did not appear to increase the development of medial arterial calcification 
when compared with the non-diabctic group of a similar age. This was apparent from 
both the total calcification score and from the statistical modelling of the calcification 
data but no previous study has compared uncomplicated diabetic patients with normal 
control subjects to confirm this. 
The increase in medial arterial calcification from non-neuropathic diabetic 
control subjects through neuropathic patients without a history of foot ulceration to 
ncuropathic diabetic patients with a history of foot ulceration is probably due to a 
combination of factors. The addition of peripheral ncuropathy is associated with a 
significant increase in the probability of the presence of calcification and the total 
amount of arterial calcification, despite the fact that the non-ncuropaNc and - 
ricuropathic non-ulccr diabetic patients have a very similar duration of diabetes. The 
ncuropathic group with pre-vious foot ulceration had a higher serum crcatinine and a 
longer duration of diabetes thin the non-ulcer ncuropathic group. Vibration 
perception threshold was not significantly different betwecn these groups and this 
may be because of the proximity to the ceiling of measurable VPT and the large 
number ofoff scale'valucs in each group, 16154 and 11/40 respectively, although the 
median and inter quartilc range wcrc higher in the ulcer group. A chi-square test of 
presence orcalcification with an off-scale VPT was also highly significant, further 
reinforcing the association of medial arterial calcification and neuropathy 
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The combinafion of factors, serum creatinine, duration of diabetes and VPT, 
all of which significantly correlated independently with the total calcification score 
and strongly predicted the presence of severe calcification in the multiple logistic 
regression model, may have contributed to the higher levels of arterial calcification 
within the ncuropathic ulcer group. It is not however possible, from the present 
analysis to infcr that the three predictor variables are independent risk factors for the 
probability of the prcscnce of sevcre arterial calcification. 
The lack of any correlation with age and calcification is surprising. Increasing 
age is associated with an increase in medial arterial calcification in a number of 
studies (Morrison and Bogan 1929, Fcrricr 1964, Strandness ct al. 1964, Neubauer 
1971, Goebel and Fucssi 1983). A possible explanation is the high median and 
narrow range of age of our subjects. Thrcc-quarters were aged over 50 years, at 
which time calcification was more common in all these studies. This may have 
masked any possible rclationship of calcification with age. However the non-diabetic 
control group were wcll =tched to the diabctic group in age and yct they had 
virtually no artcrial calcification. 
The higher total arterial calcification score in type I (insulin-dcpendent) 
diabetic patients in each group is probably due to the longer known duration of 
diabetes in these patients compared to type 2 (non-insulin-dependent) diabetic 
patients, This is in keeping %ith A report of higher ank-le-brachial pressure indices in 
type I (insulin-dcpcndcnt ) diabetic patients, which was Attributed to higher levels of 
media] arterial calcification and a longer duration of diabetes (Goss ct al. 1989). This 
was not rcflccted in an increase in the prevalence of any degree of calcification in 
type I (insulin-dependent) diabetic patients As demonstrated by the fact that diabetes 
type did not enter the logistic regression model. 
The probability of calcification in cach group suggested a trend from non- 
ncuropathic diabctic patients to ulccr diabetic paticrits and from the toe to the ankle 
region in each group. The ordcred catcgorical modcl (Agresti 1990) aflows further 
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analysis of repeated ordinal measurements by suppressing the underlying variability of 
these measurements. The increased probability of medial arterial calcification in the 
neuropathic ulcer group confirmed the trend observed in the raw data, which had 
indicated that the probability of medial arterial calcification was greater in the 
neuropathic ulcer group than in the neuropathic diabetic patients without a history of 
foot ulceration. It also confirmed the increase in calcification in neuropathic patients 
compared to non-neuropathic patients, and also that diabetes alone, when not 
complicated by neuropathy, did not add to the prevalence of calcification found in 
age and sex matched control subjects. 
The ordered effect of region, which represents the increase in calcification 
progressing from the metatarsals to the ankles provided a good linear fit of predicted 
prevalence vs observed prevalence. However the prevalence of medial arterial 
calcification at the toc in all groups was significantly lower than that predicted by a 
purely linear modd. This %oc effccfwas estimated and when introduced as a factor 
of 0.42 times the probability of calcification for a linear fit, made the model more 
representative of the data. 
The testing of the raw prevalence data with a statistical model has confirmed 
the inter-group and intcr-regional trends which would have been difficult to test 
sigigicantly using individual statistical tests. These trends arc also clinically relevant. 
Screening diabetic patients for peripheral vascular disease and implied 
cardiovascular disease (Nillson et Al. 1967, Carter 1969, Yao ct al. 1969, Neubauer 
1971, CutaJar ct Al. 1973, Janka et al. 1980, Goebel and Fuessi 1983) often includes a 
measurement of the Ankle brachial systolic pressure index (Carter 1969, Yao et al. 
1969, Cutajar ct Al. 1973, Janka et Al. 1980). This measure has however been 
discredited by the false elevation reported in diabetic patients with non-compressible 
medial arterial calcification in the tibial and ankle plexus arteries (Reimann and 
13ollinger 1974, European Consems 1989). Ankle systolic pressure and ankle- 
brachial pressure index were significantly Associated with total arterial calcification 
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score in this study, and, as calcification was more marked in the ankle and hind foot 
regions this would support this assumption. However, whilst an ankle systolic blood 
pressure of >200 mmHg is often believed to demonstrate the presence of medial 
arterial calcification, this study demonstrates that arterial calcification is present in 
8.6% of patients with ankle systolic pressures below 100 mmHg. Carter (1973)_ 
investigated the effect of medial arterial calcification on intra-arterial measurements 
of dorsalis pedis arterial pressure in five patients. One patient had a significant rise in 
cuff pressure versus directly measured arterial pressure, whilst the others had slightly 
lower cuff pressures. Similar results were found in patients with brachial artery 
calcification. However, this study was uncontrolled and requires further studies to be 
performed to confirm the main findings, particularly as they appear to contradict 
clinical and non-invasive testing experience (Cutajar et al. 1973, 'Reimann and 
Bollinger 1974, Everhart et al. 1988, European Consensus 1989, Goss et al., 1989). 
It is therefore quite likely that in diabetic patients, ankle systolic pressures and ankle- 
pressure indices may be falsely elevated even at 'normal' levels due to medial arterial 
calcification. ý For this reason, toe systolic pressure is regarded as a more reliable 
indicator of arterial inflow to the foot than ankle pressure in diabetic patients . 
(European Consensus 1989). The demonstration of significantly lower levels of 
arterial calcification in the toe regions provides a possible explanation for this premise 
and a rationale for the use of toe, - rather 
than ankle, pressure measurements in - 
diabetic patients. However, this hypothesis remains to be tested. 
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Conclusions 
In general, the results of these studies clearly demonstrate the increased prevalence of 
clinically important bone and joint abnormalities in diabetic patients with peripheral 
neuropathy, particularly in association with foot ulceration. They also suggest that 
many of the minor changes, including misalignments and medial arterial calcification, 
previously thought to be more common in diabetic patients regardless of the presence 
or absence of complications, may in actual fact be equally as common in the general 
population. 
The high prevalence of Charcot neuroarthropathy in this survey should 
increase the index of suspicion for such changes in neuropatfik patients. 
In addition this study, using standardised methods to compare well defined 
groups, has confirmed the previous assumptions about the associations of medial 
arterial calcification and neuropathy, duration of diabetes and renal dysfunction. The 
low discriminatory value of a defined level of ankle pressures to infer the presence of 
arterial calcification and the converse, that calcification may be elevating the ankle- 
pressure index, even in the normal range, must cast further doubt over the use of 
ankle pressures to screen for lower limb arterial disease particularly in diabetic 
patients with neuropathy. The demonstration of a gradient in calcification between 
the ankle and the toes supports the theoretical use of toe pressure measurements 
rather than ankle pressures in diabetic patients, but this benefit remains to be proven 
clinically. 
155 
Section Four 
Studies of Patients with 
Charcot Neuroarthropathy 
Chapter Seven 
Neurophysiological and Bone Mass Studies 
in Patients with Charcot Neuroarthropathy 
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Patients 
Two groups of patients were studied to determine the predisposing factors associated 
with the development of Charcot neuroarthropathy, and whether there was a 
qualitative difference in the degree of neuropathy present in patients with Charcot feet. 
The Charcot patients comprised 17 consecutive patients attending the diabetic foot 
clinic of the Manchester Foot Hospital presenting with radiologically proven active 
Charcot neuroarthropathy. Charcot change was defined using the criteria of Cofield et 
al. (1983), as the simultaneous presence of bone and joint destruction, fragmentation 
and remodelling as in Chapter 6. - Charcot activity was defined as a temperature 
difference of >2 *C between the active and non-active foot (Sanders and Frykberg 
1991). 
These patients were then compared with 17 age, sex and duration matched 
patients with clinical neuropathy, as recorded on the computerised database of the 
Manchester Diabetes Centre. All non-Charcot patients had normal weight bearing 
radiographs of the feet and no clinical evidence of Charcot change. 
The physical characteristics of the subjects are listed in Table 7.1. 
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Table 7.1. Physical characteristics of the patients included in the study of the 
differences in neurological deficit between Charcot and non-Charcot diabetic patients 
with neuropathy. 
Charcot Non-Charcot 
Number 17 17 
Female: Male 11 :6 7: 10 
Age (years) 49 ± 13 54±10 
-Duration of 
diabetes (years) 20 ±9 19 ± 11 
Type L 11 10: 7 10: 7 
Duration of Charcot (years)' 1.35 ± 1.02 
MAI 9.9 1.6 9.4 2.9 
Creatinine (pmol 1-1) 130 62 120 98 
BMI (kg M-2) 28: L 6 27 ±3 
'Previous Foot Ulcer 10 9 
Retinopathy* 11 11 
Proteinuria** 8 7 
Results are shown as mean ± SD, or absolute number. There were no significant 
differences between groups. 
* defined as background or worse on dilated fundoscopy. 
** defined as dipstix positive. 
159 
Methods 
Both groups of patients had the following tests of neurological function: neuropathy 
deficit score, vibration perception threshold, warm and cool thermal perception 
thresholds, peroneal nerve motor conduction velocity, and cardiovascular autonomic 
function, performed as described in Chapter Two (Methods), pages 53-57. 
Skin temperature was also measured using the Mikron infra-red thermometer 
(Methods, page 60). 
The patients Charcot neuroarthropathy also had bone mass measurements by 
single photon absorptiometry and dual energy X-ray absorptiometry to determine if 
there was a reduction in skeletal mass to account for the increased fracture risk as a 
predisposing factor in the development of Charcot neuroarthropathy (Methods, page 
78). 
Statistical Analysis 
The neurophysiological results were compared as Charcot foot versus non-Charcot 
foot in the Charcot patients, and Charcot foot versus the mean of the results for both 
feet in the non-Charcot patients, using standard comparative statistics (Mann- Whitney 
U tests, Wilcoxon Rank Sum tests and t-tests where appropriate). 
I-i 
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Results 
Neurological Function 
The results are detailed in Table 7.2. In summary, there were no significant differences 
in all the measures of neuropathy between the affected and non-affected foot in 
Charcot patients. 
The neuropathy disability score (median 10 (10- 10 interquartile range) was 
significantly worse in the Charcot patients compared to the non-Charcot patients 
(median 8 (7-10)), p=0.009. 
Peroneal. nerve motor conduction velocity was significantly worse in the 
Charcot patients versus the non-Charcot patients (3 0.0 ± 4.8 vs. 3 3.3 ± 3.5 ms- 1$ 
P=0.010). 
Vibration perception threshold and warm perception threshold were higher, but 
not significantly, in the Charcot patients compared with the non-Charcot patients. 
Cool perception threshold was similar in both groups (Table 7.2). 
Autonomic function was abnormal in all the Charcot patients, but in only 10 of 
the non-Charcot patients (p=0.03). 
Skin temperature was significantly higher in the active Charcot foot than in the 
non-Charcot foot by definition (32.8 ± 1.8 vs. 29.6 ± 2.6 *C, p=0,8). There was no 
significant difference between the non-Charcot foot and the skin temperature of the 
feet of non-Charcot patients (29.6± 2.6 vs. 29.6 ± 1.7 11C, p=0.8). 
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Table 7.2. Results of neurophysiological tests in Charcot and non-Charcot patients. 
Charcot foot Non-Charcot 
Foot 
Non-Charcot 
Neuropathic 
Patients 
Neuropathy disability score 10(10-10) 8 (7-10)* 
Peroneal. nerve MCV (ms-1) 30.0 ± 4.8 30.3 ± 3.8 33.3 ± 3.5** 
VPT (Volts) 40.4 ± 13.0 40.4 ± 13.0 33.9 ± 13.2 
Warm Thermal Threshold (*C) 10.4 ± 3.0 10.2 ± 6.2 8.2 ± 7.2 
Cool Thermal Threshold (OC) 7.0 ± 5.0 5.4 2.2 6.5 ± 5.9 - 
Skin Temperature (*C) 32.8 ± 1.8 29.6 2.6 29.6 ± 1.7 
Abnormal autonomic function 17/17 10/17 
Results are shown as mean ± SD, except for neuopathy disability score (median 
(interquartile range)) and abnormal autonomic function (number of patients with 
abnormal tests). 
*p=0.009 Non-Charcot vs. Charcot 
**p=0.0 10 Non-Charcot vs. Charcot 
*** p=0.03 Non-Charcot vs. Charcot 
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Bone Mass Measurements 
Table 7.3. Results of bone mass measurements in patients with Charcot 
neuroarthropathy. Results are shown as Z scores of deviance from the mean of age, 
sex and weight matched healthy control subjects. Scores of -1 or less indicate 
increased fracture risk (SPA - single photon absorptiometry, DEXA - dual energy X- 
ray absorptiometry). 
Charcot patients 
SPA DEYCA 
Distal Proximal Spine Right and Left 
radius radius Femoral Necks 
Mean Z Score -0.84 -0.53 -0.10 -1.01 -1.03 
SD 1.27 1.31 1.70 2.04 2.07 
Median 1 -0.50 -0.65 -0.40 -1.70 -2.00 
The results show a marked loss of bone mineralisation in the cortical bone of the lower 
limbs. 
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Chapter Eight 
A Study of Pamidronate as a 
a Possible New Treatment for Diabetic 
Charcot Neuroarthropathy 
164 
Patients and Methods 
The last eight consecutive patients from the studies of neurophysiological and bone 
mass changes (described in Chapter Seven), attending the Manchester Diabetes Centre 
with typical changes of active Charcot neuroarthropathy, were studied to assess the 
potential of Pamidronate (Aredia, Ciba-Geigy) to halt to progression of the Charcot 
process. 
The subjects comprised five women and three men with a mean age of 37.1 ± 
19.9 (SD) years. Full details of the subjects are given in Table 8.1; they all had long 
standing diabetes mellitus and a variety of long term complications including in every 
case, a dense peripheral sensory neuropathy and autonomic neuropathy. In each case 
the presence of Charcot neuroarthropathy was initially suspected on the basis of the 
clinical picture of a swollen uncomfortable hot foot in the absence of any evidence of 
infection. The diagnosis of Charcot neuroarthropathy was confirmed by the 
simultaneous presence of bone destruction and fragmentation, with joint destruction or 
subluxation on examination of weight bearing radiographs of the feet as in the 
previous studies in this thesis (Chapters 6,7). Activity was confirmed by increased 
bone turnover on three phase scintigraphy using 99mTc-hydroxymethylene 
bisphosphonate (Edmonds et al. 1985). If there was significant clinical doubt as to the 
absence of infection this was confirmed by scintigraphy using radiolabelled leukocytes 
(Hetherington 1982). 
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Table 8.1. Physical characteristics of the Charcot patients receiving Pamidronate 
treatment. 
I Number 18 
I Female: Male 15: 3 
Age (years) 46 ± 13 
Duration of diabetes (years) 
1 
20 ±9 
Type 111 5: 3 
Duration of Charcot (years) 
1 
0.8 ± 0.4 
HbAl (%) 9.1±1.0 
Creatinine (gmol 1-1) 141± 90 
BMI (kg M-2) 25+5 
Previous Foot Ucer 15 
Retinopathy* 4 
Proteinuria* 3 
All results are shown as mean ± SD or as absolute numbers. 
*defined as background or greater retinopathy on dilated fundoscopy. 
defined as dipstick positive proteinuria. 
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Methods 
Each subject was treated with intravenous pamidronate as described in the 
methods, Chapter 2, page 79. 
The activity of the Charcot process was monitored by measuring the 
temperature of the affected foot with a Mikron infra red thermometer (Mikron 
Instrument Company, Inc., Wyckoff, New Jersey, USA) as described in the methods 
page 60. Measurements were taken immediately prior to each infusion and two weeks 
following the final infusion. The normal difference between the feet does not exceed 2 
"C (Sanders and Frykberg 1991). At each visit blood was drawn for the measurement 
of alkaline pIA)sphatase activity and creatinine concentration. Patients were also asked 
to describe their symptoms of pain, swelling and immobility. 
Statistical analysis 
Statistical analysis was undertaken using the SPSS/PC program. Analysis of variance 
was used to seek differences in each of the variables measured with time, with the 
subsequent use of Duncatfs range test to identify differences in the means of these 
variables. 
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Results 
Tolerability 
Apart from a minor pyrexial reaction in two subjects the pamidronate therapy was well 
tolerated. Neither subject requested that the treatment be discontinued, nor was the 
reaction felt significantly serious enough to require an end to their participation. The 
patients' descriptions of their symptoms did not lend themselves to quantification but 
all subjects reported a marked decrease in pain and swelling so that their mobility was 
markedly improved. In the three patients who received treatment first this clinical 
improvement has been maintained for over a eighteen months after the completion of 
the course of pamidronate infusions. There was no change in renal function during the 
course of treatment. 
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Activity Measurements 
Skin Temperature 
From a basal temperature difference of 3.4 ± 0.7 (SE) *C between the affected and 
intact foot there was a rapid fall to 1.0 ± 0.5 *C after the initial 30mg infusion (Figure 
8.1). Throughout the rest of the period of observation the temperature difference 
remained within the normal range (within 2 *C of other foot). The overall temperature 
change was significant (F=2.32; p=0.05) and the pretreatment values were significantly 
different from those obtained at all other time points. 
Alkaline phosphatase 
To remove the variation introduced by the wide scatter of initial values for alkaline 
phosphatase activity (273-503 units 1-1: reference range 70-330 units 1-1) subsequent 
results were expressed as a percentage of the initial value for each individual (Figure 
8.2). There was a steady decline in alkaline phosphatase activity after the third 
infusion, such that it had reached 75% of its initial value after the final infusion. This 
change was highly significant (F=8.5; p=0.001) and was significantly different from 
baseline at all points subsequent to the third infusion. 
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Igure 8.1. Change in skin temperature difference between the Charcot and non-Charcot -foot during treatment with Pamidronate. Temperature difference shown as mean + SE. 
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Figure 8.2. Graph showing the change in 
mean alkaline phosphatase activity from pre 
study level in the Charcot patients treated 
with Pamidronate. 
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Chapter Nine 
Discussion of Results in Section Three 
172 
Discussion 
Charcot neuroarthropathy is a severe complication of diabetes. Taken together with 
previous published studies (Pogonowska et al. 1967, Tawn et al. 1988), the study in 
Chapter 6 suggests that it is more common amongst neuropathic diabetic patients than 
previously recognised (Sanders and Frykberg 1993). The aetiology of Charcot 
neuroarthropathy is also poorly understood. The studies in Chapter 7 dispute the 
recent suggestion that there is a specific neuropathy in diabetic patients with Charcot 
neuroarthropathy (Stevens M et al. 1992b), but support the more traditional view of 
patients with Charcot feet having a dense peripheral sensorimotor neuropathy 
associated with a long duration of diabetes (Sanders and Frykberg 1993), and the 
universal presence of cardiovascular autonomic dysfunction (Edmonds et al. 1985). 
This autonomic dysfunction is believed to lead to arterio-venous shunting in the feet of 
neuropathic diabetic patients, increasing the vascularity of the bone and precipitating 
the rapid destruction of bone following a (minor) traumatic event (Edmonds et al. 
1985). It is also possible that this increased vascularity leads to reduced bone 
mineralisation, such as that found in the lower limbs of the Charcot patients measured 
in these studies. Neuropathy has has been previously suggested by Edmonds et al. 
(1985), and Selby (1988), to be one of the causes of osteoporosis in diabetic patients. 
The combination of insensitivity to pain and reduced bone mineralisation may then 
explain the clinical syndrome of acute Charcot fractures following relatively trivial 
injury (Sanders and Frykberg 1993, McEnery et al. 1993). 
None of the present treatments for Charcot neuroarthropathy has a significant 
effect on the underlying process of bone destruction. The results of this study suggest 
that pamidronate may be able to fulfil this role. Even in the absence of a placebo 
treated group it would appear highly unlikely that the activity of a Charcot joint would 
diminish spontaneously within two weeks of infusion of pamidronate in eight separate 
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patients, whose disease process had been highly active and unchanged for several 
weeks, and in most for up to a year, prior to treatment. Nevertheless, such a 
controlled trial may need to be performed. An additional benefit of Pamidronate is 
that it may also treat any underlying osteoporosis and possibly reduce the risk of 
further fractures. 
Temperature changes are widely accepted as being an appropriate means of 
assessing the activity of the Charcot process (Sanders and Frykberg 1991), and given 
the profound changes observed in skin temperature of the foot and alkaline 
phosphatase in the patients studied, together with the subjective improvements in 
symptoms, there is little doubt that the Charcot activity was been markedly reduced 
during the treatment period. The change observed in alkaline phosphatase was not 
due to improved diabetic control, since there was no significant change in this over the 
period of study. There have been few studies of the bisphosphonates in normal 
volunteers but one such experiment suggested that the expected change in alkaline 
phosphatase activity after administration of pamidronate to volunteers without bone 
disease was only 10% (Netelenbos et al. 1991). It would have been desirable to obtain 
a further measure of disease activity such as repeated isotope scans, but it proved 
impossible to obtain sanction for this from the Administration of Radioactive 
Substances Advisory Committee in time to complete these studies. 
The pamidronate regimen used in this study was based upon the use of a 
protocol which has proved successful in Manchester in the management of patients 
with Paget's disease of bone (Anderson et al. 1993). This is by no means the only 
possible regimen and recent research has suggested that a variety of different 
protocols, some of them based on single infusions of bisphosphonate, are equally 
effective in the management of Paget's disease (Hooper et al. 1993, Watts et al. 1993) 
and so may well be equally effective in the treatment of Charcot neuroarthropathy 
givine that a reduction in skin temperature was apparent after the first half dose 
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(30mg) infusion. In the treatment of Paget's disease with pamidronate the regimen of 
Anderson et al. appears to be effective at suppressing disease activity for between six 
and eighteen months, following which there is a similar response to repeated therapy in 
patients who relapse (Anderson et al. 1993). There is no obvious reason to believe 
that a similar disease free interval could not be expected in patients with Charcot 
neuroarthropathy. Indeed, five of the initial patients have been maintained in clinical 
remission for over one year, and no patient has yet relapsed. 
It is generally held that Charcot neuroarthropathy is a rather rare complication 
of diabetes, whilst this is undoubtedly true for the relatively late stages of the process 
with gross deformity and fracture (Sinha et al. 1972), this is not so for less severe 
changes. The survey of radiological findings in diabetic patients described in Chapter 
6, and work by others (Cofield et al. 1983) would suggest that early signs of 
neuroarthropathy are present radiographically in up to 10% of diabetic patients with 
neuropathy, which would suggest that the complication might be present in up to 2% 
of people with diabetes. With increased awareness of the early stages of the Charcot 
process, including the management of otherwise trivial fractures (Johnson 1967), along 
with expertise in the use of bisphosphonates, particularly following a controlled trial, it 
might be possible to treat patients at much earlier stage of the disease and hence avoid 
the later development of bony deformity and subsequent morbidity due to ulceration. 
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Conclusions 
In conclusion, patients with Charcot neuroarthropathy have been shown to 
have reduced bone mass and a dense global peripheral neuropathy. These, together 
with autonon-dc neuropathy are in keeping with current theories for the aetiology of 
Charcot foot as a neurotraumatic process (Sanders and Frykberg 1993). 
Pamidronate, unlike any previous therapy, appears to moderate the underlying 
bone destruction inherent in the active phase of the Charcot process. It is therefore 
possible that bisphosphonates may have an important future role in the prevention of 
the progression of this distressing condition. 
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Section Five 
Final conclusions 
and references 
Conclusions 
Rheological parameters are significantly abnormal in diabetic patients with 
neuropathy, and adversely altered, although not significantly in this study, in non- 
neuropathic diabetic patients. These changes might lead to increased formation of 
capillary microthrombi due to increased red cell tWogatioa and increased fibrinogen 
concentrations. Taken together with impaired fibrinolysis, leading to reduced 
clearance of such microthrombi there is evidence that microvascular flow might be 
impaired in neuropathic patients. The inverse correlations between 
transcutaneous oxygen and rheological parameters support the view that they 
might influence microvascular flow. 
2. The finding that transcutaneous oxygen levels are significantly reduced in 
neuropathic patients is in keeping with other studies and provides further evidence 
for microvascular impairment in peripheral neuropathy. 
3. The improvement in peroneal conduction velocity with improved tissue 
oxygenation following revascularisation of the legs of non-diabetic and diabetic 
patients with peripheral vascular disease strongly suggests that endoneurial 
hypoxia due to whatever cause has an adverse effect on peripheral nerve function 
and may be implicated in the aetiology of peripheral neuropathy. 
4. Diabetes alone does not seem to increase the number of skeletal and soft tissue 
abnormalities found on radiographs of the feet when compared to age and sex 
matched non-diabetic control subjects. 
5. Neuropathy, particularly in association with foot ulceration, is however associated 
with a marked increase in skeletal abnormalities, including fractures, most of 
which were unknown to the patient, medial arterial calcification, and Charcot 
changes. 
6. Medial arterial calcification is so common in neuropathic diabetic patients that 
ankle systolic pressures are likely to be unreliable in the majority of patients. 
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However, they are unlikely to be as unreliable in non-neuropathic diabetic 
patients. 
7. The demonstration of a gradient in the prevalence of calcification between the 
ankle and the toes would suggest that toe pressure measurements might be more 
reliable than ankle pressures in neuropathic diabetic patients, but as yet there is no 
clinical evidence to support this. 
8. Charcot neuroarthropathy is probably more common than widely recognised. 
9. Charcot patients appear to have a severe global neuropathy; in keeping with the 
generally held view that it is the densely neuropathic patients who develop 
Charcot changes. 
10. Charcot patients have a reduced bone mass in the lower limbs, and this might be 
part of the reason why they develop fractures after minor trauma which then start 
the Charcot process. 
11. Pamidronate is an effective treatment for acute Charcot neuroarthropathy, 
reducing the disease activity and relieving the physical symptoms. It may also 
help to improve the low bone mass found in Charcot patients. 
179 
References 
180 
Agresti A (1990) Categorical data analysis. John Wiley and Sons, New York. 
Allawi J, Jarrett RJ (1990) Microalbuminuria and cardiovascular risk factors in type 2 
diabetes mellitus. Diabetic Med 7: 115-118 
Anderson DC, Richardson PC, Brown JY, Freemont AJ, Hollis S, Denton J (1993) 
Treatment of Paget's disease of bone - the Salford experience. Seminars in 
Arthritis and Rheumatism (In Press). 
Atalli JR, Valensi P and the French group for research and study of diabetic 
neuropathy (1990) Reproducibility of the parameters of nerve function 
investigations in diabetics. Diabetologia 33 (suppl): Al 5 
Auwerx J, Bouillon R, Collen D, Geboers J (1988) Tissue-type plasnýnogen activator 
antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 
8: 68-72. 
Baldwin SC, Black JR (1986) Pedal stress fracture associated with peripheral 
neuropathy. J Am Podiatr Med Assoc 76: 30-32 
Bays HE, Pfeifer MA (1988) Peripheral Diabetic Neuropathy. Med Clin North Am 
72: 1439-1464. 
Behse F, Buchtal F, Carlsen F (1977) Nerve biopsy and conduction studies in diabetic 
neuropathy. J Neurol Neurosurg Psychiatry 40: 1072-1082. 
Bertlesmann FW, Heimans JJ, Weber EJK van der Veen EA, Schouten JA (1985) 
Thermal discrimination thresholds in normal subjects and in patients with 
diabetic neuropathy. J Neurol Neurosurg Psychiatry 48: 685-690. 
Birke JA, Sims DA (1986) The use of Semmes-Weinstein monofilaments in the 
identification of feet at risk of insensitive injury. Lepr Rev 57: 261-264. 
181 
Bloom SR, Till S, Sonksen P, Smith S (1984) Use of a biothesiometer to measure 
individual vibration threshold and their variation in 519 non-diabetic subjects. 
Br Med J: 228: 1973-1995. 
Boulton AJM, Scarpello JIHB, Ward JD (1982) Venous oxygenation in the diabetic 
neuropathic foot: evidence for arteriovenous shunting? Diabetologia 22: 6-8. 
Boulton AJK Hardisty CA, Betts RP, Franks Cl, Worth RC, Ward JD, DuckworthT 
(1983) Dynamic foot pressures and other studies as diagnostic and management 
aids in diabetic neuropathy. Diabetes care 6: 26-33. 
Boulton AJM, Knight G, Drury J, Ward JD (1985) The prevalence of symptomatic, 
diabetic neuropathy in an insulin-treated population. Diabetes Care 8- 125-128. 
Boulton AJM, Kubrusly DB, Bowker JIL Gadia MT, Quintero L, Becker DM, Skyler 
JS, Sosenko JM (1986) Impaired vibratory perception and diabetic foot 
ulceration. Diabetic Med 3: 335-337. 
Boulton AJM (1988) The diabetic foot. Med Clin N Amer 72: 1513-1530. 
Boulton AJM (1990a) The Diabetic Foot: Neuropathic in Aetiology? Diabetic Med 7: 
852-858. 
Boulton AJM, Levin S, Comstock J (1990b) A multicentre trial of the aldose 
reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. 
Diabetologia 33: 431-437. 
Boulton AJM, Veves A, Young MJ (1993) Etiopathogenesis and Management of 
Abnormal Foot Pressures. In: Levin AE, OWeal LW, Bowker JH (Eds) The 
Diabetic Foot 5th Edition. Mosby Year Books. St Louis pp233-246. 
Brand PW (1983) The diabetic foot. In: Ellenberg XL Rifkin H. (Eds) Diabetes 
Mellitus. Theory and Practice. 3rd edition. New Hyde Park, N. Y.: Medical 
Examination Publishing; pp829-850. 
182 
Burden AC, Jones GR, Jones R, Blandford RL (1983) Use of theScotchcast boot'in 
treating diabetic foot ulcers. Br Med J 286: 1555-1557 
Cameron JR, Sorenson J (1963) Measurement of bone mineral in vivo; an improved 
method. Science 142: 230-232. 
Cameron NE, Cotter MA, Robertson S (1989) Chronic low frequency electrical 
activation for one week corrects nerve conduction velocity deficits in rats with 
diabetes of three months duration. Diabetologia 32: 759-761. 
Cameron NE, Cotter MA, Robertson S (199 1) Essential fatty acid diet 
supplementation: effects on peripheral nerve and skeletal muscle function and 
capillarisation in streptozocin-induced diabetic rats. Diabetes 40: 532-539. 
Cameron NE, Cotter MA, Low PA- (I 992a) Nerve blood flow in early experimental 
diabetes in rats: relation to conduction deficits. Am J Physiol 261: El-E8. 
Cameron NE, Cotter MA, Robertson S (I 992b) Angiotensin converting enzyme 
inhibition prevents development of muscle and nerve dysfunction and stimulates 
angiogenesis in streptozotocin-diabetic rats. Diabetologia 35: 12-18. 
Cameron NE, Cotter MA, Dines Y, Love A (I 992c) Effects of aminoguanidine on 
peripheral nerve function and polyol pathway metabolites in streptozotocin- 
diabetic rats. Diabetologia 35: 946-950. 
Carter DR, Hayes HC (1977) The compressive behaviour of bone as a two-phase 
porous structure. J Bone A Surg 59A: 954-962. 
Carter SA (1969) Clinical measurement of systolic pressures in limbs with arterial 
occlusive disease. JAMA 207: 1869-1872. 
Carter SA (1973) The relationship of distal systolic pressures to healing of skin lesions 
in limbs with arterial occlusive disease, with special reference to diabetes 
mellitus. Scand J Clin Lab Invest 31 suppl 128: 239-243 
183 
Cavanagh PR, Derr JA, Ulbrecht JS, Maser RE, Orchard TJ (1992) Problems with gait 
and posture in neuropathic patients with insulin dependent diabetes mellitus. 
Diabetic Med 9: 469-474. 
Chanteleau E, Ma XY, Hermberger S, Dohmen C, Trappe P, Baba T (1990) Effect of 
medial arterial calcification on 02 supply to exercising diabetic feet. Diabetes 
39: 513-516. 
Charcot JM (1868) Sur quelques arthropathies qui paraissent dependre dune lesion du 
cerveau ou de la moelle epiniere. Arch Physiol Nonn Pathol 1: 161-164 
Charcot JM (1992) On some arthropathies apparently related to a lesion of the brain 
or spinal cord (translated by Hoche G, Sanders LJ). J Hist Neurosci 1: 75-87 
Cho MJ, Allen MA (1978) The kinetics of prostacyclin metabolism. Prostaglandins 
' 15: 943-954 
Claus A (1957) Gerinungsphysiologische schnell methode zur bestimmung des 
fibrinogens. Acta Haematologica 17: 237-246. 
Clements RS, Bell DSH (1982) Diagnostic, pathogenetic and therapeutic aspects of 
diabetic neuropathy. Special Topics Endocrinol Metab 2: 1-42. 
Clohisy DR. Thompson RC (1988) Fractures associated with neuropathic arthropathy 
in adults who have juvenile-onset diabetes. J Bone Joint Surg 70A: 1192- 
Coburn JW (1980) Renal Osteodystrophy. Kidney Int 17: 677. 
Cofield RK Morrison MJ, Beabout JW (1983) Diabetic neuroarthropathy in the foot: 
patient characteristics and patterns of radiographic change. Foot and Ankle 4: 
15-22. 
Cogan DG, Merola L, Laibson PR (1961) Blood viscosity, serum hexosamine and 
diabetic retinoPathy. Diabetes 10: 393-395. 
184 
Coleman WC, Brand PW, Birke JA (1984) The total contact cast: a therapy for plantar 
ulceration on insensitive feet. J Am Pod Assoc 74: 548-552. 
Colwell JA, Halushka PV, Saýi KE, Sagel KE (1978) Platelet function and diabetes 
melEtus. Med Clin North Am 62: 753-766 
Connolly JF, Jacobsen FS (1985) Rapid bone destruction after a stress fracture in a 
diabetic (Charcot) foot. Nebr Med J 70: 438-440. 
Consensus Statement: report and recommendations of the San Antonio conference on 
diabetic neuropathy (1988) Diabetes 37: 1000-1004. 
Coventry M[B, Rothacker GW (1979) Bilateral os calcis ftactures in a diabetic patient. 
J Bone Joint Surg 61A: 462- 
Cundy TF, Edmonds ME, Watkins PJ (1985) Osteopenia and metatarsal fractures in 
diabetic neuropathy. Diabetic Med. 2: 461-646. 
Cutajar CL, Marston A, Newcombe JF (1973) Value of cuff occlusion pressures in 
assessment of peripheral vascular disease. Br Med J 2: 392-395. 
Dallinger KJC, Jennings PE, Toop MJ, Gyde OHB, Barnett AH (1987) Platelet 
aggregation and coagulation in insulin dependent diabetics with and without 
n-kroangiopathy. Diabetic Med 4: 44-48. 
The DCCT Research Group (1988) Factors in the development of diabetic 
neuropathy. Diabetes 37: 476481. 
DiMinno G, Silver MJ, Cerbone AM, Riccardi G, Rivellese A, Mancini M (1986) 
Platelet fibrinogen binding in diabetes mellitus. Differences between binding to 
platelets from nonretinopathic and retinopahtic diabetic patients. Diabetes 35: 
182-185. 
Donnandy J, Flute P, Matrai ABogar L, NEkita J (1985) The new St George's 
filtrometer. Clin Hemorrheol 5: 975-980 
185 
Doman TL, Rhymes EL, Cederholm-Williams SA, Rizza CR, Pepys MB, Bron AJ, 
Turner RC (1983) Plasma hemostatic factors and diabetic retinopathy. Eur J 
Clin Invest 13: 23 1-23 5. 
Duncan H (1990) Regional osteoporosis. In: Favus MJ (Ed) Primer on the metabolic 
bone diseases and disorders of mineral metabolism. 1 st edition. Kelseville, 
California: American Society for Bone and Nlineral Research, pp 157-158. 
Dyck PJ, Sherman WS, Hallcher LM, Service FJ, O'Brien PC, Grina LA, Palumbo PJ, 
Swanson CJ (1980) Human diabetic endoneurial sorbitol, fructose and 
myoinositol related to sural nerve morphometry. Ann Neurol 8: 590-596. 
Dyck P J, Kames J L, Daube J, O'Brien P, Service FJ (1985) Clinical and 
neuropathologic criteria for the diagnosis and staging of diabetic 
polyneuropathy. Brain 108: 861-880. 
Dyck PJ, Zimmerman BR, Vilen TIL Minnerath SR, Kames JL, Yao K Poduslo JF 
(1988) Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration 
and regeneration in diabetic neuropathy. N Engl J Med 319: 542-548. 
Dyck PJ (1989) Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? 
Neurology 39: 111-118. 
Dyck PJ, Kratz M Lehman KA, Karnes JL, Melton LJ, O'Brien PC, Litchy Wi, 
Windebank AJ, Smith BE, Low PA, Service FJ, Rizza RA, Zimmerman BR 
(199 1) The Rochester diabetic neuropathy study: Design, criteria for types of 
neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 
41: 799-807. 
Edelman SV, Kosofsky ENt Paul RA, Kozak GP (1987) Neuro-osteoarthropathy 
(Charcot's joints) in diabetes mellitus following revascularisation surgery: three 
case reports and a review of the literature. Arch Intern Med 147: 1504. 
186 
Edmonds ME, Morrison N, Laws JW and Watkins PJ (1982a) Medial arterial 
calcification and diabetic neuropathy. Br Med J 284: 928-930. 
Edmonds ME, Roberts VC, Watkins PJ (1982b) Blood flow in the diabetic 
neuropathic foot. Diabetologia 22: 9-15. 
Edmonds ME, Clarke M[B, Newton S, Barrett J, Watkins PJ (1985) Increased uptake 
of bone radiopharmaceutical in diabetic neuropathy. Quart J Med 57: 843-855. 
Edmonds ME, Blundell MP, Morris NIIE, Maelor-Thomas E, Cotton LT, Watkins PJ 
(1986) Improved survival of the diabetic foot: the role of the specialist foot 
clinic. Quart J Med 232: 763-771. 
Eichenholtz SN (1966) Charcot Joints. Charles C Thomas Springfield, III 
Eickhoff JH, Jacobsen E (1980) Correlation of transcutaneous oxygen tension to 
blood flow in heated skin. Scand J Clin Lab Invest 40: 755-765. 
Eliason SG (1964) Nerve conduction changes in experimental diabetes. J Clin Invest 
43: 237-240. 
Emanuele MA, Buchanan BJ, Abraira C (198 1) Elevated leg systolic pressures and 
arterial calcification in diabetic occlusive vascular disease. Diabetes Care 4: 
289-292. 
European Consensus Document on Critical Limb Ischaemia. Dormandy J (Ed) (1989) 
Springer Verlag, Berlin 
Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH (1988) Medial arterial 
calcification and its association with mortality and complications of diabetes. 
Diabetologia 31: 16-23. 
Fagerberg SE (1959) Diabetic neuropathy: a clinical and histologic study on the 
significance of vascular affections. Acta Medica, Scand (Suppl 345): 1-80 
187 
Fagius J, Brattberg A, Jameson S, Berne C (1985) Limited benefit of treatment of 
diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled 
trial. Diabetologia 28: 323-329. 
Faris I, Agerskov K, Henrikson 0, Lassan NA, Parving H-H (1982) Decreased 
distensibility of a passive vascular bed in Diabetes Mellitus: An indicator of 
n&roangiopathy? Diabetologia 23: 411-414. 
Ferrier TM (1964) Radiologically demonstrable arterial calcification in Diabetes 
Mellitus. Aus J Med 13: 222-228. 
Fisher BM, Quin JD, Rumley A, Lennie SE, Small K MacCuish AC (199 1) Effects of 
acute insulin-induced hypoglycaernia on haernostasis, fibrinolysis and 
haemorheology in insulin-dependent diabetic patients and control subjects. Clin 
Sci 80: 525-531. 
Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour- 
induced hypercalcaemia and metastatic bone disease. Drugs 42: 919-944. 
Flynn MD, Tooke JE (1992) Aetiology of Diabetic Foot Ulceration: A Role for the 
Nlicrocirculation? Diabetic Med 8: 320-329 
Ford I, Malik RA, Newrick PG, Preston FE, Ward JD, Greaves M (1992) 
Relationships between haemostatic factors and capillary morphology in human 
diabetic neuropathy. Thromb Haemostas 68: 628-633 
Franklin GM, Kahn LB, Baxter J, Marshall JA, Haniman RF (1990) Sensory 
neuropathy in non-insulin dependent diabetes mellitus. The San Luis Valley 
study. Amer JEpideniiol 131: 633-643. 
FryckbergRG(1987)Osteoarthropathy. ClinPodiatrMedSurg4: 351-356. 
Fuller JH, Keen K Jarrett RJ, Omer T, Meade TW, Chakrabarti R (1979) Haemostatic 
variables associated with diabetes and its complications. Br Med J 2: 964-966. 
188 
Gabbay KH (1973) The sorbitol pathway and the complications of diabetes. N Engl J 
Med 288: 831-836. 
Ganda OP (1984) Pathogenesis of accelerated atherosclerosis in diabetes. In: Kozak 
GP, Hoar CS, Rowbotharn JL, Wheelock FC, Gibbons GW, Campbell D (Eds) 
Management of Diabetic Foot Problems. WB Saunders, Philadelphia, USA pp 
17-26. 
Ganda OP, Arkin CF (1992) Hyperfibrinogenaemia An important risk factor for 
vascular complications in diabetes. Diabetes Care 15: 1245-1250. 
Garcia Frade LJ, de la Calle I-L Torade MC, Lara JL, Cuellar L, Garcia Avella A 
(1990) Hypofibrinolysis associated with vasculopathy in non-insulin dependent 
diabetes mellitus. Thromb Res 59: 51-59. 
Gaylarde PK Fonseca VA, Llewellyn G, Sarkany I, Thomas PK, Dandona P (1988) 
Transcutaneous oxygen tension in legs and feet of diabetic patients. Diabetes 
37: 714-716. 
Geoffroy J, , Hoeffel JC, Pointel JP, Drouin P, Debry G, Martin R (1979) The feet in 
diabetes. Roentgenologic observations in 1501 cases. Diag Imaging 48: 286- 
293. 
Gerrard JK Stuart MJ, Rao GHR (1980) Alteration in the balance of prostaglandin 
and thromboxane synthesis in diabetic rats. J Lab Clin Med 95: 950-958. 
Giugliamo D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello 
A, Torella R (1993) Tolrestat for mild diabetic neuropathy. A 52-week, 
randomized, placebo controlled trial. Ann Intern Med 118: 7-11 
Goebel F-D, Fuessi HS (1983) M6nckeberg's sclerosis after sympathetic denervation 
in diabetic and non-diabetic subjects. Diabetologia 24: 348-350. 
Goodman JL, Baumoel S, Frankel L, Marcus LJ, Wasserman S (1953) The Diabetic 
Neuropathies. CC Thomas, Springfield, Illinois pp 1-66. 
189 
Gordge NT, Patel A, Faint RW, Rylance PB, Neild GH (1990) Blood hyperviscosity 
and its relationship to progressive renal failure in patients with diabetic 
nephropathy. Diabetic Med 7: 880-886. 
It 
Goss DE, de Trafford J, Roberts VC, Flynn MD, Edmonds MIE, Watkins PJ (1989) 
Raised ankle pressure index in insulin-treated diabetic patients. Diabetic Med 6: 
576-578. 
Grant PJ, Medcalf RL (1990) Hormonal regulation of haemostasis and the molecular 
biology of the fibrinolytic system. Clin Sci 78: 3-11. 
Grant PJ (1991) Disorders of the fibrinolytic system in diabetes mellitus. Treating 
Diabetes 34. Medicom, Kingston upon Thames pp 8-11 
Greene DA, Dejesus PV, Winegrad AI (1975) Effects of insulin and dietary 
myoinositol on impaired motor nerve conduction velocity in acute streptozotocin 
diabetes. J Clin Invest 55: 1326-1336. 
Greene DA, Lattimer SA (1984) Action of sorbinil in diabetic peripheral nerve: 
relationship of polyol (sorbitol) pathway inhibition to a myoinositol mediated 
effect in sodium-potassium ATPase activity. Diabetes 33: 712-716. 
Greene DA, Lattimer SA, Sima AAF (1988) Are disturbances of Sorbitol, 
Phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of 
diabetic neuropathy? Diabetes 37: 688-693. 
Gregersen G (1967) Diabetic neuropathy: Influence of age, sex, metabolic control, 
and duration of diabetes on motor conduction velocity. Neurology 17: 972-980. 
Gregerson G, Bertelsen B, Harbo 11, Larsen E, Anderson JR, Helles A, Schmiegelow 
K Christensen JE (1983) Oral supplementation of myoinositol: effects on 
peripheral nerve function in human diabetes and on the concentration in plasma, 
erythrocytes, urine and muscle tissue in human diabetics and normals. Acta 
Neurologica Scand 67: 164-172. 
190 
Griffey RK Eaton P, Sibbitt RR, Sibbitt WL, Bicknell JM (1988) Diabetic Neuropathy 
Structural analysis of nerve hydration by magnetic resonance spectroscopy. 
JAMA 260: 2872-2878. 
fUe PJ, Nattrass M, Silvennan SA Sennit C, Perkins CM, Helen A Sundkvist G 
(1987) Peripheral nerve concentrations of glucose fructose, sorbitol and 
myoinositol in diabetic and non-diabetic patients. Diabetologia 30: 464-467 
Halushka PV, Rogers RC, Loadholt CB. Colwell A (198 1) Increased platelet 
thromboxane synthesis in diabets mellitus. J Lab Clin Med 97: 87-96 
Hamsten A, Wiman B, deFaire U, Blomback M (1985) Increased plasma levels of a 
rapid inhibitor of tissue plasminogen activator in young surviors of myocardial 
infarction. New Engl J Med 313: 1557-1563( 
Hauser CJ, Ydein SR, Mehringer M, Appel P, Shoemaker WC (1984) Assessment of 
perfusion in the diabetic foot by regional transcutaneous oximetry. Diabetes 33: 
527-531 
Hetherington VJ (1982) Technetium and combined Gallium and Technectium. scans in 
the neurotrophic foot. J Am Podiatr Assoc 72: 458-463. 
Hooper MJ, Clifton-Bligh P, Marel GM, Lang FV, Tancred J, McDowall D (1993) 
Single day intravenous pamidronate in Paget's disease. Serninars in Arthritis and 
Rheumatism(In Press). 
Hunter GC, Song GW, Nayak NN, Zapotowski D, Guernsey JM (1988) Peripheral 
nerve conduction abnonnalities in lower extrenýty ischaeýnia: the effects of 
revascularisation. J Surg Res 45: 96-103 
Isogai Y, Yokose T, Maeda T, Akiyama M, Onogi S, Masuda T, Ohmachi T, 
Iwamoto S (1984) The OP-rheometer system, a new device for analysis of 
viscosity and viscoelasticity of blood: description and clinical application. 
Biorheology Suppl L 35-41 
191 
Jamal GA (1990) Pathogenesis of diabetic neuropathy. The role of the n-6 essential 
fatty acids and their eiconasoid derivatives. Diabetic Med 7: 574-579 
Jamal GA, Carmichael H (1990) The effect of Gamma-linoleic acid on human diabetic 
peripheral neuropathy: A double blind placebo controlled trial. Diabetic Med 7: 
319-323 
Janka HU, Stadl E, Mehnert H (1980) Peripheral vascular disease in diabetes mellitus 
and its relation to cardiovascular risk factors: screening with Doppler ultrasonic 
technique. Diabetes Care 3: 207-213. 
Jay RH, Ones SL, Ilill CE, Richmond W, Viberti GC, Rampling MW, Betteridge DJ 
(199 1) Blood rheology and cardiovascular risk factors in type I diabetes: 
Relationship with rnicroalburninuria. Diabetic Med 8: 662-667 
Jensen T, Borch-Johnsen Y, Kofbed-Enevoldsen A, Deckert T (1987) Coronary heart 
disease in young Type I (insulin-dependent) diabetic patients with and without 
diabetic nephropathy: incidence and risk factors. Diabetologia 30: 144-148. 
Johnson JTH (1967) Neuropathic fractures and joint injuries: pathogenesis and 
rationale of prevention. J Bone Joint Surg 49A: 1-30 
Johnson K Harrison BE, Raftery AT, Elder JB (1979) Vascular prostacyclin may be 
reduced in diabetes in man. Lancet i: 325-326 
Jones DB, Carter RD, Haitas B, Mann JI (1983) Low phospholipid araclUonic acid 
levels in diabetic platelets. Br Med 1286: 173-175 
Jordan WR (1936) Neuritic manifestations in diabetes mellitus. Arch Intem Med 57: 
307-312 
Juhan-Vague I, Rahmani Jourdheuil D, Nfishal Z, Roul C, Mourayre Y, Mlaud Nff, 
Vague P (1986) Correction by insulin added in vitro of abnormal membrane 
fluidity of the erythrocyte from type I (insulin-dependent) diabetic patients. 
Diabetologia 29: 417-420 
192 
Juhan-Vague L Vague P, Alessi MC, Backer C, Valadier J, Aillard NE, Atlan C 
(1987) Relationship between plasma insulin, triglyceride, body mass index and 
plasmingen activator inhibitor 1. Diabete Metabol 13: 331-336 
Juhan-Vague 1, Roul C, Alessi MC, Ardisssone JP, Heim K Vague P (1989) 
Increased plasminogen activator inhibitor activity in insulin dependent diabetic 
patients. Relationship with plasma insulin and the acute phase response. 
Thromb Haemostas 61: 370-373 
Juhan-Vague 1, Alessi MC, Vague P (1991) Increased plasma plasminogen activator 
inhibitor I levels. A possible link between insulin resistance and 
atherothrombosis. Diabetologia 34: 457462 
Kamada T, Otsuji STI (1983) Lower levels of erythrocyte membrane fluidity in 
diabetic patients. A spin label study. Diabetes 32: 585-591 
Kamada T, McNfillan DE, Yamashita T, Otsuji S. (1992)Lowered membrane fluidity 
of younger erythrocytes in diabetes. Diabetes Res Clin Pract 16: 1-6 
Karpen CW, Pritchard KA, Merola AJ, Panganamala RV (1982) Alterations of the 
prostacyclin-thromboxane ratio in streptozotocin-induced diabetic rats. 
Prostaglandins, Leukotrienes, and Medicine 8: 93-103 
Keen H (1993) The gamma-finoleic acid multicentre trial group. Treatment of diabetic 
neuropathy with gamma-linoleic acid. Diabetes Care 16: 8-15 
Kernoff PBA, Willis AL, Stone KJ, Davis JA, McNicol GP (1977) Antithrombotic 
potential of dihorno-garnma-linolenic acid in man. Br Med J 275: 1441-1444 
Kerr R, Sartoris DJ, Fix CF, Resnick D (1991) Imaging of the Diabetic foot. In: 
Frykberg RG (Ed. ) The high nsk foot in Diabetes Mellitus. New York, 
Churchill Livingstone, 
Kluft C, Potter van Loon BJ, de Maat MPM (1992) Insulin resistance and changes in 
haernostatic variables. Fibrinolysis 6 (suppl 3): 11-16 
193 
Knezevic W, Mastalgia FL (1984) Neuropathy associated with Bresica-Cinýino 
arteriovenous fistulas. Arch Neurol 41: 1184-1192. 
Knuirnan MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ (1986) 
Prevalence of diabetic complications in relation to risk factors. Diabetes 35: 
1332-1339 
KoziakM (1959) Etiology and pathology of ischaernic ulcers. Arch Phys Med Rehab 
40: 62-69. 
Kumar S, Ashe K Parnell L, Tsigos C, Fernando DJS, Young RJ, Ward JD (1992) A 
population-based prevalence study of foot ulceration, peripheral neuropathy and 
peripheral vascular disease in Type 2 diabetes. Diabetic Med 9 (suppl 2): S40. 
Kumar S, Fernando DJS, Veves A, Knowles A, Young MJ, Boulton AJM (1991) 
Semmes-weinstein monofilaments: a simple, effective and inexpensive screening 
device for identifying diabetic patients at risk of foot ulceration. Diabetes Res 
Clin Practice 13: 63-67. 
Lachman AS, Spray TL, Kerwin DM, Shugoll GI, Roberts WC (1977) Medial 
calcinosis of M6nckeberg. A review of the problem and a description of a patient 
with involvement of Peripheral, visceral and coronary arteries. Am J Med 63: 
6715-6722. 
Landin K, Tengborn L, Chmielewska J, von Schenk H. Smith U (199 1) The acute 
effect of insulin on tissue plasminogen activator and plasminogen activator 
inhibitor in man. Thromb Haemost 65: 130-133. 
Lehtinen J Nt Uusitupa Nt Siitonen 0, Pyorala K (1989) Prevalence of neuropathy in 
newly diagnosed NIDDM and non-diabetic control subjects. Diabetes 38: 1307- 
1313. 
194 
Leiper JK Lowe GD, Anderson J, Bums P, Cohen HN, Manderson WG, Forbes Cd, 
Barbanel JC, MacCuish AC (1984) Effects of diabetic control and biosynthetic 
human insulin on blood rheology in established diabetics. Diabetes Res 1: 27-30. 
Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237: 1154- 
1162. 
Low PA, Schmelzer JD, Ward KK, Yao JK (1986) Experimental chronic hypoxic 
neuropathy: relevance to diabetic neuropathy. Am J Physiol 250: E94-99 
Low PA (1987a) Recent advances in the pathogenesis of diabetic neuropathy. Muscle 
and Nerve 10: 121-128. 
Low PA, Tuck RR, Takenchi M (1987b) Nerve rnicroenviromnent in diabetic 
neuropathy. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad Al, Porte D 
(Eds) Diabetic Neuropathy. Philadelphia. WB Saunders pp266-278 
Lowe GD, Lowe JM, Drummond MK Reith S, Belch JJ, Kesson CXL Wylie A, 
Foulds WS, Forbes CD, MacCuish AC, Manderson WG 0980a) Blood viscosity 
in young male diabetics with and without retinopathy. Diabetologia IS: 359- 
363. 
Lowe GDO, Drummond NK Forbes CD, Barbanel JC (1980b)The effects of age and 
cigarette smoking on blood and plasma viscosity in men. Scott Med J 25: 13-17. 
Lowe GDO, Ghafour IM, Belch JJF, Forbes CD, Foulds WS, MacCuish AC (1986) 
Increased blood viscosity in diabetic proliferative retinopathy. Diabetes Res 3: 
67-70 
Lukkari-Rautiarinen E, Lepantalo M, Pietila J (1989) Reproducibility of skin blood 
flow, perfusion pressure and oxygen tension measurements in advanced lower 
limb ischaemia. Eur J Vasc Surg 3: 345-350. 
MacFarlane IA, Benbow SJ, Chan AW, Bowsher D, Williams G (1993) Diabetic 
peripheral neuropathy: the significance of plantar foot temperatures as 
195 
demonstrated by liquid crystal contact thermography. Diabetic Med 10 (suppl 
1): P 104. 
Macleod AF, Williams DRR, Sonksen PR Boulton AIM (1991) Risk factors forroot 
ulcers in diabetic patients attending a hospital clinic. Diabetologia 34 (suppl): 
A39 
MacMillan DE (1974) Disturbance of serum viscosity in diabetes mellitus. J Clin 
Invest 53: 1071-1079. 
MacRury SNt Lowe GDO (1990) Blood rheology in diabetes mellitus. Diabetic Med 
7: 285-291. 
MacRury SK Lockhart JC, Small K Weir AI, MacCuish AC, Lowe GDO (1991) Do 
rheological variables play a role in diabetic peripheral neuropathy? Diabetic Med 
8: 232-236. 
MacRury S, Maduako C, Lowe G, MacCuish A, Barbenel J (1993a) Transcutaneous 
oxygen tension in diabetes: relation to peripheral neuropathy and blood 
rheology. J Tissue Viability 3: 6-9. 
MacRury SM, Lennie SE, McColl P, Balendra R, MacCuish AC, Lowe GDO (1993b) 
Increased red cell aggregation in diabetes mellitus: Association with 
cardiovascular risk factors. Diabetic Med 10: 13-20. 
Malik RA, Masson EA, Sharma AY, Lye PJL Ah-SEe AY, Compton AM, Tomlinson 
DR, HAnley SP, Boulton AJM (1990) Hypoxic neuropathy: relevance to human 
diabetic neuropathy. Diabetologia 33: 311-318. 
Malik RA, Newrick PG, Sharma AY, Jennings A, Ah-See AY, Mayhew TM, 
Jakubowski J, Boulton AJNL Ward JD (1989) Microangiopathy in human 
diabetic neuropathy: relationship between capillary abnormalities and the severity 
of neuropathy. Diabetologia 32: 92-102 
196 
Maser RE, Steenkiste A R, Donnan J S, Nielsen VK, Bass EB, Manjoo Q, Drash AL, 
Becker DL, Kuller DL, Greene DA, Orchard TJ (1989) Epidemiological 
correlates of Diabetic Neuropathy: Report from Pittsburgh epidemiology of 
diabetes complications study. Diabetes 38: 1456-1461. 
Masson EA, Church SE, Woodcock AA, Hanley SP, Boulton AJM (1988) Is 
resistance to ischaemic conduction failure induced by hypoxia? Diabetologia 3 1: 
762-765. 
Masson EA, 'Veves A, Fernando D, Boulton AJM (1989a) Current perception 
thresholds: a new, quick and reproducible method for the assessment of 
peripheral neuropathy in diabetes mellitus. Diabetologia 32: 724-728. 
Masson EA, Hay EM, Stockley 1, Veves A, Betts RP, Boulton AJM (1989b) 
Abnormal foot pressures alone may not cause ulceration. Diabetic Med 6: 426- 
428. 
Masson EA, Boulton AJM (1990a) Aldose reductase inhibitor in the treatment of 
diabetic neuropathy. A revieýv of the rationale and clinical evidence. Drugs 39: 
190-202. 
Masson EA, Boulton AJM (1990b) Calibration problems with the Biothesiometer. 
Diabetic Med 7: 261-262. 
Matrai A, Whittingdon RB, Ernst E (1987) A simple method of estimating whole 
blood viscosity at a standardised haematocrit. Clin Hemorheol 7: 261-265. 
Mayne N (1965) Neuropathy in the diabetic and non-diabetic populations. Lancet ii: 
1313-1316. 
McEnery KW, Gilula LA, Hardy DC, Staple TW (1993) Imaging of the diabetic foot. 
In: Levin ME, OWeal LW, Bowker JH (Eds). The Diabetic Foot 5th Edition. 
Mosby Year Books. St Louis pp341-364 
197 
McLaren Nt Jennings PF, Forbes CD, Belch JJF (1990) Fibrinolytic response to 
vcnous occlusion in diabctes Aith and %%ithout microangiopathy compared to 
nomul aged and sex-nutched controls. Fibrinolysis 4: 95-96. 
Meade T%V, Chak-rabarti P, Ilaincs AP, North %VRS, Stirfing Y, Thompson SG 
(1980) Hamostatic function and cardioNwcular death: early results of a 
prospective study. Lancet i: 1050- 1053. 
Modesti PA, Abbate R, Gensini GF, Coldla A, Semeri GGN (1991) Platelet 
thromboxine A2 rcccptors in qW I diabctes. Clin Sci 80: 101-105. 
hioncada S, Vane JR (1979) Pharmacology and endogenous roles of prostaglandins, 
endopcroxides, thromboxane Al and prostacyclim Phannacol Rev 30: 293-315. 
hlorrish NJ. Stcvctu LK, Fuller JI 1, Keen IL Jarrett RJ (199 1) Risk factors for 
macrovascular disease in diabetes mellitus: the London follow-up to the WHO 
Multinational Study of Vascular Disease in Diabetics. Diabetologia 34: 590- 
594. 
Morrison LB, Bogan IK (1929) Calcification of the vessels in diabetes. JANIA 92: 
1424-1426. 
Nctclenbos JC, van Ginkcl FC, Lips P, Lccuwcnkamp OR, Barto R, van der Vijgh JF 
0 99 1) Effccl ors single infusion ofaminohydroxypropylidene on calcium and 
bone metabolism in healthy volunteers monitored during two months. J Clin 
Endocrinol Nictab 72: 223-228. 
Neubauer B (197 1) A quantitative study of peripheral arterial calcification and glucose 
tolerance in elderly diabetics and non-diabctics. Diabctologia 9: 409413. 
Newrick IIG, Wilson AJ, JAubowski J, Boulton AINI, Ward JD (1986) Sural nerve 
oxygen tension in diabetes. Dr INfed J 293: 1053-1054. 
198 
Nillson SE, Lindholm I-L Bfllow S, Frostberg N, Emilsson T, Stenkula G (1967) The 
Kristianstad survey 63-64 (Calcifications in arteries of lower limbs). Acta 
Medica Scand 428(Suppl): 146. 
Nowak D, Bruch Nt Amaud F, Fabel a Kiessling D, Nolte D, Overlack A, Rolke Nt 
Ulmer WT, Worth H (1990) Peripheral neuropathies in patients with chronic 
obstructive pulmonary disease: a multicenter prevalence study. Lung 168: 43- 
51. 
O'Brien JAO, OHare P, Corral RJM (1986) heart rate variability in healthy subjects: 
effect of age and the derivation of normal range for tests of autonomic function. 
Br Heart J 62: 348-354. 
O'Donnell MJ, Le Guen CA, Lawson N, Gyde OHB, Barnett AH (199 1) Plaetlet 
behaviour and haemostatic vaiiables in type I (insulin dependent) diabetic 
patients with and without alburninuria. Diabetic Med 8: 624-628. 
O'Malley BC, Timperley WR, Ward JD, Porter NR, Preston FE (1975) Platelet 
abnonnalities in diabetic peripheral neuropathy. Lancet ii: 1274-1280. 
Ohno A, Kanazawa A, Tanaka A, Nfiwa T, Ito H (1992) Effect of prostaglandin 12 
derivative (Iloprost) on peripheral neuropathy of diabetic rats. Diabetes Res 
Clin Prac 18: 123 -13 0. 
Paganini-l-lill A, Ross RK, Gerkins VR, Henderson BE, Arthur K Mack TM (198 1) 
Menopausal estrogen therapy and hip fractures. Ann Int Med 95: 28-3 1. 
Paisey RB, Harkness J, Hartog M, Chadwick T (1980) The effect of improvement in 
diabetic control on plasma and whole blood viscosity. Diabetologia 19: 345- 
349. 
Partsch H (1978) Gestyorte Gefassregulation bei ulzero-multierenden. Neuropathien 
der unteren Extrernitaten. Vasa 7: 119-125. 
199 
Parving HII, Viberti GC, Keen IL Christiansen JS, Lassen NA (1983) Haemodynamic 
factors in the genesis of diabetic microangiopathy. Metabolism 32: 943-949 
Patel V, Rassam S, Newsom R, Wiek J, Kohner E (1992) Retinal blood flow in 
diabetic retinopathy. Br Med J 305: 678-683. 
Pecoraro RE, Ahroni JI-L Boyko EJ, Stensel VL (1991) Chronology and deterninants 
of tissue repair in diabetic lower-extremity ulcers. Diabetes 40: 1305-1313. 
Pfeifer MA, Weinberg CR, Cook DL, Reenan A, Halar E, Halter JE, LaCava EC, 
Porte D (198 5) Correlations among autonomic, sensory, and motor neural 
function tests in untreated non-insulin dependent diabetic individuals. Diabetes 
Care 8: 576-584. 
Pirart J (1978) Diabetes mellitus and its degenerative complications: A prospective 
study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1: Part 
1,168-188; Part 2,252-263. 
Pogonowska MJ, Collins LC, Dobson HL (1967) Diabetic osteopathy. Radiology 89: 
265-271. 
Poon PYW, Doman TL, Orde-Peckar C, Mullins 1; ý Bron AJ, Turner RC (1982) 
Blood viscosity, glycaeinic control and retinopathy in insulin-dependent diabetes. 
Clin Sci 63: 211-216. 
Potter van Loon BJ, De Bart ACW, Radder JY, Frolich K Kluft C, Meinders AE 
(1990) Acute exogenous hyperinsulinaemia does not result in elevation of 
plasma plasminogen activator inhibitor- I (PAI- 1) in humans. Fibrinolysis 4 
(suppl 2): 93-94. 
Pryce TD (1887) A case of perforating ulcers of both feet associated with diabetes and 
ataxic symptoms. Lancet ii: I 1- 12. 
Rabinowe SL, Brown M Watts M, Kadrofske NM Vinik AI (1989) Anti- 
sympathetic ganglia antibodies and postural blood pressure in IDDM subjects of 
200 
varying duration and patients at high risk of developing IDDM. Diabetes Care 
12: 1-6 
Railton R, Newman P, Hislop J, Harrower ADB (1983) Reduced transcutaneous 
oxygen tension and impaired vascular response in type I (insulin-dependent) 
diabetes. Diabetologia 25: 340-342. 
Ram Z, Sadeh K Walden R, Adar R (199 1) Vascular insufficiency quantitatively 
aggravates diabetic neuropathy. Arch Neurol 48: 123 9-1242 
Rampling MW, Feher MD, Sever PS, Elkeles RS (1989) Hemorheological 
disturbances in non-insulin-dependent diabetes and the effects of concomitant 
hypertension. Clin Hemorrheol 9: 101-107. 
Rayman G, Willams SA, Spencer PD, Smaje LK Wise PK Tooke JE (1986) Impaired 
microvascular response to minor skin trauma in Type I diabetes. Br Med J 292: 
1295-1298. 
Rehman MTA, Clayson AD, Marsh D, Adams J, Canteril J, Anderson DC (1992) 
Treatment of reflex sympathic dystrophy with intravenous pamidronate. Bone 
13: 116. 
Reimann H, Bollinger A (1974) Pseudohypertonie bei mediasklerose. Schweiz Med 
Wochensch 104: 1813-1817. 
Renton P (1990) Orthopedic Radiology. Chicago, Year Book Medical Publishers, 
Reubi FC (1953) Glomerular filtration rate, renal blood flow and blood viscosity 
during and after diabetic coma. Circulat Res 1: 410-413. 
Riggs JE, Moss AK Labosky DA, Liput JR Morgan JJ, Gut Mann L (1989) Upper 
extremity ischaemic monomelic neuropathy: a complication of vascular access 
procedures in uremic diabetic patients. Neurology 39: 997-998. 
201 
Robey C, Dasmahapatra A, Cohen NP, Suarez S (1987) Sorbinil partially prevents 
decreased erythrocyte deformability in experimental diabetes mellitus. Diabetes 
36: 1010-1013. 
Rodriguez-Sanchez C, Sanchez MPvL Malik RA, Ah-See AK, Sharma AK (199 1) 
Morphological abnormalities in the sural nerve from patients with peripheral 
vascular disease. Histol Histopath 6: 63-7 1. 
Sammarco GJ (1991) Diabetic arthropathy. In: Sammarco GJ (Ed) The Foot in 
Diabetes. Lea& Febiger. Philadelphia, USA ppl53-172. 
Sandernan DD, Shore AC, Tooke JE (1992) Relation of skin capillary pressure in 
patients with insulin-dependent diabetes mellitus to complications and metabolic 
control. N Eng J Med 327: 760-764. 
Sanders LJ, Frykberg RG (1991) Diabetic neuropathic osteoarthropathy: The Charcot 
foot. In: Frykberg RG (Ed) The I-1igh Risk Foot in Diabetes. Churchill 
Livingstone. New York pp297-238 
Sanders LJ, Frykberg RG (1993) Charcot Foot. In: Levin ME, ONeal LW, Bowker 
JH (Eds) The Diabetic Foot 5th Edition. Mosby Year Books. St Louis pp149- 
180 
Schneider SK Kein HC, Khachdurian AY, Ruderman NB (1988) Impaired fibrinolytic 
response to exercise in Type II diabetes: effects of exercise and physical training. 
Metabolism 37: 924-91^49. 
Seeman E, Martin TJ( 1989) Non-invasive techniques for the measurement of bone 
mineral. In: Chan FL, Wang C (Eds) Bailliere's Clinical Endocrinology and 
Metabolism Vol. 3 Number 1. Imaging Endocrine Disorders. Bailliere Tindall, 
London ppl-33. 
Selby PL (1988) Osteopenia and diabetes. Diabetic Med 5: 423-428. 
202 
Shore AC, Price KJ, Sandeman DD, Green EK Tripp JH, Tooke JE (199 1) Impaired 
microvascular hyperaerrýc response in children with diabetes mellitus. Diabetic 
Med 8: 619-623. 
Silberkane NO, Silberbauer Y, Schernthauer G, Sinziger K Pizakalzer H, Winter M 
(1979) Decreased vascular prostacyclininjuvenile-onset diabetes. NEngJMed 
300: 366-367. 
Sima AAF, Bouchier K Christensen H (1988) Axonal atrophy in sensory nerves of 
the diabetic BB-Wistar rat: a possible early correlate of human diabetic 
neuropathy. Ann Neurol 319: 548-555. 
Sima AAF, Cherian V, Albers JW, Greene DA and the Tolrestat Study Group (1992) 
Nerve fiber loss in diabetic neuropathy correlates with impaired evoked potential 
amplitudes and nerve conduction velocity. Diabetologia 35 (suppl 1): A157. 
Simpson LO (1988) Altered blood rheology in the pathogenesis of diabetic and other 
neuropathies. Muscle and Nerve 11: 725-744. 
Sinha S, Munichoodappa CS, Kozak GP (1972) Neuroarthropathy (Charcot joints) in 
diabetes mellitus. Medicine (Baltimore); 51: 191-210. 
Sladky JT, Tschoepe RL, Greenberg JH, Brown MJ (1991) Peripheral neuropathy 
after chronic endoneurial ischaen-ýia. Ann Neurol 29: 272-278. 
Small K Lowe GDO, MacCuish AC, Forbes CD (1987) Thrombin and plasmin 
activity in diabetes mellitus and their association with glycaen& control. Quart J 
Med 65: 1025-103 1. 
Stein JA, Hochberg AM, Lazewatsky L (198 8) Quantitative digital radiography for 
bone mineral analysis. In: Deqeucker J, Geusens P. Wahner HW (Eds) Bone 
Mineral Measurement by Photon Absorptiometry. Leuven University Press. 
Leuven, Belgium pp412-414. 
203 
Steiness IB (1957) Vibratory perception in Diabetics. Acta Medica Scand 158: 327- 
355. 
Steiness 113 (1959) Vibratory perception in diabetics during arrested blood flow to the 
limb. Acta Medica Scand 163: 195-205. 
Stevens EJ, Lockett MJ, Carrington AI, Tomlinson DR (1993) Essential fatty acid 
treatment prevents nerve ischaernia and associated conduction anomalies in rats 
with experimental diabetes. Diabetologia36: 397-401. 
Stevens MJ, Edmonds ME, Foster AVK Douglas SLE, Watkins PJ (1992a) 
Paradoxical blood flow responses in the diabetic neuropathic foot: an 
assessment of the contribution of vascular denervation and microangiopathy. 
Diabetic Med 9: 49-54. 
Stevens MJ, Edmonds NIIE, Foster AVK Watkins PJ (1992b) Selective neuropathy 
and preserved vascular responses in the diabetic Charcot foot. Diabetologia 3 5: 
148-154. 
Stewart MA, Sherman WR, Kurien MK Moonsammy GI, Wisgerhof M (1967) 
Polyol accumulation in nervous tissue of rats with experimental diabetes and 
galactosaemia. J Neurochem 14: 1057-1066. 
Strandness DE Jr, Priest RE, Gibbons GE (1964) Combined clinical and pathologic 
study of diabetic and non diabetic peripheral arterial disease. Diabetes 13: 366- 
372. 
Tawn DJ, OHare JP, O'Brien IAD, Watt 1, Dieppe PA, Corrall RJM (1988) Bone 
scintigraphy and radiography in the early recognition of diabetic osteopathy. 
Brit J Radiol 61: 273-279. 
Tesfaye S, Harris N, Jakubowski J, Mody C, Ward JD (1990) Impaired blood flow 
and arterio-venous shunting in human diabetic sural nerve. Diabetic Med 7 
(suppl 2): 29A. 
204 
Tesfaye S, Harris ND, Wilson RK Ward JD (1992) Exercise-induced conduction 
velocity increment: a marker of impaired peripheral nerve blood flow in diabetic 
neuropathy. Diabetologia 35: 155-159. 
Thomas DJ, Marshall J, Ross Russell RW, Wetherley-Mein G, du Boulay GK Pearson 
TC, Symon L, Zilkha E (1977) Effect of haematocrit on cerebral blood flow in 
man. Lancet ii: 941-943. 
Thomson FJ, Veves A, Ashe I-L Knowles EA, Gem J, Walker MG, Mrst P, Boulton 
AJM (1991) A team approach to diabetic foot care - the Manchester experience. 
The Foot 2: 75-82. 
Tooke JE, Nfilligan DW (1987) Capillary blood flow in hernatological disorders: the 
role of the red cell, -white cell, and plasma viscosity. Clin Hemorrheol 7: 311- 
319. 
Tooke JE (1986) Microvascular haernodynarnics in diabetes mellitus. Clin Sci 70: 
119-125. 
Uhthoff HK, Jaworski ZFG (1985) Periosteal stress-induced reactions resembling 
stress fractures in dogs. Clin Orthop Rel Res 199: 284-291. 
Valensi P, Attali JR, Behar A, Attalah M, S ebaoun J (199 1) Increased capillary 
permeability to albumin and diabetic neuropathy. Diabetes Res Clin Prac 11: 41- 
46. 
Veves A, Malik RA, Lye RK Masson EA, Shanna AY., Schady W, Boulton AJM 
(1991 a) The relationship between sural nerve morphometric findings and 
measures of peripheral nerve function in mild diabetic neuropathy. Diabetic Med 
8: 917-921. 
Veves A, Femando DJS, Walewski P, Boulton AJM (1991b) A study of plantar 
pressures in a diabetic clinic population. The Foot 1: 89-91. 
205 
Veves A, Boulton AJM (1992a) Diabetic neuropathy: the diabetologist's view. In: 
Horrobin DF (Ed) Treatment of diabetic neuropathy. A new approach. 
Churchill Livingstone, Edinburgh pp I- 10. 
Veves A, Murray HJ, Young MJ, Boulton AJM (1992b) The risk of foot ulceration in 
diabetic patients with high foot pressure: a prospective study. Diabetologia 35: 
660-663. 
Walmsley D, Wales JY, Wiles PG (1989) Reduced hyperaemia following skin trauma; 
evidence for an impaired microvascular response to injury in the diabetic foot. 
Diabetologia 32: 736-739. 
Walmsley D, Hampton KK, Grant PJ (199 1) Contrasting fibrinolytic responses in type 
I (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabetic 
Med 8: 954-959. 
Ward JD, Simms JK Knight G, Boulton AJK Sandler DA (1983) Venous distension 
in the diabetic neuropathic foot (physical sign of arteriovenous shuliting). J Roy 
Soc Med 76: 1011-1014. 
Ward JD, Barnes CG, Fisher DJ, Jessop JD (1971) Improvement in nerve conduction 
following treatment in newly diagnosed diabetics. Lancet i: 428-43 1. 
Ward M Low PA, Schmelzer JD, Zochodne DW (1989) Prostacyclin and 
noradrenaline in peripheral nerve of chronic experimental diabetes. Brain 112: 
197-208. 
Watkins PJ, Edmonds NIEE (1983) Sympathetic nerve failure in diabetes. Diabetologia 
25: 73-77. 
Watkins PJ (1992) Clinical observations and experiments in diabetic neuropathy. 
Diabetologia 3 5: 2-11. 
206 
Watts RA, Skingle S, Bharnbani K Pountain G, Crisp AJ (1993) Treatment of Paget's 
disease with single dose intravenous pamidronate. Seminars in Arthritis and 
Rheumatism (In Press). 
WHOADF (1990) Diabetes Care and Research in Europe. The St Vincent 
Declaration. Diabetic Med 7: 360. 
Wieczorek I, Pell ACK McIver B, MacGregor IR, Ludlam CA, Frier BM (1993) 
Coagulation and fibrinolytic systems in type I diabetes: effects of venous 
occlusion and insulin-induced hypoglycaernia. Clin Sci 84: 79-86. 
Wilboum AJ, Furlan AJ, Hulley W, Ruschhuap TW (1983) Ischaemic monomelic 
neuropathy. Neurology 33: 447-45 1. 
Wiles PG, Pearce SM, Rice PJS, Nfitchell JMO (1991) Vibration perception threshold: 
influence of age, height, sex, and smoking, and calculation of accurate centile 
values. Diabetic Med 8: 157-161. ( 
Williams CE, Carey BM, Birtwell AJ, Wales JK, Wiles PG (1988) Metatarsal 
periosteal reactions: a common non-specific finding in radiographs of the 
diabetic foot. Br Med J 297; 1243-1244. 
Williamson JR, Kilo C (1977) Current status of capillary basement membrane disease 
in diabetes mellitus. Diabetes 26: 65-73. 
Yao ST, Hobbs JT, Irvine WT (1969) Ankle systolic pressure measurements in arterial 
disease affecting the lower extremities. Br J Surg 56: 676-679. 
Ylikorkala 0, Kaila J, Viinikka L (198 1) Prostacyclin and thromboxane in diabetes. 
Br Mcd J 283: 1148-1150. 
Young MJ, Manes C, Boulton AJM (1992) Vibration perception predicts foot 
ulceration: A prospective study. Diabetic Med 9 (suppl 2): P75. 
207 
YoungMJ, Boulton AJK Macleod AF, Williams DRR, Sonksen PH (1993a) A 
multicentre study of the prevalence of diabetic peripheral neuropathy in the 
United Kingdom hospital clinic population. Diabetologia 36: 150-154. 
Young MJ, Every N, Boulton AJM (1993b) A comparison of the Neurothesiometer 
and Biothesiometer for measuring vibration perception in diabetic patients. 
Diabetes Res Clin Prac 20: 129-132. 
Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clark BF (1986) Variable 
relationship between peripheral somatic and autonomic neuropathy in patients 
with different syndromes of diabetic polyneuropathy. Diabetes 35: 192-197. 
208 
